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Abstract 
 
Leprosy is an infectious disease which is considered one of the most common causes of 
non-traumatic peripheral neuropathy worldwide. The actual treatment is based in a 
multidrug therapy (MDT), which is selected according to the classification of the disease. 
For the most complicated cases (multibacillary leprosy, MB), patients should take a daily 
dose of dapsone (DAP) and clofazimine (CLZ). The standardization of the MDT regarding 
duration and therapeutic agents seems seem to be a trend as may help to improve patient 
compliance. Despite the effectiveness of DAP and CLZ, their action is greatly limited by 
their physicochemical features, specially their low solubility. The main goal of this thesis 
was to develop new drug delivery systems for oral administration of DAP and CLZ, in 
order to overcome limitations associated with their poor water solubility using Quality by 
Design tools. The rational development of amorphous solid dispersions (SD) with DAP 
and polyvinylpyrrolidone K30(PVP K30) by freeze-drying improved drug solubility and 
dissolution rate by shifting DAP physical state from crystalline to the amorphous form. 
Further, the design of pH-sensitive DAP-loaded nanoparticles of Eudragit L100 (NPs—
EL100-DAP) was performed by the application of Placket-Burman screening design (PBD) 
with subsequent optimization by Box-Behnken design (BBD). Fourier-transformed infra-
red spectroscopy (FTIR) and differential scanning calorimetry (DSC) analyses confirmed 
the association of DAP; transmission electron microscopy (TEM) micrographs revealed 
the spherical morphology of the nanoparticles. The DAP in vitro release assay from NPs-
EL100-DAP confirmed the nanoparticles’ pH sensitivity and the ability to deliver DAP at 
the intestinal environment. NPs-EL100-DAP demonstrated enhanced intestinal 
permeation in comparison to free DAP, in the Caco-2 monolayers model. Solid lipid 
nanoparticles (SLNs) loaded with CLZ (SLNs-CLZ) were developed aiming to improve its 
bioavailability and decrease its intrinsic toxicity. The study was conducted after 
preliminary risk assessment of the process and product variable which allowed the 
implementation of control actions. A new UV-Vis spectrophotometric method to quantify 
CLZ was developed and validated to determine the drug association efficiency (AE) of the 
optimized SLNs-CLZ. Optimized SLNs-CLZ presented suitable particles size (230 nm), 
zeta potential (-34.28 mV), AE (72%) and drug loading (2.4 %). Physicochemical 
characterization by FTIR and DSC confirmed the drug association within SLNs in 
amorphous state. The storage stability studies ensured stability over 12 weeks at 4ºC, and 
no significant toxic effect of SLNs-CLZ on gastric cells (MKN-28) and intestinal Caco-2 
and HT29-MTX cells (up to 25 and 50 respectively) was observed. The optimized SLNs-
CLZ showed to be suitable to orally deliver CLZ, even though some improvement in the 
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drug payload was found to be important for the application in leprosy treatment, aiming 
to reach the suitable systemic levels. For this purpose, poly(lactic-co-glycolic acid) (PLGA) 
CLZ-loaded nanoparticles (NPs-CLZ) were obtained after assessing the critical factors 
during nanoparticles formulation through PBD. The obtained NPs-CLZ had a particle size 
of 210.8 nm, polydispersity (PDI) of 0.211, an AE of 70% and DL of 12 %. NPs-CLZ were 
characterized regarding morphology and physicochemical properties which showed the 
spherical shape and amorphous state of associated CLZ within NPs-PLGA. In vitro drug 
release revealed the sustained release of CLZ. Cytotoxicity studies showed that the NPs-
CLZ were not toxic on the studied intestinal cells (Caco-2 and HT29-MTX) while free CLZ 
exhibited an IC50 of 16.3 and 20.3 µg mL-1 for Caco-2 and HT29-MTX cells, respectively. 
Similar apparent permeability values for free CLZ and when associated within 
nanoparticles were found after 8 h of permeation assays across Caco-2. The obtained NPs-
CLZ was found to be an alternative to the SLNs as they presented higher DL, being a 
promising platform to deliver of CLZ. Lastly, the DAP/ CLZ combinatory therapy used for 
MB leprosy was studied using the developed polymeric nanosystems per se and in 
association. After 8 h no toxicity was observed for Caco-2 incubated with DAP alone and 
within NPs, up to 100 µg mL-1, while CLZ per se was toxic, reducing cell viability to 30% at 
50 µg mL-1. Caco-2 exposed to NPs-DAP/ NPs-CLZ (100 and 50 µg mL-1, respectively) had 
80% viability. No significant differences were observed between the nanosystems per se or 
in combination for the apparent permeability values and the amount of permeated drug. 
Thus, the two polymeric nanosystems containing DAP and CLZ in combination seemed to 
be a promising platform to deliver both drugs in association, representing an important 
step toward the improvement and of MB leprosy therapy, as they may decrease the toxicity 
associated with the drugs and increase patient compliance (a single dose with both MDT 
drugs). Overall, different platforms to deliver DAP and CLZ were obtained to overcome 
the limitations associated with both these drugs, showing to be promising systems for 
future use in leprosy treatment as single systems or in association. Nevertheless, 
complementary assays should be performed to better elucidate the effect and security of 
DAP/ CLZ association into nanodelivery systems. 
 
Key words: Leprosy; Dapsone/ Clofazimine association; Solid dispersions; Nanocarriers, 
Design of Experiment
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Resumo 
 
A lepra é uma doença infecciosa considerada uma das principais causas de neuropatias 
não-traumáticas no mundo. O seu tratamento actual é baseado na poliquimioterapia 
(PQT), que é selecionada de acordo com a classificação da doença. Para os casos mais 
complicados de lepra multibacilar (MB) os pacientes tomam uma dose diária de dapsona 
(DAP) e clofazimina (CLZ). A padronização da PQT relativamente ao tempo de tratamento 
e aos agentes antimicrobianos parece ser uma tendência visto que poderá auxiliar na 
adesão dos pacientes ao tratamento. Apesar da eficácia da DAP e da CLZ, a ação destes 
fármacos é comprometida pelas suas características físico-químicas, especialmente devido 
à baixa solubilidade. O principal objetivo desta tese foi desenvolver novos sistemas para 
entrega de fármacos para administração oral da DAP e da CLZ, de modo a ultrapassar as 
suas limitações utilizando uma abordagem Quality by Design. Assim, o desenvolvimento 
racional de dispersões sólidas amorfas (DS) com DAP e polivinilpirrolidona K30 por 
liofilização promoveu um aumento da solubilidade e velocidade de dissolução da DAP 
através da mudança do seu estado de cristalino para o estado amorfo. Posteriormente, o 
desenho de nanopartículas de Eudragit L100, sensíveis ao pH, contendo DAP (NPs-
EL100-DAP) foi realizado através da aplicação do Plackett-Burman design (PBD) e 
subsequente otimização pelo Box-Behnken design (BBD). As análises de espectroscopia na 
região do infravermelho, com transformada de Fourier (FTIR) e calorimetria exploratória 
diferencial (DSC) confirmaram a associação da DAP, enquanto a microscopia eletrónica de 
transmissão revelou a morfologia esférica das nanopartículas. O ensaio de libertação in 
vitro da DAP a partir das NPs-EL100-DAP confirmou a capacidade de entrega do fármaco 
em ambiente intestinal. As NPs-EL100-DAP conduziram a um aumento da 
permeabilidade intestinal da DAP, em comparação com o fármaco livre utilizando o 
modelo de monocamada de Caco-2. Nanopartículas lipídicas sólidas (SLNs) carregadas 
com CLZ (SLNs-CLZ) foram desenvolvidas com o objetivo de aumentar a 
biodisponibilidade da CLZ e, diminuir a sua toxicidade intrínseca. Uma avaliação 
preliminar permitiu identificar o risco das variáveis envolvidas no processo e na 
formulação. Um novo método espectrofotométrico UV-Vis para quantificação expedita da 
CLZ foi desenvolvido e validado. As SLNs-CLZ apresentaram tamanho de partícula, 
potencial zeta, eficiência de associação e capacidade de carga adequadas para 
administração oral. A caracterização físico-química por FTIR e DSC confirmaram a 
associação da CLZ nas SLNs no estado amorfo. Os estudos de estabilidade de 
armazenamento confirmaram a estabilidade das formulações no período de 12 semanas, a 
4ºC, e nenhum efeito citotóxico foi observado para as SLNs-CLZ em células gástricas 
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(MKN28) e intestinais (Caco-2 e HT29-MTX). As SLNs-CLZ mostraram-se adequadas 
para entrega oral de CLZ, no entanto seria necessário aumentar a capacidade de carga 
para atingir níveis sistémicos adequados ao tratamento da lepra. Com esse propósito, 
nanopartículas de poli(acido lático-co-glicolico) (PLGA) veiculadas com CLZ (NPs-CLZ) 
foram obtidas após avaliação de fatores críticos na formulação das nanopartículas através 
de um PBD. As NPs-CLZ obtidas apresentaram características fisíco-químicas adequadas 
para administração oral. NPs-CLZ foram caracterizadas quanto à morfologia (esférica) e 
as propriedades físico-quimicas que evidenciaram estado amorfo da CLZ associada às 
NPs-PLGA. O estudo de libertação in vitro revelou uma entrega lenta de CLZ em meio 
ácido. Os estudos de citotoxicidade mostraram que NPs-CLZ não foram consideradas 
tóxicas nas células intestinais estudadas enquanto a CLZ na forma livre exibiu um IC50 de 
16.3 e 20.3 µg mL-1 para Caco-2 e HT29-MTX, respectivamente. Os valores de 
permeabilidade aparente para CLZ associada às NPs-PLGA foram registados após 8 h de 
ensaio. As NPs-CLZ desenvolvidas mostraram ser uma alternativa às SLNs já que 
descritas, pois apresentam uma capacidade de associação mais elevada, podendo ser uma 
plataforma promissora para a entrega de CLZ. Por último, a combinação terapêutica DAP/ 
CLZ usada no tratamento da lepra MB foi estudada utilizando-se os nanosistemas 
poliméricos desenvolvidos per se e em combinação. Após 8 h nenhuma toxicidade foi 
observada para Caco-2 incubadas com DAP livre ou associada às NPs até 100 µg mL-1, 
enquanto que a CLZ livre apresentou toxicidade, reduzindo a viabilidade celular para 30% 
a 50 µg mL-1. Células Caco-2 expostas à combinação NPs-DAP/ NPs-CLZ (100 e 50 µg mL-
1, respectivamente) apresentaram 80% de viabilidade. Não foram observadas diferenças 
significativas entre os nanosistemas per se ou em combinação para os valores de 
permeabilidade aparente e a quantidade de fármaco permeado. Assim, os dois 
nanosistemas poliméricos contendo DAP e CLZ em combinação demonstraram ser 
plataformas promissoras para administrar os fármacos em associação, representando um 
passo importante para a melhoria e da terapia da lepra MB, uma vez que podem diminuir 
a toxicidade associada aos fármacos e aumentar adesão do paciente através de uma toma 
única com ambos os medicamentos da PQT. De um modo geral, foram obtidas diferentes 
plataformas para administrar DAP e CLZ para superar as limitações associadas a ambos os 
fármacos, mostrando terem sido desenolvidos sistemas promissores para uso futuro no 
tratamento da lepra como sistemas únicos ou em associação. No entanto, ensaios 
complementares devem ser realizados para melhor elucidar o efeito e a segurança da 
associação DAP /CLZ em nanosistemas de libertação controlada.  
 
Palavras-Chave: Lepra; Associação dapsona/ clofazimina; Dispersões sólidas; 
Nanocarregadores; Desenho experimental.  
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1. Motivation 
 
Leprosy continues to be a significant issue of public health as it affects a large proportion 
of the World population [1, 2]. Brazil, India and Indonesia present the highest levels of the 
reported cases, accounting for 81% of new cases globally [3]. It is characterized as a 
chronic and infectious disease caused by an intracellular microorganism, the 
Mycobacterium leprae (M. leprae) [4], that mainly affects the peripheral nervous system, 
skin, and certain other tissues such as the reticuloendothelial system, bones and joints, 
mucous membranes, eyes, testis, muscles, and adrenals [1, 5]. Leprosy disease is one of 
the most common causes of non-traumatic peripheral neuropathy worldwide [6]. Acute 
episodes of clinical manifestations occurs during the chronic course of disease, affecting 
30 to 50% of patients and often appear at the beginning of the treatment [1, 6]. Such 
reactions may cause permanent damage to the nerves, which lead to an increase in the 
morbidity due to sensory loss, dysfunction and eventual deformities in the skin and other 
organs [1, 6, 7]. To address issues related to leprosy control, new strategies have been 
proposed involving the improvement of political commitment and the reduction of 
patients disabilities in the next few years [3]. For treatment purposes, the World Health 
Organization suggests a simple scheme to classify leprosy patients based on visible 
symptoms and (ideally) the presence or absence of bacilli in slit-skin smears [1, 8]. 
Patients are classified as having paucibacillary (PB) leprosy (1 -5 skin patches) or 
multibacillary (MB) (with > 5 skin patches) [1, 8]. The actual recommended treatment for 
leprosy disease is based in a multidrug therapy (MDT), consisting of clofazimine (CLZ), 
dapsone (DAP) and rifampicin, as first line drugs. For patients with PB leprosy, rifampicin 
(600 mg) is monthly (supervised) administered and dapsone (100 mg) is daily (non-
supervised) administered during 6 months; while MB patients are treated with rifampicin 
(200 mg) and clofazimine (300 mg) monthly (supervised) administered, and dapsone 
(100 mg) and clofazimine (50 mg) daily (son-supervised) administered, during 12 months 
[8].  
The majority of the countries that have reported new leprosy cases in 2014 presented 
higher incidence of MB leprosy cases [3]. Thus, the standardization of the MDT regarding 
time of treatment and therapeutic agents seems to be a trend in leprosy eradication 
program as the implementation of a unique therapeutic regimen may help to improve 
patient compliance. In this context, DAP and CLZ which are the daily drugs used in MDT 
for MB cases become the most important components of leprosy therapy [9]. 
On the other hand, the idea of shortening the duration of MB treatment associated with 
the non-supervision of daily-drugs administration (DAP and CLZ) highlights the risk of 
antimicrobial resistance in leprosy [9]. Thus, research in the therapy of leprosy is still 
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needed, and some efforts must be done specially to improve delivery of drugs and 
compliance of patients, [5, 10, 11], as the research for alternative bactericidal agents are 
currently limited [12, 13].  
Despite their proven effectiveness, the therapeutic potential of the anti-leprotic drugs is 
greatly limited by their physicochemical features, specially their insolubility in water [14]. 
This fact is especially relevant for daily dosages, i.e., for DAP and CLZ as they play an 
important role in the success of MDT. In this context, it seems to be of great relevance to 
develop new drug delivery systems with these drugs aiming to both overcome 
physicochemical limitations and improve their bioavailability, as well as to contribute to 
the improvement of leprosy therapy through the drug association. 
 
2. Aims 
 
Based on previous considerations, the main goal of this thesis was to develop new drug 
delivery systems with the first-line drugs used in leprosy MB treatment regimen, for daily 
administration of CLZ and DAP. The application of delivery systems aim to overcome 
limitations associated with their physicochemical characteristics particularly regarding 
poor water solubility. In parallel, this work intended to systematic design new drug 
delivery systems with DAP and CLZ through the application combined analytical 
approaches such as design of experiments (DoE) and response surface methodology 
(RSM), as Quality by Design tools. 
 More specifically, this thesis intended to develop and characterize: (i) amorphous solid 
dispersions with DAP to improve its dissolution rate; and (ii) pH sensitive polymeric 
nanoparticles targeted to intestinal environment, trying to avoid undesired DAP release 
under acidic conditions. Moreover, nano-delivery systems with CLZ, namely solid lipid 
and polymeric nanoparticles were also systematically developed and characterized aiming 
to overcome drug low bioavailability and associated toxic effects upon oral administration. 
Finally, the assessment of cell viability and in vitro permeability of DAP and CLZ were 
compared to the developed nano-delivery systems alone, and in association. 
 
3. Structure 
 
This thesis is organized in 5 chapters: 
Chapter I: Introduction. This chapter includes the motivation for this work, as well as 
the definition of the main and specific goals. A brief description of the thesis organization 
and structure is also provided.  
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Chapter II: Theoretical background. This chapter started with the state of the art of 
leprosy disease, in which theoretical considerations, epidemiologic records, transmission, 
diagnosis and treatment were approached. Then, two published review works entitled 
“Quality by Design: Discussing and Assessing the Solid Dispersions Risk” and 
“Nanocarriers as strategy for oral bioavailability improvement of poorly water-soluble 
drugs” supported the strategies that have been used to overcome the drawbacks associated 
with the mainly anti-leprosy drugs: clofazimine and dapsone. 
Chapter III: Methods. In this chapter, is presented a general overview of the 
fundamental aspects related to the techniques and methodologies used in this thesis to 
develop, characterize and validate the drug delivery systems developed in this thesis. 
Chapter IV: Progress beyond the state of art. This chapter presents published and non-
published works originated in the context of this thesis: 
A. Rational and precise development of amorphous polymeric systems with dapsone 
by response surface methodology; 
B. pH-sensitive nanoparticles for improved oral delivery of dapsone: risk assessment, 
design, optimization and characterization; 
C. Optimization of solid lipid nanoparticles for clofazimine delivery: risk 
management, statistical design and physicochemical characterization; 
D. Characterization of PLGA nanoparticles loaded with clofazimine for oral delivery: 
assessment of formulation variables and intestinal permeability; 
E.  Polymeric nanosystems combination allows dapsone and clofazimine intestinal 
permeation 
F. Integrated Discussion 
Chapter V: Concluding Remarks and Future Perspectives. In this final chapter, the main 
conclusions and perspectives are presented, considering the contributions of the present 
studies for the improvement of leprosy therapy as well as for the development of new 
delivery systems to overcome poor solubility of clofazimine and dapsone, enhancing its 
applicability in future associated therapy.  
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A. Leprosy disease: state of the art 
 
1. Introduction 
 
Leprosy, also known as Hansen’s disease, is a non-fatal ancient bacterial disease that, 
continues to be a significant issue of public health as it affects a large proportion of the 
World population [1, 2]. Currently it is one of the most common causes of non-
traumatic peripheral neuropathy worldwide [6].  
Epidemiologic data demonstrate that, despite important advances in the political, 
social, and economic status of developing countries, leprosy is still endemic in several 
countries of Africa, South-East Asia, and America. In Europe, it is considered a rare 
disease, although it is still a disease of concern among immigrants coming from risk 
areas [2]. 
Leprosy is characterized as a chronic and infectious disease caused by an intracellular 
microorganism, the Mycobacterium leprae (M. leprae) [4]. It mainly affects the 
peripheral nervous system, skin, and certain other tissues such as the 
reticuloendothelial system, bones and joints, mucous membranes, eyes, testis, muscles, 
and adrenals [1, 5]. 
Several clinical manifestations have been reported and depend on the host immune 
response [4]. Since the inflammation takes place, it is important to have immediate 
medical attention due to severe pain and to prevent nerve damage and deformity [4]. 
  
1.1 Epidemiology 
 
The prevalence of leprosy globally decreased from >5 million cases in the mid-1980’s to 
less than 200,000 in 2015 with the introduction of multidrug therapy [3]. Lower 
prevalence rates do not necessarily mean the reduction in the number of new cases 
found nor a decrease in M. leprae transmission; rather, it may be related to the shorter 
period of treatment recommended by the World Health Organization (WHO) or to the 
exclusion from registries of patients who have been cured or who have died [15]. 
According to data obtained from WHO, in 2015, several countries or territories 
reported cases of leprosy, namely: 28 cases from the African Region, 23 from the 
Region of the America, 11 from the South-East Asia Region, 20 from the Eastern 
Mediterranean Region, 28 from the European Region and 26 from the Western Pacific 
Region [16]. Figure 1 depicts the incidence of leprosy worldwide, based on WHO 
records. 
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Figure 1. World distribution of new cases of leprosy in 2015, according to WHO [16]. 
 
At a global level, between 2005 and 2014 the number of new cases was maintained 
constant [3], which reveals that leprosy continuous to be highly prevalent in many 
countries. Among them, 13 countries reported >1,000 new cases (5 from Africa, 1 from 
America, 6 from South-East Asia and 1 Western Pacific), which together contributed to 
94% of all new leprosy cases Worldwide [3]. Brazil, India and Indonesia, presented the 
higher levels of new cases with >10,000 new cases reported, accounting for 81% of new 
leprosy cases globally [3]. 
Regarding the diagnosis, 60.6% of new cases were classified as multibacillary, which 
indicate presence of advanced cases of leprosy and indirectly the magnitude of infection 
in the community [3]. Between 2007 and 2015, more than 110,000 people diagnosed 
with leprosy had physical deformities at diagnosis, an indicator of delayed detection 
[17]. The trend in the number of new cases indicates stagnation in leprosy control. 
Thus, early diagnosis and complete treatment with multidrug therapy continue to be 
key strategies for reducing disease burden due to leprosy [3]. 
To address issues related to stagnation in leprosy control, new strategies have been 
proposed and included (i) improved political commitment, (ii) reduction of patients 
disabilities, (iii) inclusion of persons affected by leprosy until 202o [3]. 
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1.2 Etiologic agent: Mycobacterium leprae  
 
M. leprae (order Actinomycetales ; family Mycobacteriaceae) is an acid-fast obligate 
intracellular bacillus, differing from other mycobacteria that may grow beyond cells 
[15]. Morphologically the bacillus appears as pleomorphic rods with 1 to 8 µm long for 
0.3 µm large [18], and replicate by binary diffusion [7, 15]. which takes from 12-13 days, 
in temperatures between 27-30ºC [15]. 
M. leprae are naturally Gram-positive but can be differentially stained, appearing acid-
fast using the Ziehl-Neelsen stain on smears or the Fite’s acid fast stain in paraffin-
embedded tissue sections [7]. The inability to culture M. leprae in vitro is one of the 
main specificities of that bacterium, and can be explained by its very long doubling time 
(14 days) [18]. Nowadays, it is still difficult to culture M. leprae in the laboratory, but it 
can be done by inoculating the bacterium into the footpad of female Swiss mice [18]. 
The in vitro replication allowed the research in the development of new antibiotic 
therapies and the study of drug resistance [18]. 
Despite the M. leprae be highly infective, the progression of the disease is slow due to 
the long incubation period of the bacteria [19, 20]. It shows tropism for cells of the 
reticuloendothelial and peripheral nervous system, more specifically for Schwann cells 
(SC), showing propensity to infect cold areas of the body as skin, nasal mucosa, and 
peripheral nerves [15]. Once inside cells, they get arranged in aggregates called globi 
[20, 21]. The specificity of M. leprae for SC is explained by the attachment to laminin-
a2 and adhesins located in the basal lamina and to a-dystroglycan and ErbB2 receptors 
on the cell surface of peripheral nerves [1, 6]. When inside the SC, the pathogen triggers 
the differentiation into immature cells, creating a suitable environment for its 
proliferation [1]. The replication proceeds slowly until the recognition of the bacteria by 
T cells, starting up a chronic inflammatory reaction [15]. A schematic representation of 
the interaction between M. leprae and laminin-2 glycoprotein is represented in Figure 
2. The infection of SC induces demyelination and loss of axonal conductance with 
consequent disability [6, 15, 20]. 
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Figure 2. Schematic representation of the interaction between M. leprae and laminin-
2 in the basal lamina of myelinated and non-myelinated Schwann-cell–axon units. 
Adapted from [20] 
 
1.3  Transmission 
 
The transmission and dissemination of M. leprae is low, and the mechanism by which 
the pathogen is transmitted is poorly understood [15]. M. leprae has been found in high 
numbers in the nasal mucosa. Thus, the respiratory tract may play a relevant role in its 
transmission as it may be a site of entry of the bacillus [15, 18]. 
No relationship between the M. leprae and a vector has been established, although the 
possibility cannot be ignored. Vertical transmission has been reported, so it is 
recommended to follow mother-child dyads [15]. 
The most contagious form of the disease is the lepromatous (see section 1.4) as patients 
usually have a very large number of bacilli, presenting up to 7 billion bacilli per one 
gram of tissue [18]. Although, the bacilli dissemination is not restricted to leprosy 
patients, healthy carriers and individuals with subclinical infections who carry M. 
leprae in their nasal and or oral mucosa may play an important role in the disease 
chain of transmission [22]. 
 
1.4 Classification 
 
The classification of leprosy is determined by clinical prognosis and it serves to 
distinguish which cases may be potentially infectious [23]. In addition, the clinical 
determination of leprosy subtype may provide major pathophysiological information 
[23]. 
A more detailed and used system of classification, called Ridley and Jopling system, 
categorizes the disease into five types according to cell-mediated responses and these 
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include, from the least to the most severe tuberculoid (TT), borderline tuberculoid 
(BT), borderline borderline (BB), borderline lepromatous (BL), and lepromatous (LL) 
[1]. The borderline leprosy is considered an intermediate manifestation between 
lepromatous and tuberculoid leprosy, and the designation BT, BB and BL came to 
better characterize the borderline group that could comprise patients with different 
clinical, immunological, bacteriological, or histological findings [23]. 
Tuberculoid leprosy is characterized by the presence of few (or single) small lesions 
which may be hyposensitive or anesthetic, showing well-defined and elevated borders 
(papules and plaques), that can sometimes be infiltrated [2, 18]. Rare acid-fast bacilli 
are found in the damaged tissue [7]. If left untreated, they form copper colored papules 
or nodules known as leproma. Nerve damage is usually observed around skin lesions 
and is associated with sensory and/or motor impairment when the hands and feet are 
affected [18]. 
Borderline leprosy is classified according to the number of clinical signs, corresponding 
to a transition between TT and LL cases [2, 18]. The BT presentation of leprosy is 
defined by the presence of several asymmetrical and hypoesthetic lesions with 
peripheral macules or infiltration of the skin [18]. Lesions may vary in size, shape, and 
color, even in the same patient [2]. Histopathological analysis of skin smears may be 
negative or positive, even though bacteriologic index is usually low [2]. The BB 
presentation is defined by the presence of several non-anesthetic annular lesions 
characterized by infiltrated plaques with an apparent normal skin in the center and 
well-defined inner edge [2, 18]. The BL presentation is characterized by the 
disseminated presence and symmetric lesions, bilateral and non-anesthetic lepromas 
and annular lesions [2, 18]. The elevated number of lesion is due to the reduced 
immunologic resistance [2].  
Lepromatous leprosy is caused by a strong inability for an immunologic reaction 
against M leprae. At skin levels, patients present a high number of bilateral and 
symmetrical not anesthetic leproma (20 to 100) that frequently occurs in the face, 
earlobes, fingers, and toes [15, 18]. Histopathology reveals very large numbers of bacilli 
in the dermis [7]. Non-skin manifestations may compromise the eyes, nose, bones, 
testis, spleen, liver, and adrenals, leading to systemic repercussions and more severe 
disability [2, 15]. 
For treatment purposes, WHO suggests a simple scheme to differentiate leprosy types. 
In this scheme, leprosy is classified based on visible symptoms and (ideally) the 
presence or absence of bacilli in slit-skin smears from cooler regions of the body 
(generally from earlobes, elbows, and/or knees) where bacilli proliferate [1, 8]. Patients 
with 1 -5 skin patches and no apparent bacilli in slit-skin smears are classified as having 
New technologies for the improvement of leprosy MDT  
		
 14 
“paucibacillary” (PB) disease, while those with > 5 skin patches and bacilli visible by 
microscopic analyses of skin smears are classified as having “multibacillary” (MB) 
disease. In areas without access to slit-skin smears, the criterion for diagnosis is the 
number of visible lesions [1, 8]. 
A schematic representation of leprosy classification according immune response, 
clinical manifestation and treatment is depicted in Figure 3. 
 
 
 
Figure 3. Schematic representation of leprosy classification according immune 
response, clinical manifestation and treatment. Adapted from [18]. 
 
Another important classification use by WHO to assess the efficacy of the public health 
program is to classify leprosy according disability grading system. This is a practical 
and simple classification that has been used as an epidemiological indicator [24, 
25].Briefly, disability can be defined as any change that may compromises the proper 
functioning of the body, and may be at biological, activity, personal (psychological 
aspects), environmental or societal (context and participation) levels, which can be 
experienced by an individual affected by a disease or a special health condition [24, 25]. 
In this classification, Grade 0 means no impairment, Grade 1 means loss of sensation in 
the hand, eyes or foot, and Grade 2 means visible impairment [24, 25]. 
 
1.5 Leprosy reactions 
 
Leprosy reactions are acute episodes of clinical inflammation which occurs during the 
chronic course of disease, affecting 30 to 50% of patients and often appear at the 
New technologies for the improvement of leprosy MDT  
		
 15 
beginning of the treatment [1, 6]. Reactions may cause permanent damage to the 
nerves, which lead to an increase in the morbidity such as sensory loss, dysfunction and 
eventual deformities. They can affect skin and other organs as well [1, 6, 7]. The 
appearance of the reactions are related to the immune system changes, that may be 
caused by the multidrug therapy, most often arising in the first two months after the 
beginning of the treatment, stress, or pregnancy [1, 6, 26]. They are classified as Type I 
also known as reversal reaction (RR); and Type II or erythema nodosum leprosum 
(ENL) reactions [26] .Both types of reactions have been found to cause neuritis, 
representing the primary cause of irreversible deformities [6]. 
Type I reaction occurs in 30% of patients, normally with borderline leprosy (BB or BL) 
[26] and, are associated with clinical and histopathological increased immunity toward 
M. leprae [7]. These reactions are characterized by edema and erythema of existing 
skin lesions, the formation of new skin lesions, neuritis, additional sensory and motor 
loss, and edema of the hands, feet, and face; however, systemic symptoms are 
uncommon [6, 7]. 
Type II reaction occurs mainly in patients with poor cellular immune responses but 
who have preserved humoral responses, for example in LL or LB patients with high 
levels of anti-M. leprae immunoglobulins [26]. The reactions are characterized by the 
appearance of tender, erythematous, subcutaneous nodules located on apparently 
normal skin, and is commonly accompanied by systemic symptoms, such as fever, 
malaise, enlarged lymph nodes, anorexia, weight loss, arthralgia, and edema. Other 
organs including the testis, joints, eyes, and nerves may also be affected [6, 7]. 
 
1.6 Immunological responses  
 
The immune response to M. leprae is variable due to the large variability in host 
immune response to the bacillus [13, 15]. Different immune responses are observed 
among the 5 categories of the Ridley and Jopling classification system, especially when 
comparing the extremities of the manifestations [19]. Across the five-group Ridley and 
Jopling system, gradual reduction of cell-mediated immune responses is observed 
towards the lepromatous side of the spectrum (BL and LL), associated with increased 
bacillary load and high antibody titres [22].  
The TT manifestation is characterized by vigorous T-cell responses (cell mediated 
immune response) (Th1), low antibody titers to M. leprae antigens, and the bacilli are 
organized in granulomas. Characteristic cytokine profile contains prevalence of 
interferon gamma [IFN-γ], interleukin (IL)-2, IL-15, and tumor necrosis factor alpha 
[TNF-a] [6, 26]. The primary skin lesions have epithelioid macrophages surrounded by 
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CD4+ T lymphocytes that activating macrophages to release inflammatory and 
proinflammatory cytokines that lead to cell-mediated immunity [27]. 
On the other hand, the immune response of LL patients is characterized by a Th2 
immune response and the lesions are characterized by foamy macrophages heavily 
infected with bacilli, and predominantly CD8+ T cells, with production of IL-4 and IL-
10 and activation of T regulatory cells [6, 19, 26, 28]. 
The different cytokines’ patterns of the two poles of the disease form (TT or LL) play an 
important role in helping to identify the predominance of reactions through 
polymerase chain reaction (PCR)[19].  
 
1.7 Diagnosis 
 
Currently, the diagnosis of leprosy relies on a combination of the recognition of the 
clinical manifestations by physical examination, and skin biopsy and/or smear [13, 28]. 
The analysis of the clinical manifestations requires relatively high levels of expertise 
and experience to ascertain the differential diagnosis [28]. The proper classification of 
the disease plays an important role for the success of control programs and treatment 
standardizing [29]. 
According to the WHO, leprosy is diagnosed based on the presence of cardinal signs, 
and is made when an individual who has not completed a course of treatment presents 
one or more of the following signs: hypopigmented (or erythematous) anesthetic skin 
lesion; thickened peripheral nerve or positive skin smear or bacilli observed in a biopsy 
[8, 15]. Despite the consolidation of diagnostic and treatment guidelines, the immune 
responses observed during leprosy are occasionally used to complement clinical 
diagnosis [30]. A rapid molecular assay using real-time PCR to identify and quantify M. 
leprae DNA in tissue samples have been used to complement leprosy diagnosis [13]. 
More recently, the detection of antibodies of M. leprae antigens such as phenolic 
glycolipid-I and leprosy IDRI diagnostic-1 have been used for the classification of PB or 
MB forms of the disease [29, 30]. 
 
1.8 Conventional treatment 
 
The leprosy treatment has gone under considerable evolution in the past century. The 
leprosy therapy firstly consisted of potassium iodide, arsenic, antimony, copper, sera, 
vaccines, aniline dyes, thymol, strychnine, baths, X-rays, radium, and electrical current 
[13]. In the late 19th and early 20th centuries, the chaulmoogra oil, extracted from 
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seeds of several species of the Hydnocarpus tree, was a hallmark of therapy with 
varying reports of documented success and indifferent results [13, 31]. 
In 1940’s, the first sulfone drug was introduced to treat leprosy, the promin [32, 33]. 
Later on, dapsone monotherapy was introduced [1]. In patients on dapsone 
monotherapy, bacilli extinction was completed in 3 to 6 months, and complete clinical 
regression generally occurred within 2 to 3 years [12]. Patients had to maintain the 
treatment without interruption, otherwise resistance could develop [1]. 
In 1982 the WHO introduced multidrug therapy (MDT) consisting of clofazimine 
(CLZ), dapsone (DAP) and rifampicin, as first line drugs. For patients with PB leprosy, 
rifampicin (600 mg) is monthly (supervised) administered and DAP (100 mg) is daily 
(non-supervised) administered; while MB patients are treated with rifampicin (200 
mg) and CLZ (300 mg) monthly (supervised) administered, in addition to DAP (100 
mg) and CLZ (50 mg) daily (son-supervised) administered [8]. The introduction of 
MDT have altered the course of disease in leprosy patients and, nowadays, is the most 
common way to limit the dissemination of M. leprae [32]. 
The recommended treatment duration for MB leprosy is 12 months and this therapy 
includes patients presenting LL, BL, and BB leprosy according to the Ridley and 
Jopling system. For PB patients, the treatment duration is 6 months and includes 
patients with TT, and BT leprosy forms [15]. Since its introduction, MDT has not been 
revised except for the duration of therapy. Initially, the duration of treatment with 
MDT took 24 months or until smear negativity, which was responsible for decrease in 
patient compliance, resistance, and relapse, compared to dapsone monotherapy [12]. In 
1997, it was implemented worldwide a fixed-duration treatment of 6 or 12 months for 
PB and MB respectively, which reduces significantly the number of relapses cases 
compared to the first adopted duration (24 months) [12].  
Since 1995, the cocktail is provided in convenient monthly calendar blister packs by the 
WHO, free of charge to all endemic countries [8]. The MDT cocktail should be received 
by the patient under supervision [32]. The actual therapy for PB and MB in adults and 
child patients supplied by WHO are expressed in Figure 4.  
New technologies for the improvement of leprosy MDT  
		
 18 
 
Figure 4. Leprosy treatment for adult and child: one month-pack blister distributed 
by WHO for paucibacillary (PB) and multibacillary (MB) leprosy [8]. 
 
 
Other alternative drugs as ofloxacin, minocycline, and clarithromycin have displayed 
significant activity against M. leprae and are among the drugs used as second-line 
treatments in humans [1, 34]. Even though they are not part of the WHO official 
regimen [34]. Attempts have been done to propose new combinations of these drugs in 
order to (i) overcome drug resistance, (ii) shorten the duration of the therapy, and (iii) 
improve the therapeutic efficacy [34]. 
Ofloxacin (4-fluooquinolone) is a fluorinated carboxy-quinolone that has moderate 
anti-M. leprae activity [7]. Fluoroquinolones mechanism of action against M. leprae is 
based on the inhibition of DNA gyrase and DNA replication and, transcription [13]. It is 
considered as an important option in leprosy treatment especially in patients with 
intolerance, resistance, or clinical failure to primary therapy [13]. Minocycline is the 
only member of the tetracycline group of antibiotics to demonstrate significant activity 
against M. leprae, presumably due to its lipophilic properties, which may enhance cell 
wall penetration. Its combination with dapsone and rifampicin presented additive 
activity against M. leprae [35]. Clarithromycin is a semisynthetic macrolide which 
displays significant bactericidal activity against M. leprae in humans [7, 35]. Despite 
the bactericidal effect of the this three-drug combination and the good therapeutic 
results observed in leprosy patients, the severe gastrointestinal side-effects related to 
the use of clarithromycin were sufficient to preclude the routine use of this drug in the 
field [7, 35]. 
 
MB adult blister pack
PB adult blister pack
2120
Each blister pack contains treatment for 4 weeks.
PB adult treatment: 
Once a month: Day 1
– 2 capsules of rifampicin (300 mg X 2)
– 1 tablet of dapsone (100 mg)
Once a day: Days 2–28
– 1 tablet of dapsone (100 mg)
Full course: 6 blister packs
MB adult treatment: 
Once a month: Day 1
– 2 capsules of rifampicin (300 mg X 2)
– 3 capsules of clofazimine (100mg X 3)
– 1 tablet of dapsone (100 mg)
Once a day: Days 2–28
– 1 capsule of clofazimine (50 mg)
– 1 tablet of dapsone (100 mg)
Full course: 12 blister packs 
MDT Regimens It is crucial that patients understand 
which drugs they have 
to take once a month a d which 
every day. 
PB child treatment (10–14 years):
Once a month: Day 1
– 2 capsules of rifampicin 
(300 mg+150 mg)
– 1 tablet of dapsone (50 mg)
Once a day: Days 2–28
– 1 tablet of dapsone (50 mg) 
Full course: 6 blister packs
For children younger than 10, the dose 
must be adjusted according to body weight.
MB child treatment (10–14 years):
Once a month: Day 1
– 2 capsules of rifampicin (300 mg+150 mg)
– 3 capsules of clofazimine (50 mg X 3)
– 1 tablet of dapsone (50 mg)
Once a day: Days 2–28
– 1 capsule of clofazimine every other day
(50 mg)
– 1 tablet of dapsone (50 mg)
Full course: 12 blister packs
For children younger than 10, the dose 
must be adjusted according to body weight.
PB child blister pack
MB child blister pack
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1.8.1 Uniform multidrug therapy (MDT) 
 
Despite the efficiency of the adopted classification system for treatment purposes, it is 
common to overestimate PB cases or underestimate MB diagnosis, which may 
jeopardize the adopted treatment [36, 37]. Moreover, another operational problem is 
patient compliance with long-term treatments for MB cases [36]. In this context, some 
efforts have been done to uniform MDT [38]. Recently, WHO have published this trend 
in leprosy treatment as a strategy to eradicate leprosy until 2020 [39, 40]. Some studies 
suggest the efficacy in shortening the duration of treatment of MB cases to 6 months. 
On the other hand, the addition of clofazimine in PB regimen seemed to improve the 
clinical outcome and produced disappearance of lesions and regression of granuloma 
[9]. As continued inflammatory response results in persistent activity in leprosy, 
clofazimine would contribute to PB patients therapy [38]. These trends open the door 
for introducing an uniform treatment regimen for both PB and MB cases with three 
drugs; hence, a single regimen for both forms of the disease, also known as Uniform-
MDT (U-MDT) [40], which could simplify leprosy control, allowing its incorporation 
into primary health care units [36]. In this regard, new guidelines will be issued by 
WHO once the amount of supportive evidence is attained [40]. 
 
1.8.2 The daily multibacillary MDT agents 
 
The proportion of MB cases globally is 60.6%, and among the countries that reported 
new cases in 2014, almost the totality presented higher incidence of MB leprosy cases 
[3]. In parallel, the treatment completion rate is one of the most important outcome 
indicators of case holding activity and reflects efficiency in patient management [3]. 
Thus, the standardization of the MDT regarding time of treatment and therapeutic 
agents aiming to enhance the global strategy for further reducing disease burden seems 
to be a tendency in leprosy eradication program.  
In this context, CLZ and DAP which are the daily drugs used in MDT for MB cases 
become the most important components of leprosy therapy as their correct 
administration and compliance is essential for the efficacy of the treatment. 
 
1.8.2.1 Dapsone 
 
Dapsone (4,4’-diamino-diphenylsulfone) (Figure 5A) is a parent compound of sulfone 
drugs, which have long been the cornerstone of leprosy treatment [13, 41]. It was 
synthesized in 1908, even though its antibacterial characteristics were firstly not 
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noticed [41]. In 1945, it was adopted in the leprosy treatment as monotherapy, but 
resistance, estimated at 2–10%, has become a problem [13]. 
Chemically, DAP is an aromatic amine, aniline derivative [42, 43]. As a sulfone, it 
shows the structure of a sulphur atom linking two carbon atoms (Figure 5A). This 
group is essential for their pharmacological activity and toxicity [42]. It is considered as 
a very weak Lewis base with no readily dissociable hydrogen ion (H+) [42]. DAP 
presents low solubility in water (0.16 mg mL-1) being classified as a class II (poor 
solubility and high permeability) drug according the Biopharmaceutics Classification 
System [44]. 
Concerning the mechanisms of action, DAP combines both antimicrobial properties 
and anti-inflammatory effects resembling those of non-steroidal anti-inflammatory 
drugs [43]. As it is an analogue of p-aminobenzoic acid (PABA) its bacteriostatic 
activity is due to the competitive inhibition of the enzyme dihydrofolate synthetase, 
which is involved in the folate biosynthesis pathway in M. leprae [13, 44-46]. 
After oral administration, DAP is almost completely absorbed from the gastrointestinal 
tract (GIT) with a bioavailability of about 80%. The peak serum concentrations are 
generally attained within 2 to 8 h, and its half-life time is between 24 to 30 h [41, 47]. 
DAP is distributed through all organs and is able to cross the blood–brain and placenta 
barriers, being detectable in breast milk [47]. This antibacterial agent undergoes 
enterohepatic circulation after absorption, being metabolized both by the liver and 
activated polymorphonuclear leukocytes or mononuclear cells. The primary 
metabolites are products of acetylation by N-acetyltransferase and hydroxylation by 
cytochrome P-450 enzymes, originating monoacetyl-dapsone (Figure 5B) and dapsone 
hydroxylamine (Figure 5C), respectively [41, 47]. Approximately 20% of DAP is 
eliminated in urine as unchanged drug and 70% to 85% as water-soluble metabolites. 
Additionally, a small amount may be excreted in feces [47].  
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Figure 5. Chemical structures of (A) dapsone and its primary metabolites: (B) N-
acetyltransferase (monoacetyl-dapsone) and (C) dapsone hydroxylamine (cytochrome 
P-450 enzymes). 
 
Adverse reactions related to the use of DAP ranged from digestive problems such as 
nausea, vomiting to stomatitis. More severe occurrences as toxic hepatitis, cholestatic 
jaundice, cutaneous photosensitivity reactions and psychosis are unusual [48]. The 
metabolites of DAP, mainly hydroxylamine metabolite and other hydroxylated 
metabolites, are associated with a set of adverse effects called “sulfone syndrome” that 
includes fever, malaise, jaundice, exfoliative dermatitis or morbilliform rash, hepatic 
dysfunction, lymphadenopathy, methemoglobinemia, hemolysis, agranulocytosis, and 
hemolytic anemia [33, 41, 48]. 
The number of dapsone-resistant cases increased with the dapsone monotherapy, 
during the 1960s and 1970s [45], which forced the introduction of additional 
antimicrobial agents as clofazimine and rifampicin in the leprosy therapy [34]. One 
proposed mechanism of resistance is a mutation in the M. leprae gene that encodes 
dihydropteroate synthase (DHPS), called folp [13]. DHPS is a key enzyme during the 
folate systhesis, which participate in the condensation of PABA and 7,8-dihydro-6-
hydroxymethylpterin-pyrophosphate to form 7,8-dihydropteroate [46]. 
 
1.8.2.2 Clofazimine 
 
Clofazimine (Figure 6) is a rhimnophenazine which was first synthesized in 1954 as an 
anti-tuberculosis drug [49]. It has been used for the treatment of leprosy since 1969 
[50]. This drug has both antimicrobial and anti-inflammatory activity, which is 
A  B C  
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associated to its efficacy in leprosy treatment as this feature may be potentially useful 
in controlling harmful ENL and RR in leprosy treatment [51].  
The phenazine nucleus with an alkylimino and phenyl substituents are key features of 
the riminophenazines and essential for antimicrobial activity, varying according to the 
number and type of halogen atoms on the phenyl substituents [51]. The mechanism of 
action is undefined, but different studies have been suggesting that its antimicrobial 
activity is related to disruption of membrane structure and function [51], or it may act 
by increasing the activity of bacterial phospholipase A2 resulting in the release of 
lysophospholipids, enzymatic hydrolysis products toxic to M. leprae [52]. CFZ was also 
found to cluster with known respiratory modulators on transcriptional analysis, 
indicating that it may inhibit bacterial cell growth by interfering with electron transport 
[50]. 
CLZ is deep red to orange under normal conditions. It is a basic drug, presenting three 
amine groups, which may be protonated and charged at acidic pH and physiological 
conditions. Its color may change according to the pH shift, i.e., in more alkaline 
environment, CLZ remains uncharged and has an intense orange-yellow color; as the 
pH drops, the color became more red, tending to violet (very acidic environment) and it 
becomes more soluble [53, 54]. The changes in CLZ solubility according to pH shifts 
leads to drug precipitation in vivo, mainly along the GIT where different pH conditions 
are found [53, 55]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Chemical structure of clofazimine. 
 
CLZ has very low solubility in water, being considered virtually insoluble, and highly 
lipophilic (logP > 7) which lead to its bioaccumulation as intracellular biocrystals [56]. 
In humans, the absorption of orally administered drug varies considerably (45%–62%) 
depending on whether the drug is taken with or without food. After oral 
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administration, the peak plasma concentration is after 8-12 h, depending on fed state 
[51]. Once absorbed, it concentrates in lipid-rich tissues, primarily at the 
reticuloendothelial system, but high concentrations are also found in the breasts, liver 
and intestines [57]. Its high lipophilicity ensures that the drug is slowly eliminated, 
mainly by renal and hepatic routes, with an elimination half-life of 70 days [55, 57, 58]. 
CLZ crosses the placenta and the blood–brain barrier in very small amounts [51]. 
The adverse effects of CLZ are generally dose-related, primarily affecting the skin, eyes 
and the GIT. Reddish-brown discoloration of the skin and conjunctiva are gradually 
reversible on cessation of therapy, even though patients often feel marked and 
stigmatized by this and withdraw CLZ from their treatments as a consequence [32, 51]. 
GIT adverse effects may be mild to moderate (abdominal/epigastric pain, nausea, 
diarrhea, vomiting, gastrointestinal intolerance), or, less frequently, severe (splenic 
infarction, bowel obstruction, bleeding) [51]. 
Recent works have been reporting that CLZ can form complexes with intracellular 
membranes, and precipitate as crystal aggregates, being phagocytized by the 
mononuclear phagocytic system [55, 56]. This phenomenon may be correlated with the 
undesired and toxicological effects, often resulting in patients’ treatment 
noncompliance [59].  
 
1.9 Issues and challenges  
 
Despite significant improvements in leprosy treatment since the introduction of MDT, 
the global incidence remains high, and patients often have long-term complications 
associated with the disease [1]. Moreover, the availability of MDT in providing a 
microbiological cure is not enough to prevent nerve damage and sequelae associated 
with leprosy reactions [11], and the statistics commonly do not capture the disability 
and dysfunction that remain after treatment [1]. 
The treatment completion rates reported are sub-optimal in most of the leprosy 
programs. This highlights the risk of antimicrobial resistance in leprosy, which cannot 
be ignored [3]. The idea of shortening the duration of MB treatment through the U-
MDT regimen associated with the non-supervision of daily-drugs administration (DAP 
and CLZ) may aggravate the resistance issue [9]. Thus, research in the therapy of 
leprosy is still needed, and some efforts must be done to improve delivery of drugs, 
compliance of patients, implement the prescribed drug regimens by medical staff 
associated with effective methods for monitoring drug resistance [5, 10, 11]. 
While there appears to be a need for alternative bactericidal agents and more 
combinations that can be used in leprosy therapy, these are currently limited [12] and 
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unfortunately, there is little novel drugs being explored for future treatment of leprosy 
[13]. 
 
2. Towards the improvement of leprosy MDT: the role of new drug 
delivery strategies 
 
The therapeutic potential of leprosy drugs is greatly limited by their physicochemical 
features, specially their insolubility in water [14]. This fact is especially relevant for 
daily dosages, i.e., for DAP and CLZ as they play an important role in the success of 
MDT. Poorly water-soluble drugs often exhibit slow dissolution in the GIT, ultimately 
limiting their absorption [60, 61], resulting in low bioavailability after oral 
administration. The poor bioavailability commonly result into adjustment in the 
administered dosage aiming to reach the therapeutic range, which may aggravate 
toxicity [62]. Several approaches have been used to overcome drawbacks associated 
with poorly water-soluble drugs including micronization, salt formation, use of pro-
drug, use of surfactant and lipids, co- solvents, nanocarriers, cyclodextrins, amorphous 
solid dispersions, and others [62]. Albeit, amorphous solid dispersions and 
nanocarriers present interesting advantages compared to other techniques, and seem 
to be promising strategies as drug delivery systems. The next sections will address in 
detail some of the most common techniques used for this purpose.  
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B. Solid Dispersions1 
 
 
1. Introduction 
 
In the pharmaceutical industry, a great effort has been made in the field of drug 
discovery, with the aim of improving existing therapies. During the compound 
screening, the five key physicochemical properties includes pKa, solubility, 
permeability, stability and lipophilicity [1]. Although, the poor solubility tops the list of 
undesirable compound properties [2]. Approximately 40% of potential new drugs 
identified by pharmaceutical companies are poorly soluble in water [3-5]. 
The aqueous solubility of a drug is a critical parameter of its dissolution rate during the 
biopharmaceutical phase of pharmaceutical products. The limited dissolution rate 
arising from low solubility frequently results in low bioavailability of orally 
administered drugs [6]. In such cases, an increase of the dose would be required until 
the blood drug concentration reaches the therapeutic range, which sometimes causes 
topical toxicity in the gastrointestinal tract upon oral administration [6]. 
                                                   
1 Published in: Chaves, L., et al. "Quality by design: discussing and assessing the solid dispersions risk." 
Current Drug Delivery 11.2 (2014): 253-269. 
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 Improvement of oral bioavailability of poorly water-soluble drugs remains one of the 
most challenging aspects of drug development. Many technologies are available and 
have commonly been used to overcome drawbacks associated with poorly water-soluble 
drugs includes micronization, salt formation, use of pro-drug, use of surfactant and 
lipids, co-solvents, nanoparticles, cyclodextrins, amorphous solid dispersions, and 
others [7, 8]. 
Despite the variety of techniques that commonly have been used to increase dissolution 
rate of the drug, there are few practical limitations and the desired bioavailability 
enhancement may not always be achieved [7, 9]. 
One such formulation approach that has been shown to significantly enhance 
dissolution of such drugs is to formulate Solid Dispersions (SD). SD involves the 
dispersion of one or more active ingredients in an inert carrier or matrix at solid state 
[10]. These systems can increase dissolution rate and bioavailability of water insoluble 
drugs since, when they are exposed to aqueous media, the carrier dissolves, and the 
drug is released as very fine colloidal particles [7, 9] 
In drug product development, the formulation design of a drug product with high drug 
load is most of the times difficult to achieve. Increasing drug load might result in poor 
powder properties, such as poor powder flowability and sticking tendency during 
granulation and tableting. In addition, the manufacturing cost would increase since a 
large amount of drug substance might be consumed to develop and manufacture the 
drug product [3, 6, 11, 12]. In this way, some problems limit the studies of solid 
dispersion commercial application including preparation method, the reproducibility of 
the physical and chemical properties, dosage formulation, manufacturing process and 
large-scale chemical stability of the drug and vehicle [12-14]. 
Most studies elucidated separately either the influence of formulation factors or process 
factors on solid dispersion stability [15-18]. During recent years, the Quality by Design 
(QbD) approach has begun to change drug development, and focus on the science of 
production, which shifted from an univariate empirical understanding for a systematic 
multivariate process in order to construction a systematically quality in the final 
pharmaceutical product [16].  
QbD is a broad term that encompasses predefined target quality, with certain 
predictable quality through desired and predetermined specifications. 
Physicochemical, physiological, pharmacological and clinical considerations are 
relevant to obtain desired products that are safe and effective [19]. To attain this 
purpose, it is expected that variables associated with raw materials characteristics, 
product design, process and scale-up issues should be thoroughly investigated. 
Therefore, a very useful component of the QbD is the understanding of factors and 
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their interaction effects by a desired set of experiments. To understand the variables 
and their interactions, many statistical experimental designs have been recognized as 
useful techniques [20]. 
Although the QbD concept seems promising, currently, limited knowledge exists in the 
field of SD on the importance of process factors, as compared to formulation factors, 
for the physical stability of the drug [16]. 
The objectives of this review is to define some possible variables during the 
development process, formulation and production of SD as an alternative to increasing 
the solubility of poorly soluble drugs, introducing and applying the QbD concept. 
 
1.1 Pharmaceutical Quality by Design  
 
Pharmaceutical QbD is “a systematic approach to pharmaceutical development that 
begins with predefined objectives and emphasizes product and process understanding 
based on sound science and quality risk management” as defined by the International 
Conference on Harmonization (ICH) Q8 guideline [21-23]. 
In other words, it could be defined as the development of scientific understanding of 
critical process and product attributes, designing controls and testing based on the 
limits of scientific understanding at development stage, and utilizing this knowledge 
over the product’s lifecycle to operate in continuous improvement [22]. 
The use of QbD principles increases process knowledge and product understanding, 
once during product development provides opportunities to facilitate innovation and 
continual improvement throughout the product lifecycle, compared to traditional 
approaches [22]. Besides promotes a higher level of assurance of product quality; 
increase efficiency of manufacturing process and reduce manufacturing cost and 
product rejects; minimize/eliminate potential compliance actions, costly penalties and 
re-calls; enhance opportunities for first cycle approval; maintains opportunities for 
continual improvement [24]. 
Some elements of the QbD framework have been used for many years. Besides the 
spotlight on these techniques has intensified in the pharmaceutical industry, in 
particular with the United States Food an Administration’s (FDA) publication of their 
report “Pharmaceutical CGMPs for the 21st Century: A Risk-Based Approach to Product 
Quality Regulation Incorporating an Integrated Quality Systems Approach” [25]. 
The need for improving on-line monitoring and control methods to maintain high 
product quality during manufacturing operations [26] led to, shortly afterwards, the 
FDA guidance publication “PAT — A Framework for Innovative Pharmaceutical 
Development, Manufacturing and Quality Assurance” [27] in which was defined the 
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Process Analytical Technology (PAT) concept as a system for designing, analyzing, and 
controlling manufacturing through timely measurements (i.e., during processing) of 
critical quality and performance attributes of raw and in-process materials and 
processes, with the goal of ensuring final product quality [28]. In this way, the PAT 
concept was introduced by FDA as an initiative to bring an improved understanding of 
pharmaceutical manufacturing processes to increase the quality of their products [26, 
29]. 
The move towards science-based development and manufacturing was embraced at an 
international level by ICH [30]. Four guidelines that support this vision, namely ICH 
Q8 on Pharmaceutical Development [23], ICH Q9 on Quality Risk-Management [31], 
ICH Q10 on Quality Systems [32] and the latest one, the Q11 on Development and 
manufacture of drug substances [33] were developed. ICH Q8 (R2), currently at Step 4, 
describes the principles of QbD and provides further explanations of key concepts [23].  
QbD identifies characteristics that are critical to quality, translates them into the 
attributes that the drug product should possess, and establishes how the critical process 
parameters can be varied in order to achieve the desired characteristics. It means 
designing and developing formulations and manufacturing processes to ensure 
predefined product quality objectives [21, 34]. For these purpose, the relationships 
between formulation (drug and excipient attributes) and sources of variability of the 
manufacturing process should be established and identified. This knowledge is then 
used to implement a flexible and robust manufacturing process and products with the 
desired quality over time. [17, 21, 34]. 
 
1.1.1 Product Design 
 
In the QbD context, for the product presents a consistent quality the sources of 
variability must be very well understood, which could come from the raw materials, the 
environment and/or the process itself. Afterwards, variability must be managed in such 
a way that ensures the final product quality [35-37].  
A complete study QbD involves some important steps. At first, the Target Product 
Quality Profile (TPQP) must be set, defining the quality profile that the product should 
present, always based on prior scientific knowledge and its relevance in vivo. 
Subsequently, it is necessary to perform the product and process design, in order to 
ensure the quality profile predetermined. In this stage is important to identify, among 
the process parameters, which are the critical quality attributes (CQAs) as well as the 
sources of variability exist for risk assessment process. Once the CQAs are known, 
Design of Experiment (DoE) should be applied to perform a screening of the levels that 
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should be adopted during the experiments and defining the Design Space (DS) that 
means determining the real values which can be worked with in order to obtain the 
desired quality profile. Finally, control the manufacturing process to ensure product 
quality over time through an operation within the design space established [20, 38]. 
The figure 1 can summarize the QbD steps. 
 
 
 
 
Figure 1. Overview of QbD [20]. 
 
 
The TPQP is the quality characteristics that the drug product should possess to 
reproducibly deliver the therapeutic benefit promised in the label [39]. Some physical, 
chemical, and biological properties must be evaluated in order to design and develop a 
robust product [23]. Physical properties may include physical description (particle size, 
shape, and distribution), polymorphism, aqueous solubility as function of pH, 
hygroscopicity, and melting points while chemical properties include pKa, chemical 
stability in solid state and in solution as well as photolytic, hydrolytic and oxidative 
stability [40]. Biological properties, on the other hand, include partition coefficient, 
membrane permeability, and/or oral bioavailability [1, 21].  
CQAs could be defined as physical, chemical, biological or microbiological properties or 
characteristics that need to be controlled (directly or indirectly) to ensure product 
quality [20, 23]. The relationship between the process inputs (material attributes and 
process parameters) and the CQAs can be described in the Design Space. DS is defined 
as the space in which the quality of the product can be built. The wider the design 
space, the more robust and flexible the process is to accommodate variations. Risk 
assessment, multivariate experimental design, literature and prior 
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experience/knowledge contribute in defining the design space [37, 41, 42]. The ICH Q8 
defines design space as “the multidimensional combination and interaction of input 
variables (material attributes) and process parameters that have been demonstrated 
to provide assurance of quality. Working within the design space is not considered as 
a change; however, the movement out of the design space is considered a change and 
would normally initiate a regulatory post approval change process. Design space is 
proposed by the applicant and is subject to the regulatory assessment and approval” 
[23]. 
To establish the design space, a design-of-experiments (DoE) approach was used 
effectively to determine the multi-dimensional relationships among causal factors and 
response variables [43]. In the DoE approach, process variables are first ‘screened’ to 
determine which are important to the outcome. This is followed up by ‘optimization’ 
where the best settings for the important variables are determined. In particular, 
factorial designs and response surface methodologies have been successfully applied in 
both discovery and development [37, 41, 42]. Thus, it is generally aimed to determine 
the levels of input variables from which a robust product with high quality may be 
produced. As each unit operation has many input and output variables as well as 
process parameters, it is impossible to experimentally investigate all of them. DoE 
results can help identify optimal conditions, the critical factors that most influence 
CQAs and those that do not, as well as details such as the existence of interactions and 
synergies between factors [21, 44]. 
 
1.1.2 Process Design 
 
As mentioned before, not only the product must be designed, but also the control of the 
manufacturing process should be relevant. It is important to note that the goal of 
designing the process is not to eradicate variability but develop a process that can 
accommodate the range of acceptable variability for maintaining product quality [45]. 
The process design is the initial stage of process development where an outline of the 
manufacturing processes is identified and all the sources of variability as facility, 
equipment, material transfer, and manufacturing variables, should be taken into 
account [40]. Depending upon the product being developed, some knowledge about the 
type of process may be necessary, in order to conduct preliminary feasibility studies. 
For this purpose, the selection of the suitable process depends upon the formulation 
and the properties of the materials to be used [21, 24]. In this context, raw materials, 
process parameters and quality attributes must be investigated.  
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Physical, chemical or microbiological properties or characteristic of an input or output 
material is defined as an attribute, as well as the quality and quantity of drug substance, 
namely identity, purity, biological activity and stability [33]. On the other hand, process 
parameters include the type of equipment and equipment settings, batch size, 
operating conditions (e.g., time, temperature, pressure, pH, and speed), and 
environmental conditions such as moisture [21]. 
A pharmaceutical manufacturing process is usually composed of a series of unit 
operations, which is a discrete activity that involves physical changes, such as mixing, 
milling, granulation, drying, compaction, and coating. Therefore, the possibility of 
alterations in drug form during process development, i.e., change in the polymorphic 
form, must be considered [46]. According to ICH Q11 [33], all the potential drug 
alterations related to the process, from the beginning to the end, have to be controlled. 
A useful approach to process design and optimization is to identify all the Critical 
Process Parameters (CPP) that could potentially affect the quality or performance of 
the product in order to and prepare a process optimization protocol [40]. In other 
words, CPP could be defined as any measurable parameter whose variability has an 
impact on CQAs, and for this reason, should be monitored and controlled to ensure the 
TPQP [23, 39]. 
Designing a process where the operating limits for one or more critical parameters are 
too narrow is a challenge, and frequently cannot be consistently achieved [40]. The 
ability of a manufacturing process to tolerate the expected variability of raw materials, 
operating conditions, process equipment, environmental conditions and human factors 
is referred to as robustness [47]. In process robustness studies, effects of variations in 
process parameters aid to identify CPPs which can potentially affect product quality or 
performance, establishes limits within which the quality of drug product is assured, 
and, in addition, avoid any potential impact of scale-up [48]. Nonetheless, when 
considering scale-up additional experimental work may be required once some critical 
process parameters are scale dependent and therefore, the model generated at the 
small scale could not be predictive at the large scale [21]. 
The QbD concept has been applied by several authors, who intended to improve 
pharmaceutical product design and/or process. In the Table 1 it could be seen some 
studies realized in this framework, in which were evaluated CQAs, in the case of 
formulation design, or CPPs in the case of process optimization. 
New technologies for the improvement of leprosy MDT  
		
 36 
Table 1. Studies realizes in the framework of pharmaceutical QbD. 
PRODUCT DESIGN PROCESS DESIGN 
Pharmaceutical 
Formulation 
CQAs Ref. Pharmaceutical 
Process 
CPPs Ref. 
 
Solid Lipid Nanoparticle 
(SLN) Formulation 
Surface morphology 
Particle size 
Zeta potential 
Drug encapsulation efficiency 
Release behavior 
 
 
[49] 
 
 
Fluid bed granulation 
Inlet air temperature  
Binder spray rate  
Air flow rate  
(Spraying and drying phases) 
 
[36] 
 
 
Liposome formulation 
Particle size 
Zeta-potential,  
Drug encapsulation efficiency 
 
[38] 
 
 
Microfluidization 
Milling time 
Microfluidization pressure  
Stabilizer type  
Processing temperature 
Stabilizer concentration 
[50] 
 
 
Matrix tablets 
Dissolution efficiency  
Time necessary to dissolve 
10% 
 
 
[51] 
 
 
 
Lyophilization 
Primary drying temperature 
Secondary drying temperature 
and time  
Chamber pressure 
Freeze ramp rate 
 
 
[52] 
 
 
Dispersible tablet 
Particle size 
Superdisintegrants  
Tablet hardness 
Lubricant level 
Packaging material 
 
 
[53] 
 
 
Spray Drying 
 
 
Inlet temperature 
Spray flow rate 
Feed rate 
 
 
[54] 
 
 
Blends 
 
 
Particle size and weight ratio 
Drug/excipients 
Particle shape 
Material density 
Cohesity 
 
 
[55] 
 
 
Blending 
Order of addition 
Blend RPM 
Blending time 
Fill volume 
Equipment 
 
 
[55] 
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1.1.3 QbD: An Approach based on Biopharmaceutical Classification System 
(BCS) 
 
Establishing boundaries based on the clinical impact of the product design and 
manufacturing process is a challenge for pharmaceutical scientists, once manufacturing 
and composition variables need to be linked in order to establish the product clinical 
performance [56]. Pharmacokinetic parameters are considered to have a crucial role in the 
selection process and product development. Fundamental Biopharmaceutics Classification 
System (BCS) parameters, such as permeability, solubility and fraction dose absorbed 
should be useful in both the discovery and early development process [3, 57].  
Class I compounds have a high solubility and permeability; therefore, their bioavailability 
will depend solely on the gastric emptying rate. For class II compounds with a low 
aqueous solubility and sufficient permeability the dissolution will be the rate limiting step 
[10]. Class III compounds have sufficient solubility but poor permeability and hence the 
absorption rate will be determined by passage through the gut wall. In the case of class IV 
compounds with both low solubility and permeability, the rate limiting step will differ case 
by case [6, 58].  
 The BCS has proven to be an extremely useful guiding tool for the prediction of in vivo 
performance of drug substances and development of new drug delivery system, from early 
to clinical stages, in order to ensure the performance of pharmaceutical product [57]. 
Thus, a greater understanding of dissolution and absorption behavior of drugs with low 
aqueous solubility is required to successfully formulate them into bioavailable drug 
products [3, 6, 9]. 
Dissolution is the only test that measures in vitro drug release as a function of time, which 
may reflect the reproducibility of the manufacturing process and, in some cases, the drug's 
in vivo performance [59]. Under the QbD framework, the dissolution tests should be 
developed to reflect in vivo performance as much as possible and must be representative 
to the conditions in the gastrointestinal tract [60]. 
Several physicochemical factors control the dissolution rate of the drugs. The factors 
affecting the drug dissolution rate are defined as the effective surface area, the diffusion 
coefficient, the diffusion layer thickness, the saturation solubility, the amount of dissolved 
drug, and the volume of dissolution media. Increases in the saturation solubility and the 
effective surface area have a positive impact on the dissolution rate of the drugs, and these 
factors could be increased by efforts of pre-formulation study and formulation design [6]. 
Crystal modification, particle size reduction, self-emulsification, pH modification, and 
amorphization are considered to be effective for improving the dissolution behavior of 
drugs poor water soluble [2]. 
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1.2 Solid dispersions 
 
The improvement of the drug water-solubility by SD is already described. The mixture of a 
poorly water soluble drug and highly soluble carriers creates a surface area in the 
dissolution medium, resulting in an increased dissolution rate and consequently improved 
bioavailability [61]. The amorphous state is reported to have more solubility as compared 
to crystalline state by the fact that in the amorphous state the molecules are arranged 
randomly and no energy is required to break, what happens with the ordered arrangement 
of crystalline state [62]. In figure 2, it could be seen the types of SD that may be achieved 
depending on polymer and drug characteristics. The drug can be dispersed in amorphous 
or in crystalline particles. When the drug is dispersed in the matrix in a single phase, it is 
called solid solution [63].  
The use of SD has been extensively studied. Despite all the advantages, the commercial 
use of SD has been very limited, primarily due to the manufacturing difficulties and 
stability problems. A significant problem with the systems is the present difficulties in the 
formulation development and subsequent scaling-up. Thermo sensitive drugs and carriers 
may be destabilized during the melting or solvent-facilitated melting process since high 
melting temperatures are usually applied.  
On the other hand, it is difficult to scale up the formulation of SD. The soft and tacky 
properties of solid dispersion powders result in poor flow ability, mixing property and 
compressibility, which may complicate the operations and render poor reproducibility of 
physicochemical properties of final products.  
 
 
 
 
 
 
 
 
Figure 2. The solid dispersion formed from amorphous drug in a single phase (solid 
solution); amorphous drug in a separate-phase dispersion; and crystalline drug in a 
polymer matrix [63]. 
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Despite extensive expertise with SD, they are not broadly used in commercial products, 
mainly because there is the possibility that during processing (mechanical stress) or 
storage (temperature and humidity stress) the amorphous state may undergo 
crystallization and dissolution rate decrease with ageing. The effect of moisture on the 
storage stability of amorphous pharmaceuticals is also a significant concern, because it 
may increase drug mobility and promote drug crystallization. Moreover, most of the 
polymers used in SD can absorb moisture, which may result in phase separation, crystal 
growth or conversion from the amorphous to the crystalline state or from a metastable 
crystalline form to a more stable structure during storage [64]. Table 2 can summarize the 
main methods of manufacturing, with theirs advantages and disadvantages; and the 
carriers commonly used for SD. 
 
Table 2. Main methods of manufacturing, and carriers commonly used for SD 
METHODS OF OBTAINMENT CARRIERS USED 
Advantage  Disadvantage Polymeric material: 
 poly(vinylpyrrolidone) (PVP), 
poly(vinylpyrrolidone/vinyl acetate copolymer), 
hydroxypropylmethyl cellulose (HPMC), 
hydroxypropylmethyl cellulose acetate/succinate 
(HPMCAS), hydroxypropylmethyl cellulose phthalate 
(HPMCP), acrylic acid-based enteric Eudragit systems. 
Solvent evaporation 
 
Easy preparation 
Feasible scale up 
 
Toxicity 
Residual amount 
 
Melting Sugars: 
sucrose, dextrose, sorbitol, maltose, galactose, xylitol, 
chitosan, inulin, dextrin, cyclodextrin) 
 
Easy preparation 
Feasible scale up 
 
 
Drug degradation 
Low solubility in 
molten carrier 
Acids: 
citric acid, tartaric acid, succinic acid 
Antisolvent Surfactants: 
polyoxyethylene stearate, poloxamer, deoxycholic acid, 
tweens, spans, compritol 888 ATO, gelucire 44/14 and 
50/13, sodium lauryl sulfate, phospholipid) 
 
 
Solvent-free 
 
 
 
Low solubility in 
CO2 
Limited scale up 
Miscellenous:  
urea, urethane, hydroxyalkyl xanthene, 
pentaerythritol) 
 
In this section, will be discussed the sources of variability that may affect the quality of SD, 
with the aim to make a risk assessment for the design and production of these system. 
 
1.2.1 Methods of obtainment 
 
Several studies have demonstrated that physical-chemical properties of solid dispersion 
obtained by different methods of preparation are directly related [16, 65]. This fact is 
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established as a prerequisite in solid dispersion developing, being necessary to evaluate 
interference of the method applied, in order to choose which is most efficient regarding to 
the dissolution and stability of the products obtained under the conditions of storage [13]. 
For many preparation techniques, demixing (partially or complete), and formation of 
different phases is observed. Phase separations like crystallization or formation of 
amorphous drug clusters are difficult to control and therefore unwanted [9], which may 
condition the method of preparation of SD.  
There are mainly two processes for manufacture SD: the melt method, and those which 
involves solvent evaporation techniques [66]. Other techniques have gained increasing, as 
supercritical antisolvent methods, [65, 67] which will be discussed further. 
Although the manufacturing methods to obtain SD be quite simple once the processing 
involves just few steps, they are individualized depending on the interaction between drug 
and carrier [62].  
 
1.2.1.1 Solvent evaporation method 
 
The solvent evaporation method aims to dissolve the drug and carrier simultaneously in a 
common solvent, followed by the removal of solvent by evaporation [2]. The solvent can 
be removed by various processes including vacuum drying, heating of the mixture, slow 
evaporation of the solvent at low temperature, the rotary evaporators, spray drying and 
freeze drying [68]. 
Identification of a common solvent for both drug and carrier can be problematic and 
complete solvent removal from the product can be a lengthy process [68]. Furthermore, 
the disadvantage of the solvent method is the use of organic solvents with toxicity 
problems, safety hazards and solvent residuals and also the possible precipitation of the 
drug into various polymorphic forms with different solubilities, which could vary 
bioavailability of the drug. [69]. 
Various strategies have been applied to dissolve the lipophilic drug and hydrophilic matrix 
material together in one solution. Low drug concentrations are used to dissolve both drug 
and matrix material in water, but this requires evaporation of high amounts of solvent, 
making the process expensive and impractical [61].  
Some solubilizers or surfactants, as cyclodextrins, inulin, polysorbates, poloxamers, 
among others, have the capacity to increase the aqueous solubility of the drug 
substantially [66]. However, their use must be cautious once they may change the physical 
properties of the matrix, increase the water uptake of the formulation and, in addition, 
they can be toxic and not well tolerated in vivo [61, 70]  
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The nature of the solvent and its rate of evaporation and temperature are particularly 
critical in this method [16]. Chloroform [71], dichloromethane, ethanol [72] methanol 
[18], or mixtures of some of these solvents [73, 74], have been used to dissolve both drug 
and matrix simultaneously.  
 However, according to the ICH-Guidelines, these solvents belong to Class I, comprising 
the most toxic solvents [75]. Therefore, the use of these solvents is unacceptable and 
impractical because the amount of residual solvent present in the solid dispersion after 
drying has to be below the detection limits. One strategy for the dissolution of both drug 
and matrix is the use of solvent mixtures, in order to decrease the amount of each residual 
solvent and reduce toxicity. Water and ethanol or dichloromethane and have been used for 
this purpose. However, dissolution of drug and matrix in these mixtures is not always 
possible in the required concentration or ratio [13, 61]. 
Another challenge in the solvent method is to prevent phase separation, e.g. crystallization 
of either drug or matrix, during removal of the solvent(s). Drying at high temperatures 
speeds up the process and reduces the time available for phase separation. On the other 
hand, at high temperatures the molecular mobility of drug and matrix remains high, 
favoring phase separation [61].  
Spray-drying is one of the most commonly used solvent evaporation procedures in the 
production of SD [66]. The spray drying process consists of four basic stages: atomization 
of the liquid, mixing of the liquid with the drying gas, evaporation of the liquid and 
separation of the dried particles from the gas. Due to the large specific surface area offered 
by the droplets, the solvent rapidly evaporates and the solid dispersion is formed within 
seconds, which may be fast enough to prevent phase separation [76]. Moreover, the SD 
prepared by spray drying consist of particles of which the size may be customized by 
changing the droplet size to meet the requirements for further processing or application 
(e.g., free flowing particles or articles for inhalation). Spray drying usually yields drug in 
the amorphous state, however sometimes the drug may have (partially) crystallized during 
processing [61]. 
The achievement of the solid dispersion by spray drying involves many variables such as 
the solvent used and the concentration of the drug and excipients in solution. Since many 
excipients are polymers, they can influence the non-covalent interactions between 
different solutes in solution [77]. 
SD can also be dried by the ultra-rapid freezing, frequently termed lyophilization [65]. The 
first step is a freezing stage, where water is converted into ice and the solutes are 
crystallized or transformed into solid. Later, it is followed by a drying step, which could be 
divided in two stages: Primary drying, where the ice crystals are removed by sublimation 
under vacuum (ice sublimation); and secondary drying (moisture desorption), where most 
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of the unfrozen water is removed by desorption [28, 78, 79]. After freeze-drying, the 
resulting product is a dry porous mass, very stable, with approximately the same size and 
shape as the original frozen mass [78, 79]. During lyophilization, it is crucial to ensure that 
the endpoint of all intermediate process steps is reached before the next process step is 
initiated and to monitor the solid state of the freeze-dried product [28]. The critical 
formulation properties include the collapse temperature of the formulation, the stability of 
the drug, and the properties of the excipients used [80, 81]. 
 
1.2.1.2  Melting method 
 
The melting method involves melting of a physical mixture of drug and carrier to the 
liquid state followed by cooling until solidification [68]. The polymer could also be melted 
first, and then the drug incorporated into the melted matrix, followed by a Cooling. The 
cooling processes can be by room temperature or flash. Flash cooling could result in phase 
separation in some cases [62].  
Although frequently applied, the melt method has serious limitations. This method is not 
suitable for thermolabile drugs and incomplete miscibility is observed between the solid 
drug [61]. When drug and matrix are incompatible two liquid phases or a suspension can 
be observed in the heated mixture, which results in an inhomogeneous solid dispersion 
[13]. This can be prevented by using surfactants. In addition, a problem can arise during 
cooling when the drug-matrix miscibility changes. In this case phase separation can occur. 
Indeed, it was observed that when the mixture was slowly cooled, crystalline drug 
occurred, whereas fast cooling yielded amorphous SD, degradation of the drug and or 
matrix can occur during heating to temperatures necessary to fuse matrix and drug [61]. 
Because of the toxicity and environmental problems associated with the use of organic 
solvents, the application of this method is advantageous in the preparation of SD when the 
drug has thermal stability. However, its use is inadequate when polymorphism occurs due 
to the transition that may occur during the merger between the polymorphic forms [13].  
SD can be also prepared through a manufacturing method that involves both solvent 
evaporation and melting method in association. This method is called melt evaporation 
method. It involves preparation of SD by dissolving the drug in an appropriate solvent and 
then incorporating the solution directly into the melted polymer, which is then evaporated 
until the solvent layer disappears and forms a free-solvent film. The film is further dried to 
constant weight. This process is advantageous because the drug could be incorporated into 
a little amount of an organic solvent, which can be, in turn, incorporated into polymer 
without significant loss of its solid property. It is possible that the selected solvent or 
dissolved drug may not be miscible with the melt of the polymer and also the solvent used 
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may affect the polymorphic form of the drug, which precipitates as the solid dispersion. 
Besides, the efficacy and safety of SD with low therapeutic dose drugs could be 
compromised [82]. 
A number of convenient modifications of melt method have been developed to overcome 
problem of thermo-stability of drugs during melting process, which include hot melt 
extrusion, hot spin melting, meltrex-use of twin-screw extruder [62]. These techniques 
provide the opportunity to intensively mix a drug with a carrier at elevated temperatures 
in a continuous mode, without the need of a solvent [4, 12, 83]. Compared to the 
traditional fusion method, these techniques offer the possibility of continuous production, 
which makes it suitable for large-scale production. Furthermore, the product is easier to 
handle because at the outlet of the extruder the shape can be adapted to the next 
processing step without grinding [61]. The major disadvantage is the use of heat and the 
application of shear forces on the drug, which limits its use to heat stable compounds only 
[83]. 
One of the major problems associated with the melting method is that this process 
involves higher drug loadings and thus, there is a need for plasticizers to facilitate thermal 
processing, which can compromise the compositional glass transition temperature of the 
system, leading to the increase of the rate of drug crystallization [84]. In order to enhance 
the long term stability of amorphous systems, a novel high energy mixing process, 
KinetiSol® dispersing, was developed focused on providing improved compositional glass 
transition temperatures. In this processing, paddles within a cylindrical chamber 
containing raw materials rapidly rotate, generating all heat energy by a combination of 
shear and friction. The temperature in the chamber rapidly increase from room 
temperature to the desired ejection temperature, allowing for minimal thermal exposure 
[85]. The KinetiSol® dispersing has been already applied to prepare single phase SD of 
itraconazole in hypromellose, [86] and hydrocortisone [87]. 
With this technique, currently used in commercial polymer production, it is possible to 
prepare SD without the aid of solvents or plasticizers, which may translate into improved 
physicochemical properties and increased homogeneity of SD [84]. 
 
1.2.1.3  Supercritical antisolvent method 
 
Supercritical fluid methods are mostly applied with CO2, which is used as either a solvent 
for drug and matrix or as an antisolvent. When supercritical CO2 is used as solvent, matrix 
and drug are dissolved and sprayed through a nozzle, into an expansion vessel with lower 
pressure and particles are immediately formed. The adiabatic expansion of the mixture 
results in rapid cooling. This technique does not require the use of organic solvents and 
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since CO2 is considered environmentally friendly, this technique is referred to as “solvent 
free”. The application of this technique is very limited, because the solubility in CO2 of 
most pharmaceutical compounds is very low (<0.01wt-%) and decreases with increasing 
polarity. Therefore, scaling up this process to kilogram-scale will be impractical [12, 61]. 
 
1.2.2 Carriers used in SD 
 
It is crucial to select the right carrier based on the chemical structure of the drugs [76]. 
The selection of the carrier has the influence on the dissolution characteristics of the 
dispersed drug, since the dissolution rate of one component from the surface is affected by 
the other component in a multiple component mixture [4, 9]. The presence of functional 
groups that are either hydrogen donors or acceptors is an additional benefit, since specific 
interactions increase the solid solubility of the drug into its carrier and also seem to play 
an important role in inhibiting crystallization of a drug from a glass solution. The carrier 
should be pharmacologically inert and safe [4, 88]. 
Also, regarding to manufacturing SD, thermal stability and melt viscosity need to be 
considered for systems prepared by Hot-Melt extrusion; solubility in organic solvents is a 
prerequisite for carriers that are used for producing SD via solvent methods. In terms of 
drug release, it is obvious that the carrier should be soluble in water. The dissolved carrier 
will also influence the supersaturated drug solution that is formed following dissolution. 
Some carriers solubilize the released drug, whereas others will stabilize the supersaturated 
drug solution. A thorough insight in all of these aspects is imperative for a rational 
formulation strategy [4, 88]. 
The mainly carriers commonly used for SD are acids (citric acid, tartaric acid, succinic 
acid); sugars (sucrose, dextrose, sorbitol, maltose, galactose, xylitol); polymeric material 
(Polyvinyl pyrollidone, polyethylene glycol 4000 & 6000, carboxymythyl cellulose, 
hydroxypropylvcellulose, guar gum, xanthan gum, sodium alginate, dextrin, cyclodextrin); 
surfactants (polyoxyethylene stearate, poloxamer, deoxycholic acid, tweens and spans); 
and miscellenous (urea, urethane, hydroxyalkyl xanthene, pentaerythritol) [89]. 
Although, SD are usually prepared with water soluble low melting point synthetic 
polymers such as polyvinyl pyrrolidone (PVP), mannitol or polyethylene glycols (PEGs). 
These polymers show superior results in drug dissolution enhancement, but the amount of 
these polymers required is relatively large, around 1:2 to 1:8 (drug/ polymer) ratio. An 
obstacle of solid dispersion technology in pharmaceutical product development is that a 
large amount of carrier, i.e., more than 50% to 80% w/w, is required to achieve the 
desired dissolution [89]. 
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PEGs are widely used as vehicles for SD with the melting method because of their low 
melting point, rapid solidification rate, capability of forming solid drug solutions, low 
toxicity and low costs. This often results in SD in which many drugs are incorporated as 
separate molecules in the helical structure present in a crystalline PEG. The helices are 
aligned in orderly fashion, illustrating that PEG easily crystallizes. However, at higher 
drug concentrations, the drug is often present in the crystalline form and the PEG 
dispersion may recrystallize over time, resulting in unstable formulations with lower 
dissolution rates [61, 69]. 
On the other hand, the ability to stabilize the amorphous state of drugs due to inhibition of 
drug recrystallization as well as a rapid solidification rate and low toxicity favors the PVP 
and some derivatives as PVP co-vinylacetate for the preparation of SD. PVPs are 
amorphous polymers with glass transition temperatures between 110 and 180◦C. [61, 69]. 
However, the relatively high glass and melting transitions limit the applicability of these 
polymers for the preparation of SD by the melting method [13]. The mode of incorporation 
of the drug depends on the PVP-drug miscibility and the preparation procedure, and 
therefore, grinding is required to obtain SD as powder that is easy to handle [61, 69].  
 Attempts have been made to increase the degree of drug dispersion by adding surfactants 
to the carrier, which was shown to be effective in originating high polymorphic purity and 
enhanced in vivo bioavailability [66, 70, 90, 91]. Adsorption of surfactant on solid surface 
can modify their hydrophobicity, surface charge, and other key properties that govern 
interfacial processes such as flocculation/dispersion, floatation, wetting, solubilization, 
detergency, and enhanced oil recovery and corrosion inhibition and thereby enhancing 
solubilization. Furthermore, they may help to prevent precipitation and/or protect a fine 
crystalline precipitate from agglomeration into much larger hydrophobic particles [82].  
Some surfactants commonly used are inulin [92], inutec SP [93], compritol 888 ATO [94], 
gelucire 44/14 [95] and 50/13 [96], poloxamers 407/188 [91, 97], polysorbate 80 [98, 99], 
docusate sodium [70, 91], sodium lauryl sulfate [91, 100], phospholipids [101]. 
Poloxamers, includes a group of nonionic surfactants, have attracted considerable 
attention for application in formulation of SD [102-106]. These polymers are widely used 
as emulsifiers, solubilizing agents, and suspension stabilizers in pharmaceutical 
formulations and also act as wetting agents and plasticizers. Besides, have been reported 
for enhancing the solubility and bioavailability of sparingly soluble drugs in solid dosage 
forms [105, 106]. Phospholipids have the advantage of increasing the dissolution rate of 
drugs with low aqueous solubility, but at a much lower carrier concentration. In aqueous 
media, phospholipids disperse spontaneously to form spherical bilayer structures that can 
entrap or sequester the drug, which can be transported to the stationary or diffusion layer 
and subsequently yield more rapid and higher absorption [101]. Gelucires are glyceride-
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based amphiphilic excipients composed of mixtures of mono, di, and tri glycerides with 
PEGs esters of fatty acids [62] Because they present an amphiphilic character, they are 
able to increase significantly the drug bioavailability. 
Despite synthetic carriers have been commonly used to improve the solubility of lipophilic 
drugs, they present some problems, as high hygroscopicity, which may cause instability of 
SD. Therefore, continuous search for new carriers and new techniques have been done, 
which are useful for large-scale manufacturing [107]. 
Recently, the use of semi-synthetic hydrophilic polymers, as gum karaya [107] and 
chitosan [108-110] have been used as carriers to enhance the dissolution rate and 
bioavailability of poorly water-soluble drugs has been demonstrated by some of 
investigators.  
 Chitosan presents a vast number of applications in recent years and it is considered one of 
the most significant materials from the point of view of potential applications [108]. The 
positives attributes of chitosan are, mainly due to its complete biocompatibility, beside it 
is totally biodegradable, non-toxic, and also has a high adsorption capability [111]. From 
the technological point of view, it is miscible with other polymers, which could be very 
advantageous during the design of S formulations. 
 
1.2.3  Techniques for characterization SD 
 
Complete characterization of SD is important to assess quality of innovative and pre-
approved products. Extensive characterization of their stability and physical-chemical 
properties are prerequisites to ensure their efficacy throughout their shelf-life [112]. 
Among the important characteristics, the most relevant are amorphous content, drug 
carrier miscibility, dissolution rate, surface properties, drug carrier interactions and 
physical stability. 
Much effort has been put to differentiate amorphous and crystalline material once even 
small amounts of crystalline material can profoundly affect the in vivo performance of the 
amorphous material [63]. For this purpose, many techniques are available which detect 
the amount of crystalline material in SD. The amount of amorphous material can never be 
measured directly but can be derived from the amount of crystalline material in the 
sample [9]. 
Therefore, characterization of the structural state of the drug substance and their 
unambiguous identification in SD is a priority that still has remained a challenge [113]. 
Several methods for characterize SD, which has potential to evaluate their critical 
parameters are listed in table 3. 
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Amorphous SD is commonly characterized in terms of physical properties such as glass 
transition temperature (Tg), heat capacity, and miscibility [114]. Although, the analysis of 
Tg has been used frequently study once it is the fingerprint of a glassy material [4]. 
The Tg represents the temperature at which the non-equilibrium glass transforms to the 
super cooled liquid [63]. It is well known that compatible blends of amorphous materials 
exhibit one single Tg that is situated between the Tg of the individual components. There 
is a large number of relationships between the Tg of an amorphous system (mainly binary 
systems) and its composition, which seems to be a tool to measure physical stability of 
these systems. [88].  
Besides, characterization of in vitro dissolution performance and, in particular, 
characterization of the supersaturated state with polymer-modulated interactions is 
desired to understand supersaturatable systems [115]. Some considerations regarding 
physical stability of SD and biopharmaceutical considerations will be given in the next 
sections. 
 
Table 3. Methods for evaluate critical parameters of SD 
NMR: Nuclear Magnetic Resonance; FT-IR: Fourier transform infrared; DSC: Differential Scanning 
Calorimetry; XRD: X-ray Diffraction. 
 
There is an increasing demand for new approaches to understand the chemical and 
physical phenomena that occur during pharmaceutical unit operations [116]. With the 
introduction of the concept of PAT, the development of in-process analytics for process 
PARAMETER TECHNIQUE 
Drug–carrier miscibility 
Hot stage microscopy 
DSC  
Powder X-ray Diffraction (XRD) 
NMR 1H Spin lattice relaxation time 
Drug carrier interactions 
 
FT-IR spectroscopy 
Raman spectroscopy 
Solid state NMR 
DSC 
Physical Structure 
Scanning electron microscopy 
Surface area analysis 
Surface properties 
Dynamic vapor sorption 
Inverse gas chromatography 
Atomic force microscopy 
Raman microscopy 
Amorphous content 
 
Polarized light optical microscopy 
Hot stage microscopy 
Humidity stage microscopy 
DSC 
Powder XRD 
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monitoring are new efficient tools that have been used during pharmaceutical 
development, manufacturing, and quality control, maintaining or improving the current 
level of product quality assurance [116, 117]. 
Recently, some optical spectroscopy techniques, as Raman and Near Infrared (NIR) has 
been used a PAT tool (process analyzer) for the in-line and real time once they are non-
destructive and solid samples can be analyzed in their native state without any sample 
preparation [80, 81, 118]. The IR spectra are generated by a change in the dipole moment 
of a molecule, while Raman scattering occurs as a result of changes in its polarisability 
[117, 118]. 
NIR and Raman spectroscopy present a number of applications in the pharmaceutical 
industry. In the case of NIR, it is commonly used for identity substances, measurement of 
water content, monitoring blends, drug substance content, etc. The usefulness of Raman 
spectroscopy, on the other hand, has been applied for monitoring synthesis and 
determination of polymorphic forms of the active component and also blend monitoring 
[118] 
These spectroscopy techniques have been Also Implemented in the solid dispersion design 
/ production framework [119-122]. 
Raman could be a very useful tool to predict the crystallinity of the solid dispersion and 
also monitor the presence of polymorphic forms during and after process manufacturing, 
in both real time and off-line [119, 122]. Besides, it can monitor the homogeneity in a 
mixture of polymers, compare powder samples that were prepared with different 
techniques, evaluate the chemical structure of drug and possible interactions, and others 
[119, 122]. 
NIR spectroscopy provides information about the spatial distribution of the components 
that compose the sample, in addition can provide important information of formulation 
chemical and physical parameters in order to measuring process performance [18, 120, 
121]. 
 
1.2.3.1 Physical stability of SD 
 
For a solid dispersion to be suitable as a pharmaceutical product it needs to show 
improved dissolution of an incorporated drug and, still, be stable on storage. Commonly 
the dissolution profile of the drug in a solid dispersion changes on storage due to physical 
instability which imposes phase separations and re-crystallizations of the dispersed 
components [90]. 
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Phase instability as a function of time and/or triggered by storage conditions (temperature 
and/or elevated humidity) is often reported and contributes to the large discrepancy 
between scientific and developmental efforts [88]. 
Basically, changes occur in several systems in crystallinity and a decrease in dissolution 
rate with ageing and system may be destabilized through physical treatment such as 
pulverization. There is more deteriorating effect of moisture and temperature on SD than 
on physical mixtures [9]. 
A key formulation goal for an SD formulation is to prevent or predict nucleation and 
growth in drug-excipients matrix and dissolution medium. In the solid state, the 
inhibitory effects of polymers against crystallization have been attributed to some 
mechanisms including antiplasticization by the polymers, a reduction in local molecular 
mobility due to coupling between the polymer and drug substance, and an increase in the 
activation energy for nucleation [123].  
In general, relatively small amounts of polymer in dispersions have been shown to 
significantly inhibit crystallization both in the solid state before administration and after 
introduction of the dispersion into dissolution media and gastrointestinal (GI) tract fluids 
[124].  
Therefore, preparing a formulation with a high Tg by using high Tg excipients such as PVP 
or hydroxypropylmethycellulose, and storing it well below the Tg should slow down the 
solid-state transformation and prolong product shelf-life. On the contrary, the presence of 
a powerful plasticizer such as water may destabilize a solid dispersion [125]. 
The initial product Tg alone may not accurately reflect the physical stability of drug in a 
solid dispersion [125]. Several factors may influence the extent and rate of crystal 
nucleation and growth of amorphous drug substance which are quite complex, making it 
difficult to predict long-term stability as a function of temperature and relative humidity, 
as in studies conducted under accelerated conditions [124]. 
Therefore, it is important to understand the factors that could affect nucleation and 
growth of crystals in a solid solution such as temperature dependence of drug solubility 
supersaturation. In addition, the temperature dependence of both the molecular mobility 
and activation energy of nuclei formation needs to be known in order to predict the 
crystallization rate of amorphous drugs [125]. 
Unfortunately, the effect of interacting excipients on the physical stability of drugs is 
frequently observed but not predicted. Although, the use of mechanistic models can 
reduce cost to feasibility evaluations and facilitate solid dispersion formulation 
development [125]. 
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1.3 Biopharmaceutical considerations 
 
While determining the fundamental physicochemical properties of the drug, such as 
solubility and lipophilicity, are central to any oral formulation strategy, it is important not 
to focus solely on these parameters. The interaction between a drug and the 
gastrointestinal environment, or the biopharmaceutical properties of the drug, requires 
close consideration. The complex physiological factors that influence the rate of drug 
presentation at the intestinal surface, transmembranal transport process and finally 
release into the systemic circulation, are also essential and cannot be taken in isolation 
[126]. For example, low molecular weight drugs with moderate lipophilicity can be easily 
transported through passive transcellular pathway, while high lipophilicity drugs show 
poor permeation characteristics towards basolateral side due to being trapped inside the 
epithelial tight junctional cells. High molecular weight drugs with poor solubility show 
bioavailability problems as they cannot permeate through the barriers [127, 128]. 
Thus, if the physicochemical and biopharmaceutical limitations of the drug are known 
then appropriate excipient selection and logical formulation design is feasible [126]. 
The rate of absorption of many slightly soluble drugs from the GIT and other sites is 
limited by the rate of dissolution of the drug. A more physiologically relevant in vitro 
dissolution measurement is especially important for poorly water-soluble drugs 
formulated into supersaturatable systems where precipitation/crystallization of drug in GI 
tract is of a concern. Supersaturation and solution mediated phase transformation of the 
drug may result from pH-induced precipitation (e.g., free-base from salt/ionized form), 
precipitation from solution formulations (e.g., cosolvents, lipids), or 
amorphous/metastable to stable polymorph/ hydrate phase, transformations (e.g., 
crystallization of an amorphous solid dispersion) [115, 129]. 
Therefore, evaluating supersaturatable formulations with the use of biorelevant in vitro 
dissolution tests which can better represent in vivo conditions is more meaningful and 
highly desirable [115]. 
Several in vitro-in vivo screening methods are used as quality control tool to evaluate the 
intestinal permeability and real time bioavailability of drug formulations for oral 
administration, especially for drug belonging to BCS-II, once these assays provide 
reproducible results for bioavailability [130]. 
With respect to dissolution assays, the use of biorelevant fluids, especially Fasted 
Simulated Small Intestinal Fluid (FaSSIF), has been well established within the 
pharmaceutical industry. However, this medium represents only the proximal jejunum, 
and hence cannot take into account the rapid and dynamic changes in the conditions along 
the intestine [131]. For this reason, several modifications have been made for automation 
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of dissolution test with apparatus strongly resembling with simulated condition of 
stomach and intestines, while all conditions like temperature, peristaltic motion, pH, 
gastrointestinal transit time, secretion of gastric acid and enzymes, bile salts, pancreatic 
juice are maintained. Drugs belonging to BCS-II category with poor solubility are specially 
evaluated by such system [127]. 
Regarding to the intestinal permeability of drug formulations, several in vitro 
permeability assay methods are used. Mostly Caco-2 cell line, Parallel artificial membrane 
permeability assay (PAMPA) cells, MDCK cell line, immobilized artificial membrane 
(IAM), chromatography, advanced compartmental absorption and transit (ACAT) models 
are being used in screening the permeability of test formulations [127]. 
Typically, traditional in vitro dissolution methods and in vivo testing in animals serve as 
the primary tools to guide development of pharmaceuticals. Only at later stages, human in 
vivo bioequivalence trials are performed to verify therapeutic equivalence. However, 
introducing more clinically relevant methods during early stages of development, 
especially in the context of QbD, could make manufacturing more cost-effective while 
maintaining or even improving quality for the patients [131] 
In this context, very recently, a new European project (OrBiTo) in the area of oral 
biopharmaceutics tools, including public and private institutions has addressed key gaps 
in the knowledge of GIT drug absorption and delivers in a framework for rational 
application of predictive biopharmaceutics tools for oral drug delivery [131]. 
This work tried to discuss mainly the directives of intestinal absorption; address 
biopharmaceutical aspects in oral pharmaceutical formulation development; give an 
approach about the current status of predictive biopharmaceutics tools; and finally 
introduce main objectives of the OrBiTo project. 
 The approach gives an unparalleled opportunity to initiate a transformational change in 
industrial research and development to achieve model-based pharmaceutical product 
development in accordance with the QbD concept, particularly for challenging projects 
such as low solubility molecules (BCS II and IV) [131]. 
 
1.4 Risk assessment of solid dispersions 
 
During the solid dispersion formulation development phase, many factors originating 
from both formulations as well as processing can have decisive influence of the physical 
stability of the drug, and the importance of evaluating the combined influence of these 
factors has been highlighted. From a formulation perspective, numerous studies have 
investigated and found factors such as polymer-to-drug ratio, polymer type, and its 
molecular weight to have decisive influence for the drug physical stability. When solid 
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dispersion is prepared using the solvent evaporation method, several studies have 
highlighted the influence of various process parameters including solvent evaporation rate 
on solid dispersion physical stability [15]. 
According to QbD, pharmaceutical development includes identifying potential CQAs of the 
drug product, determining material attributes of excipients, selecting an appropriate 
manufacturing process (CPPs) and defining a control strategy. 
 Although CQAs define the objectives for formulation and process design, they are also 
very dependent upon other parameters of the final product as dosage form, formulation 
and manufacturing method chosen among many possible and clinically equivalent 
alternatives. Consequently, formulation and process development typically rely on 
empirical prior knowledge, small-scale feasibility studies and empirical statistical studies 
[132]. 
 The identification of key factors (sources of variability) in early stages of development was 
done through risk assessment. In general, risk assessment is a systematic application of 
policies, procedures, and practices to identifying, assessing, analyzing, treating, 
monitoring, and communicating risks to life, property, or other valuables [133]. 
There are a number of different risk assessment tools available in a range of detail and 
complexity, and it is important to use a methodology suited to the purpose of the 
assessment.  
The first step in the risk assessment is to systematically gather up all the possible factors 
that could influence product quality. To identify these factors, some reviewed the 
literature, past experiences, and data collected during the initial formulation development 
studies are useful. This information then could be hierarchically in a diagram using, for 
example, an Ishikawa or “fishbone”, which may help to identify the failure related to 
system, process step, or piece of equipment. From this information, the variables (CQAs) 
that need to be further studied and controlled can be identified [132]. 
Based on this and in all the topics discussed in this work, figure 4 shows an Ishikawa 
diagram proposed to risk management of design and production of SD, taking into 
account the desired characteristic of the product, i.e. the increased solubility of drugs. As 
mentioned before, all the parameters involved during pre-formulation and formulation 
step, as drug and polymer critical peculiarities as well as external factors related to the 
manufacturing process may affect the targeted profile of the final product. 
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Figure 3. Ishikawa diagram for design and production of SD. 
 
With the many factors influencing on the solid dispersion physical stability, an emerging 
recognized challenge is related to the systematic Design of Experiments (DoE) planning, 
and minimizing the complexity of the following multivariate modeling step, so that 
understanding of the underlying phenomena and latent factors influencing on the drug’s 
physical stability can be maximized [15, 44]. 
Recent studies demonstrate the application of the QbD using the DoE for the development 
of SD. In 2011, Basalious et al. conducted a study that aimed to identify CQAs and the 
material attributes of the felodipine SD, which includes amount and type of hydrophilic 
carriers and/or surfactants, and determinate the process parameters for their preparation. 
For this study, Box –Behnken experimental design was applied to develop space design 
and determine the control space of the optimized felodipine SD that have maximum 
solubility, maximum dissolution, and ability to inhibit felodipine crystallization from 
supersaturated solution [44]. 
In 2009, Shrivastava and co-workers tried to improve the solubility of valsartan by 
formulating SD with gelucire 50/13, and evaluate the flow properties by surface adsorbent 
techniques, applying a full factorial experimental design. The independent variables were 
the ratio drug/gelucire and the amount of lubricant added in order to improve the flow 
properties. The dissolution rate, as amount dissolved in 10 and 30 minutes, and 
compressibility index were selected as dependent variables. Three-dimensional response 
surface plots and two-dimensional contour plots were drawn in order to estimate the 
effects of the independent variables on each response [134]. 
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A similar study was done in 2013 by Katharia and co-workers, in which the authors tried 
to improve the dissolution rate of olanzapine by formulating SD using combination of 
hydrophilic polymers (PEG & PVP). A central composite design of two-factor and three 
level was used to determine the effect of content of PEG 20000 and PVP K 30 on the 
dissolution of drug and to statistically optimize the levels of these factors using 
multivariate analysis and response surface plots [135]. 
The adoption of statistical techniques based on the desirability approaches, and the 
evaluation of the optimization capability of response surface, in order to achieve optimized 
SD has been widely used and has shown to be an important tool during the design of SD. 
It is important to note that in all the studies cited, involving DoE and response surface 
analysis, the dissolution rate was adopted as dependent variable, which confirms and 
emphasizes the importance of this essay, which must always be a critical parameter in the 
development of DS.  
As described in the Ishikawa diagram, the stability of the drug in SD, and even the stability 
of SD regarding the crystallinity have to be controlled once these parameters may affect 
the quality of the final formulation. In this way, the DoE has been applied in another 
framework. In 2012, Wu et al., tried to assess and monitor the physical stability of SD 
during the development, using both formulation and process factors, in addition to long-
term physical stability storage as a time factor [15]. 
The evidence and availability of recently marketed pharmaceuticals prepared by thermal 
processes reflect the benefits to the manufacture of solid dispersions at a large scale in a 
cost-effective manner, in particular hot melt extrusion and spray drying [136]. 
The spray drying process is a complex technological process that requires all processing 
conditions to be well controlled to avoid poor product performance [137]. Some of the 
conditions includes process parameters (inlet temperature, drying gas, flow rate, feed rate, 
nozzle size, compressed air flow rate) and formulation parameters (feed composition, 
solid content in feed and solvent type) [138]. Inadequate process conditions can lead to 
lower yields, sticking, or high moisture content in spray-dried SD [137]. On the other 
hand, hot-melt extrusion has stood out with advantages due to its single-step, simple and 
organic solvent-free preparation process, and gained increasing popularity. However, the 
elevated processing temperature has certainly limited the application of this technique for 
heat-sensitive drugs. In many cases, thermal degradation of drug is mainly related to the 
cumulative exposure to heat, which is a function of temperature and exposing duration 
[139]. 
Besides, in the phase of development, the process selection is also an important factor in. 
For example, for early stage or discovery-support activities, the availability of the drug in 
study is often limited, which tends to make spray drying the preferable process because its 
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feasibility can be determined with as little as 50 to 100 mg of drug, whereas several grams 
of the same are typically required to develop an initial hot-melt extrusion (HME) process 
[140]. 
Some recent studies have focused on the comparison between the two techniques in the 
design of DS. In 2013, Grawal, et al., investigated systematically the effect of SD 
manufacturing methods such as hot-melt extrusion and spray drying on physicochemical 
properties and understand how these properties can affect manufacturability, physical 
stability and product performance of SD. The authors observed that the solid state 
properties and dissolution performance were similar for SD prepared by both processing 
techniques, although the different techniques impact the physical characteristics of SD, as 
morphological characteristics, surface area, bulk and tap density, and flow property. Also, 
under the accelerated stability conditions, SD dispersion prepared by spray drying process 
was physically less stable compared to the dispersion prepared by the hot-melt extrusion 
process [141]. 
In another study, Tian et al., in 2013, in addition to use pre-formulation tools to rank 
polymers in terms of suitability to formulate molecular drug dispersions, the authors tried 
to understand the effects hot-melt extrusion and spray drying during the production of 
SD. The authors concluded that SD were affected by the nature of preparation technique; 
spray drying provided the greatest potential to generate SD across a wider concentration 
in which the sample should be thermodynamically unstable, and thus a high tendency to 
recrystallize, although it presented itself as a very fast technique. On the other hand, hot-
melt extrusion has shown a limited window for extrusion in terms of temperature and 
drug composition; therefore, within this window, the viscosity of the system may prevent 
intimate mixing, and hence the inability to generate fully amorphous systems [142]. 
 
2. Conclusions 
 
In spite of enormous research efforts both in academia and pharmaceutical industry very 
few products relying on solid dispersion technology reached the market. Moreover, the 
link between manufacturing process parameters and formulation parameters with the 
obtained physical structure and pharmaceutical performance of the solid dispersion is still 
not completely understood [88]. 
Understanding the functional relationship between quality attributes and process 
parameters as they progress through the manufacturing process is the most universally 
challenging aspect of QbD for drug development. Analytical specifications and control 
strategy aspects of the QbD plan remain the foundation for change throughout the 
evolution of the manufacturing process. Designed experiments generate the data required 
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to establish a design space for commercial manufacturing processes, while providing the 
process understanding that facilitates sound business decisions [53, 143]. 
Thus, it was clear that the influence of solid state and material properties on various 
aspects of SD such as product performance, physical stability and manufacturability 
should be considered by formulators. In addition, a systematic evaluation of SD prepared 
by different processing techniques can provide an early insight during initial stage of 
development to enable selection of an appropriate lead rational dispersion formulation 
and process in the pharmaceutical industry.  
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The oral route is still considered the most used way of administration due to its non-
invasive nature and high patient compliance. However, the low solubility of drugs often 
results in poor bioavailability (BA) and, consequently, to inconstant plasma 
concentrations. The use of nanoformulations is one of the most promising strategies to 
overcome this issue due to their significant enhancement in the solubility and intestinal 
permeation. The major purpose of this chapter is to outline the main nanosystems 
commonly used to improve solubility of poorly-soluble drugs. 
 
1. Introduction 
 
The major portion of the drug delivery market is occupied by oral drug delivery systems 
[1]. The oral route is still considered the most convenient route for drug administration as 
it offers a high patient compliance allowing a flexible and controlled dosing schedule, 
especially important for chronic therapy [2]. It is associated with the low costs for both 
industry and patient, when compared to other administration routes [3]. Apart of the 
highlighted attributes, therapeutic efficacy of oral delivery systems is often concealed due 
                                                   
2 Chaves, L., et al., Nanocarriers as strategy for oral bioavailability improvement of poorly water-soluble drugs, 
in Nanoparticles in the Life Sciences and Biomedicine. 2017, Pan Stanford Publishing. ISBN 978-981-4745-
98-7.  
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to certain factors associated with physicochemical, anatomical, and biochemical, as well as 
physiological constraints [4]. Despite this complexity, the fundamental events controlling 
oral drug absorption are the solubility/dissolution of the drug in the gastrointestinal (GI) 
environment, and its permeability through the GI tract [4], which are the main causes of 
poor oral BA [5].  
Nanocarriers have attracted increasing attention in recent years, for oral chemotherapy 
particularly for poorly soluble drugs [6]. Incorporation of drugs inside an appropriate 
nanocarrier seems to be a promising strategy, since the biodistribution of the drug will be 
dictated by the properties of the nanocarriers and not by the drug molecule itself [7]. 
This chapter will address the most commonly used nanocarriers to improve the BA of 
poorly soluble drugs, focusing on the main challenges during their formulation, the 
mechanisms of internalization, and the characterization techniques for nanocarriers with 
poorly soluble drugs. 
 
2. Oral bioavailability 
 
Oral BA is strictly related to pharmacokinetics of drugs and comprises two essential 
features: the rate of absorption which means how fast the drug enters the systemic 
circulation; and the extent of absorption which determines how much of the initial dosage 
reaches the circulation [6]. For both parameters, the solubility/dissolution rate is crucial 
since it determines how fast a drug reaches a maximum concentration in the luminal 
intestinal fluid, becoming available to be absorbed [8]. When a drug presents poor BA, the 
recommended dosage must be higher, as only a fraction of the drug enters the systemic 
circulation and reaches the site of action. On the other hand, a high drug dosage is often 
associated with the side effects and increased costs [6]. Poorly water-soluble drugs often 
exhibit slow dissolution in the GI tract, ultimately limiting their absorption [4]. 
Nowadays, poorly soluble compounds represent approximately 40% of the top oral 
marketed drugs. In addition, they stand for 90% of new chemical entities. This 
characteristic of poor water-solubility seems to be a tendency in the drug discovery field 
due to the sources used for this purpose such as combinatorial chemistry and high 
throughput screening, in which both aim to maximize drug-receptor interaction by 
stressing hydrophobic interactions [5]. 
A better understanding of the physicochemical and biopharmaceutical properties of drugs 
is not only helpful to develop new pharmaceutical products with already approved drugs, 
but also important during the screening of new drug candidates, allowing to identify 
potential absorption problems after oral administration [8]. In 1995, Amidon and co-
workers stablished a Biopharmaceutical Classification System (BCS) based on their 
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solubility and intestinal permeability [9]. According to the Food and Drug Administration 
(FDA), a drug substance is considered “highly permeable” when the extent of absorption 
in humans is determined to be 90% or more of an administered dose, while is considered 
“highly soluble” when the highest dose strength is soluble in 250 mL or less of aqueous 
media over the pH range of 1–7.5 at 37 ºC [9, 10]. 
The BCS categorizes drug substances in four categories: high solubility/high permeability 
(class I), low solubility/high permeability (class II), high solubility/low permeability (class 
III), and low solubility/low permeability (class IV) [9]. Regarding formulation design, BCS 
can provide an indication of the experimental work difficulty. For instance, 
pharmaceutical formulations containing drugs belonging to class I or III can be prepared 
with a simple strategy, while for class II and IV drugs, formulation designs are often 
required [8].  
Recently, the application of nanotechnology to improve BA of poorly water-soluble drug 
through incorporation in nanocarriers is gaining attention, as drug molecules size is 
reduced to the nanometer range. By downsizing drug molecules, thermodynamic and 
kinetic characteristics of the drug changes [6], and leads to a saturation solubility in the GI 
mucosa, thus consequent greater gradient concentration for drug absorption [11]. The 
nanocarriers affect drug molecules interfacial energy resulting in colloidal instability and 
spontaneous aggregation into a more thermodynamically stable state [12].  
 
3. Nanocarriers for oral delivery 
 
Nanocarriers are generally defined as a nanometer size scale system, consisting of at least 
two components in which one is the active compound [2]. 
 
 
Figure 1. Different classes and types of nanocarriers. 
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The use of nanocarriers to encapsulate poorly soluble drugs offers additional advantages 
such as protection of the drug from GI degradation, improved circulation half-life, active 
and passive targeting to specific intestinal cells, reduced systemic side effects, co-delivery 
of multiple drug combinations using a single nanocarrier and the possibility to modulate 
drug release, which is often appropriate [7]. In addition, they may improve the oral BA by 
overcoming the first-pass effect and/or P-glycoprotein efflux, and enhancing cellular 
uptake [3]. 
There are several nanocarriers (Figure 1) already used for this purpose namely lipid-, 
phospholipid- or polymer-based, which may be designed case by case, in order to optimize 
their physicochemical features as well as in vivo efficacy [7]. In the case of lipophilic 
molecules only nanocarriers with enough high lipophilicity should be used. 
The various types of nano-architectures mostly used to improve BA of poorly soluble 
drugs upon oral administration and their features will be addressed in the subsequent 
sections [11]. 
 
3.1 Polymeric-based nanocarriers 
 
3.1.1  Polymeric nanoparticles 
 
Polymeric nanoparticles are solid particles ranging from 10 to 1000 nm in size [13] and, 
compared to the lipid-based nanocarriers, have advantages such as higher stability in the 
GI tract, mainly in acidic environment, and possibility to achieve a more controlled drug 
release by modulating physicochemical characteristics [6].  
Polymeric-based nanocarriers can be divided into two categories namely nanocapsules, 
which are vesicular systems with core like ”reservoir-type” where the drug is confined; or 
nanospheres, that are matrix systems where the drug may be uniformly dispersed. In the 
case of nanocapsules, the inner phase may store the drug in liquid (oily phase or water 
with surfactant) or solid state as a molecular dispersion, depending on the preparation 
method and raw materials used, which is an advantage compared to the nanospheres 
especially for poorly soluble drugs [13]. 
Nanoparticles may be composed of synthetic or natural polymers and their choice affects 
directly the drug association efficiency [14]. The synthetic polymers mostly used to 
formulate polymeric nanoparticles are polyesters derivatives such as polylactide (PLA), 
polylactide–polyglycolide copolymers such as poly(lactic-co-glycolic acid) (PLGA), 
polycaprolactones (PCL), and polyacrylates (PCA). PLGA is the most widely used polymer 
due to its biocompatibility and already described predictable biodegradability [6]. Natural 
polymers, also called biopolymers due to their biocompatibility, may also be used to 
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obtain nanoparticles. In general, biopolymers, such as alginate and albumin, exhibit lower 
immunogenicity than synthetic ones [14], and may also provide additional features as 
mucoadhesion and the possibility to chemical modification as chitosan [6].  
Table 1. Examples of polymeric nanocarriers as oral delivery systems with poorly soluble 
drugs, and their main characteristics 
*Belongs to Class II; **Belongs to Class IV 
 
Regarding the method of fabrication, different methods can be reported such as 
nanoprecipitation, emulsion/solvent evaporation or emulsification, depending on the 
nature of the polymer as well as on the drug to be encapsulated [22]. One of the major 
disadvantages of the polymeric nanoparticles is the use of solvents, irrespective to the 
method of choice. The solvent choice is quite relevant for a successful encapsulation of 
poorly soluble drugs, as their proportion directly influence particle size and drug 
association efficiency [14]. 
When the objective is to encapsulate lipophilic drugs, the organic phase contains the 
polymer together with the drug. The emulsion-solvent evaporation is the most common 
method used to prepare polymeric nanoparticles, though the encapsulation of water-
insoluble drugs is yet quite challenging [23]. It is crucial to define and control the critical 
parameters of the nanoparticles synthesis since they affect their physicochemical 
characteristics. 
Polymeric nanoparticles increased the rate and extent of oral absorption of class II (eg. 
atazanavir, atorvastatin, celecoxib, daidzen, lopinavir and resveratrol) and class IV (eg. 
paclitaxel) drugs, resulting in augmentation in the values of drug plasma levels thus 
significant enhancement in the rate and extent of BA by the nanocarriers compared to 
Drug Therapeutic class  Excipient(s) Diameter 
(nm) 
AE / LC (%) Ref 
Atazanavir* Antiretroviral  Eudragit RL 100 466 60 / n.a. [15] 
Atorvastatin* Antilipidemic  Zein 183 30 / 15 [16] 
Celecoxib* Anti-inflammatory  Ethyl cellulose 100-150 n.a / 10-50 [17] 
Daidzein* Hypertension, coronary 
heart disease, cerebral 
thrombosis, and 
menopause syndrome 
PLGA  309-323 81-83 /  
1.3-1.8 
[18] 
Lopinavir* Antiretroviral  PCL 195 94 / n.a [19] 
Resveratrol* Chemopreventive, 
cardiopreventive, 
antioxidant, anti-
inflammatory 
PLGA 170 78 / n.a [20] 
Paclitaxel** Antineoplasic Poly(anhydride) 178 - 188 75 -88 / n.a [21] 
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pure drug [17-23]. Table 1 illustrates some of the diversity of polymeric-based 
nanocarriers to improve BA of poorly soluble drugs. 
 
3.1.2  Polymeric micelles 
 
Polymeric micelles are nanosystems with an average hydrodynamic diameter less than 
100 nm [24], composed by amphiphilic block co-polymers, with self-assemble properties. 
They are characterized by a core-shell structure, in which the core is a dense grid formed 
by the hydrophobic fragments, while the shell has hydrophilic characteristics [25]. One of 
the most commonly used hydrophilic fragment is poly(ethyleneglycol) (PEG), although 
other have been explored such as poly(N-vinylpyrrolidone) (PVP) and PCA. 
For the hydrophobic core, cationic or anionic polymers may be used, although 
biodegradable polymers, such as PCL, PLA and poly(amino acids), are expected to be 
more promising for in vivo administration than the non-degradable ones [26]. They have 
the special feature of loading drugs with low solubility since their core serves as a reservoir 
due to the non-covalent hydrophobic drug/ polymer interactions, thus confer chemical 
stability to the drug inside the micelles [24]. Hydrophobic core characteristics are critical 
to determine the micelles loading capacity, and may be assessed by evaluating the degree 
of polarity between the drug and the polymer hydrophobic fragments [24]. 
By physical entrapping poorly-soluble drugs, polymeric micelles have the ability to 
increase their intrinsic water solubility and consequently drug BA in the targeted site of 
action. They generally have high thermodynamic stability and, compared to polymeric 
nanoparticles, they do not need organic solvent to be produced, which decrease the 
possibility of toxicity. 
Besides polymer-drug miscibility, another important parameter that governs the 
association efficiency is the hydrophilic-lipophilic balance of the block co-polymers as well 
as polymer/ drug (P/D) ratio. As general rule, block co-polymers with longer hydrophobic 
fragments seem to promote a higher lipophilic drug loading. Furthermore, the drug 
loading tends to increase with the decreasing of the P/D ratio. Optimization of this 
parameter for lipophilic drugs allows high drug loading with minimum amount of 
polymer, as smaller amounts of polymer will be required for solubilizing a higher amount 
of drug [24]. 
Despite the advantages of the use of micelles to deliver poorly soluble drugs, their 
stability, mainly in physiological environment, is still an issue. Once administered, the 
micelles must resist to premature dissociation after dilution in the stomach and remain 
intact until reach intestinal environment. One of the parameters that dictate their stability 
is the critic micellar concentration (CMC) of the system. In general, lower CMC values 
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denote more resistance to effects of dilution and therefore confer greater stability [24]. 
Another disadvantage of micellar systems is their biocompatibility and cytotoxicity. 
Clinical studies have shown that these systems often may lead to unexpected adverse side 
effects. Minimal options of co-polymers that are safe are available and have been studied. 
On the other hand, there is still a lack of information about the effects that the amphiphilic 
co-polymers produce after oral administration. Thus, it is important to get know-how on 
the safety of micellar systems, by in vitro and in vivo studies [24]. 
Recently, Class II (efavirenz) and Class IV (oxcarbazepine, quercetin and paclitaxel) drugs 
were successfully incorporated into polymeric micelles (Table 2). Reports indicate for 
paclitaxel micelles higher in vitro cytotoxicity when compared with commercial 
formulation and the effective targeting to M-cells by micelles incorporating efavirenz with 
higher anti-HIV activity as compared to that of free drug. In vivo assays have been 
described with improvement quercetin BA by polymeric micelles as compared to free 
drug. 
 
Table 2. Examples of micelles developed for oral delivery of poorly soluble drugs, and 
their main characteristics 
Drug Therapeutic 
class  
Excipient(s) Diameter 
(nm) 
AE/ LC 
(%) 
Ref 
Efavirenz* Antiretroviral  Carboxylated 
functional Pluronic 
F127 
140 n.a / > 10 [27] 
Oxcarbazepine** Antiepileptic Pluronic P84, F127 
and F108 
15-28 11-98 / n.a 
-- 
[28] 
Paclitaxel** Antineoplasic H40-PCL-b-PCA-
b′-methoxy 
PEG/PEG-folate 
450 62 / 10 [29] 
Quercetin** Anti-
inflammatory, 
antioxidant, 
anticancer 
Soluplus® 79 96 / n.a [30] 
*Belongs to Class II; **Belongs to Class IV 
 
3.2 Lipid-based nanocarriers 
 
Lipid-based nanocarriers seem to have the most suitable features to load poorly soluble 
drugs since they may offer high drug loading, present suitable long-term storage stability 
and are feasible to scale-up compared to other colloidal carriers [31]. 
The variety of materials available, the biocompatibility of the lipids and other lipophilic 
substances as phospholipids and their ability to improve oral BA have made lipid 
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nanocarriers very attractive for oral delivery [1]. Lipid nanocarriers may enhance the 
solubility of lipophilic drugs through their interaction with the intestinal 
microenvironment and by modifying drug release, which prevent the supersaturation of 
the drug and consequent precipitation in the intestinal lumen, leading to BA improvement 
[32]. 
Furthermore, lipid systems may stimulate intestinal lymphatic drug transport, and the 
interaction with enterocyte-based transport processes, which can reduce undesired effects 
and may be of particular interest for dietary lipids and certain highly lipophilic 
compounds (for example, lipid-soluble vitamins and drugs) [32]. 
On the other hand, lipid nanocarriers are not universal platforms to delivery poorly 
soluble drugs due to the fact that lipophilic drugs do not necessarily display a high 
solubility in lipid phase. Therefore, besides the solubilization of the drug in the lipid 
phase, the partition of the drug between aqueous and oil phase should be taken into 
consideration. 
A number of nanocarriers based on biocompatible lipids and oils have been efficiently 
used to improve the BA of poorly soluble drugs. The most commonly used will be 
discussed in this section. 
 
3.2.1  Liposomes 
 
Liposomes are vesicular structures made of natural or synthetic amphiphilic 
phospholipids that spontaneously self-assemble into bilayers when in contact with 
aqueous medium. Depending on the production conditions, they can form unilamellar or 
multilamellar vesicles, which make their size vary from 50 to >1000 nm. Inside the 
circular structures of the phospholipids, they form an aqueous compartment. Thus, due to 
its amphipathic nature, they are able to enclose hydrophilic drugs in the aqueous core and 
lipophilic drugs within the phospholipid membrane [14]. 
The most common production method of liposomes for drug delivery is based on the 
dehydration-rehydration technique, since it may provide a higher drug loading efficiency 
as compared to other methods [14]. Particularly for poorly soluble drugs, achieving a high 
drug loading is quite challenging, as the aqueous core space is much higher in comparison 
to the lipid bilayer that limits the accommodation of large amounts of drug. Thus, for 
drugs with very lipophilic characteristics, the utilization of multilamellar liposomes would 
be a better strategy, as their lipid bilayers structural organization should entrap more 
lipophilic drugs, compared to unilamellar vesicles. The composition of the bilayer can be 
easily changed in order to achieve a suitable partition between the drug and the 
phospholipid layer, without disrupting the integrity of the liposomal system [33]. 
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There are still challenges regarding their stability under physiological conditions, mainly 
in the GI tract [39]. Once in the gastric environment, the phospholipids are found to be 
highly susceptible to gastric acid, bile salts and lipases, whose destructive effects 
commonly lead to losing of the liposomal integrity and leakage of the drug. In addition, 
even if the liposomes can reach the intestinal lumen, another challenge is the permeation 
of the vesicles across the GI epithelia due to its physicochemical characteristics and the 
presence of the mucus layer [40]. In order to overcome these limitations, many attempts 
have been made to ameliorate their stability by modifying constituents, and to improve 
liposomal BA. Surface modification is one of the most used strategy as this parameter may 
alter both stability and introduce new functionalities to improve their cellular 
internalization [40]. The surface modification may be achieved by the attachment of 
surfactants as bile salts or polysorbates (Tweens), or by coating with functional polymers 
such chitosan or PEG [40]. For instance, chitosan may increase the liposome residence 
time in the intestinal mucosa due to its mucoadhesive properties, leading to an enhanced 
BA [40]. 
 
Table 3 Examples of liposomes as oral delivery systems with poorly soluble drugs, and 
their main characteristics 
Drug Therapeutic class  Excipient(s)  Diameter 
(nm) 
AE / LC 
(%) 
Ref 
Daidzein* 
 
Hypertension, coronary 
heart disease, cerebral 
thrombosis, and 
menopause syndrome 
Soybean 
phospholipid, 
sodium oleate 
and glycerol 
monostearate 
45 92 / n.a [34] 
Resveratrol* Chemopreventive, 
cardiopreventive, 
antioxidant, anti-
inflammatory 
Distearoyl 
phosphatidyl 
choline and 
cholesterol 
493 92-100 / 
n.a 
[35] 
Cyclosporine A** Immunosuppressant  Cholesterol and 
lecithin 
63 - 72 ~98 / ~9 [36] 
Nimodipine** Cardiovascular agent Soybean 
phospholipid 
317 - 379 73-85 / n.a [37] 
Sorafenib** Antineoplasic Lipoid e80 
cholesterol 
165 91 / 4  [38] 
*Belongs to Class II; **Belongs to Class IV 
 
Recently, polymersomes have been applied to improve oral BA of poorly soluble drugs, as 
they exhibit enhanced stability and tunable properties [41]. These polymeric nanocarriers 
are self-assembled vesicles similar in the structure and function to liposomes. To improve 
incorporation of low water soluble drugs an amphiphilic β-cyclodextrin-centered tri-arm 
star polymer (mPEG2k-PLA3k)3-CD is used resulting in a considerable drug loading 
capability. 
New technologies for the improvement of leprosy MDT  
		
 75 
In vivo assays revealed that Class IV drugs (e.g. nimodipine, sorafenib and cyclosporine A) 
incorporated into liposomes exhibited higher drug plasma level and improved biological 
activity as compared to free drug. Few reports indicate higher pharmacokinetic profile of 
Class II drugs (daidzein and resveratrol) loaded in liposomes than plain drug. Table 3 
shows the potential of liposomes to enhance BA of poorly soluble drugs for oral 
administration.  
 
3.2.2  Solid lipid nanoparticles  
 
Solid lipid nanoparticles (SLN) are composed by lipids that are solid at room temperature, 
and in aqueous medium, the colloidal system must be stabilized by an emulsifier. The 
resultant nanosystem generally contains submicron particles with size between 50 and 
1,000 nm [31]. 
SLN combine advantages of polymeric nanocarriers such as possibility to achieve a drug 
controlled release and efficient encapsulation, together with the biocompatibility of the 
material used as in the case of lipid-based nanocarriers [33]. Additional advantages of 
SLN include: improved stability both in storage and in the GI tract, feasibility to scale-up, 
low cost, and production without the use of organic solvents [1]. 
A broad range of solid lipids with huge degrees of polarity are available to produce SLN, 
ranging from non-polar, as triglycerides and waxes through glyceride mixtures, to fatty 
acids and emulsifying wax. Furthermore, many surfactants may also be used to stabilize 
the nanoformulation as phospholipids, bile salts, non-ionic surfactants as polysorbates 
and poloxamers [32]. In addition, particularly for poorly soluble drugs, the possibility to 
screen different biocompatible lipid compositions according to their compatibility with the 
drug is an added value, as this kind of study may improve physicochemical characteristic 
of the systems as well as drug association. 
Regarding the methods of production, SLN are usually produced by the formation of an 
oil-in-water emulsion, followed by the solidification of the dispersed lipid phase. Other 
methods have been reported such as high-shear homogenization, high-pressure 
homogenization and ultrassonication. Still, the production of lipid nanocarriers with 
suitable diameter and narrow polydispersity index remains a challenge, and a critical step 
during SLN design [3]. 
Depending on the method of production and on the constituents, the drug may be 
incorporated into the particles in different ways. For example, high-pressure 
homogenization process usually produces particles with matrix-like behavior, in which the 
drug is dispersed molecularly in the lipid phase. On the other hand, in the case of drug 
enriched shell type, the drug is dispersed in the outer shell of the lipid phase, which 
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happens when phase separation occurs during cooling process. The drug may also stay in 
the inner core of the nanocarrier when the drug concentration is close to the saturation 
solubility in the lipid, and starts to precipitate, while a lipid shell with fewer drugs is 
formed around the core [42].  
The crystallinity of the solid lipids is one of the most important issues during SLN design, 
which are commonly associated with polymorphism and dynamic transition, leading to 
low drug incorporation, drug expulsion and consequent drug release due to the lipid 
rearrangement, and tendency to particle aggregation [42].  
In vitro studies described an improved cytotoxicity of classe II (eg. paclitaxel) drugs when 
loaded in SLNs as compared to free drug, and also enhanced drug cellular uptake, 
suggesting potential as an oral drug delivery system. Others report biocompatibility of 
SLN containing class II drugs (risperidone) and enhanced in vitro permeability for class 
IV drug curcumin loaded in SLN. In vivo assays revealed oral BA improvement for class II 
drugs (eg. Efavirenz, raloxifene, miconazole, glibenclamide, dapsone) when delivered by 
SLN in comparison to plain drug. Some Class II and Class IV compounds have been 
successfully incorporated into SLN for enhanced oral BA and are detailed on Table 4. 
 
Table 4. Examples of SLN as oral delivery systems with poorly soluble drugs, and their 
main characteristics 
Drug Therapeutic class  Excipient(s)  Diameter 
(nm) 
AE / LC (%) Ref 
Dapsone* Antibiotic Cetyl palmitate 308 68 / 17 [43] 
Efavirenz* Antiretroviral  Compritol 888 
ATO 
Gelucire 44/14 
160  86 / 39 [44] 
Glibenclamide* Antidiabetic  Precirol® ATO5 105-112 20-70 / n.a 
 
[45] 
Miconazole* Antifungal Precirol ATO5 22 90 / n.a [46] 
Raloxifene* Prevention and 
treatment of 
osteoporosis  
Glyceryl 
tribehenate 
167  92 / n.a [47] 
Curcumin** Antioxidant, anti-
inflammatory, 
antibacterial, antifungal 
and chemopreventive  
Compritol 888 
ATO 
270  80 / 2 [48] 
Paclitaxel** Chemotherapeutic agent  Stearic acid 251  71 / n.a [49] 
*Belongs to Class II; **Belongs to Class IV 
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3.2.3 Nanostructured lipid carriers 
 
In order to overcome some drawbacks associated with the SLN, mainly regarding stability 
and loading capacity, a second generation of lipid-based nanocarriers were developed. The 
nanostructured lipid carriers (NLC) are systems composed by a blend in appropriate 
proportion of solid and liquid lipids as a core matrix, in which the final physical state is 
still solid [50]. 
 
Table 5 Examples of NLC as oral delivery systems with poorly soluble drugs, and their 
main characteristics. 
*Belongs to *Class II; **Belongs to Class IV 
 
The presence of liquid and solid lipids allow the immobilization of higher amounts of 
drugs, compared to SLN, thus increasing the loading capacity, and prevent the premature 
expulsion of the drug, providing a greater long-term stability. This happens due to the 
chemical differences between the two types of lipids, which lead to imperfections inside 
the matrix. The larger this imperfection, the higher is the association efficiency, which can 
be modulated by varying the ratio solid/ liquid lipid, and their composition [50]. Another 
mechanism by which NLC may improve drug loading is probably by the partition of the 
solubilized drug between solid/liquid lipids. Many times, in SLN the drug is soluble in 
molten lipids before preparation and reaches saturation, but during the cooling phase it 
may precipitate resulting in immediate expulsion of the drug. In NLC, this saturation may 
not occur as the solubilized drug may be partitioned within solid and liquid lipid, as they 
Drug Therapeutic class  Excipient(s)  Diameter 
(nm) 
AE / LC 
(%) 
Ref 
Budesonide* Corticosteroid  Precirol ATO 5 and 
miglyol 812 
204 96 / n.a [51] 
      
Resveratrol* Chemopreventive, 
cardiopreventive, 
antioxidant, anti-
inflammatory 
Cetyl palmitate, 
miglyol 812 
150-250 ≈70 / n.a [52] 
Vinpocetine* Vasodilators, 
treatment of chronic 
cerebral vascular 
ischemia, acute stroke, 
senile cerebral 
dysfunction and 
alzheimer's disease  
Compritol 888 
ATO or 
monostearin, 
miglyol 812 
136 95 / 2  [53] 
Curcumin** 
 
Antioxidant, anti-
inflammatory, 
antibacterial, 
antifungal and 
chemopreventive 
Precirol ATO 5 and 
miglyol 812 
280 95 / n.a [54] 
Saquinavir** Antiretroviral  Precirol ato 5, 
miglyol 812 
165- 1090 99 / 1 [55] 
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have different polarity, avoiding the precipitation [50]. This feature is even more 
important when the drug used has very high lipophilicity, since the lipids are able to 
solubilize easier these types of drugs. 
Unlike SLN, NLC may exhibit a biphasic drug release, i.e., an initial burst release followed 
by a second release phase more controlled. This fact occurs due to the presence of a 
considerable amount of drug in the outer oily layer of the nanocarriers, which is rapidly 
expulsed; while in the second release phase the drug is released at a constant rate from the 
lipid core. Modulation of the release profiles as a function of the lipid matrix composition 
is very advantageous. These single features make nowadays, NLC the “smarter” lipid 
systems, having improved properties in contrast to other lipid-based formulations [50]. 
Table 5 presents some examples of these lipid nanocarriers for oral delivery of poorly 
soluble drugs from class II and IV. Few reports indicate in vitro potential of NLC to 
improve oral BA of class IV (eg. saquinivir) and class II drugs (eg. resveratrol). In vivo 
studies revealed the contribution of NLC significantly improve the biological activity of 
classe IV (eg. curcumin) and class II (eg. budenoside) drugs and in few cases enhanced 
oral BA (eg. vinpocetine). 
 
3.3 Oral absorption: crossing the intestinal barrier 
 
The understanding of how different nanocarriers interact with biological systems is 
important as it dictates the rate of absorption to reach systemic circulation and where the 
medicinal effects take place [56]. For oral route, the absorption step involves several 
stages and is determined by the drug’s physicochemical and formulation properties. 
The human GI tract is a dynamic structure that, besides the role of absorption, acts as an 
efficient barrier against undesired bacteria and toxins. To overcome this barrier is still a 
challenge during the development of drug nanosystems for oral delivery [4]. Upon 
ingestion, the first obstacle for nanosystems is to retain their integrity in the complex 
gastric medium, that contains numerous compounds such as bile salts, ions, lipids, 
cholesterol, and enzymes, and an extremely acidic pH environment [4]. Afterwards, upon 
reaching the small intestine portion, where approximately 90% of the absorption occurs, 
nanocarriers can be absorbed or internalized. 
In the intestinal lumen nanocarriers find at the mucus layer, which cover the epithelium 
and is constantly renewed. The mucus consists of mucin glycoproteins, enzymes, 
electrolytes and water, and due to its cohesive and adhesive nature, the passage of 
nanocarriers with certain physicochemical properties may be a challenge [57]. To 
overcome this drawback, development of nanosystems with mucoadhesion properties may 
increase the residence time at the absorption site [14]. 
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 Below the mucus layer, particles will find the intestinal epithelium which is formed by a 
monolayer composed by a heterogeneous population of cells derived from undifferentiated 
cells called crypt. The cells from the crypt may differentiate into absorptive cells 
(enterocytes); mucus secreting cells (goblet); endocrine cells; Paneth cells, which secrete 
large amounts of protein-rich materials; and in M cells that compose a lymphoid region 
called Peyer’s patches, which are specialized in antigen sampling [4].  
Despite this heterogeneity, the enterocytes are the most predominant cells in the intestine. 
Although the mechanisms by which they absorb or internalize nanocarriers varies and will 
be addressed in the next section. In addition, M cells also represents a target in the drug 
delivery framework due to its specialization in phagocytosis, which may be useful to 
transfer nanocarriers from the lumen to the basolateral membrane, where there are 
several populations of lymphocytes and mononuclear phagocytes, as macrophages, which 
serves as host cells for innumerous diseases [4]. Despite this heterogeneity, the 
enterocytes are the most predominant cells in the intestine.  
 
3.4 Nanocarrier absorption mechanisms  
 
Oral absorption initiates in the mouth and follows to the stomach, small intestinal until 
reaching the colon. This process occurs throughout the GI tract membranes by 
mechanisms of passive transport and carrier-mediated transport. The primary route of 
membrane permeation for many drugs and small size nanocarriers, in several cells of the 
intestinal membrane, is the passive diffusion. Drugs with low passive permeation are often 
transported through a transport carrier, and ligand-targeted nanocarriers by an 
endocytosis-mediated mechanism. 
Biological cell membranes are fluidic hydrophobic barriers composed of a lipid bilayer, 
cholesterol and membrane anchor proteins (eg. transporters).  
 
3.4.1 Passive transport 
 
Passive diffusion occurs when substances (free drug or drug nanocarriers) diffuse across a 
cell membrane from a region of high concentration to one of low concentration. It can take 
place by two pathways: the paracellular pathway, in which substances diffuses through the 
intercellular space between the intestinal enterocytes [58]; and the transcellular (or 
lipophilic) pathway, which requires substances travel through the cell, passing through 
both the apical membrane and basolateral membrane (Figure 2).  
The tight junctions between the intestinal enterocytes are negatively charged, thus 
positively charged substances cross through more readily and negatively charged 
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substances are repelled [59]. Paracellular route (Figure 2, II) represents less than 0.01% of 
the total surface area of intestinal membrane, and closer to the colon the junctional 
complex become tighter. The transcellular route (Figure 2, I) is the major responsible for 
the intestinal absorption of substances. It involves the movement of substances based on a 
diffusion gradient and may include transcellular diffusion, active carrier mediated 
transportation (Figure 2, IV) and transcytosis (Figure 2, V). The physicochemical 
properties of the substances control the rate of transport through the transcellular 
pathway [60]. 
The lipid bilayer portion of the cell membrane is fluidic with no specific binding sites, thus 
passive transport is not saturable, not subject to inhibition, and non-sensitive to molecules 
stereospecific structure [61]. The lipid bilayer portion of cell membrane is similar to most 
cells, thus passive diffusion occurs regardless of cell type, but may be dependent on the 
membrane lipid composition. 
 
 
Figure 2. Schematic representation the transport pathways across the intestinal barrier: 
(I) transcellular passive diffusion, (II) paracellular passive diffusion, (III) influx/efflux 
facilitated transport by membrane proteins, (IV) endocytosis with lysosome degradation, 
(V) transcytosis and (VI) uptake by M cells. 
 
Usually, the absorption of colloidal carriers (e.g. polymer based nanocarriers) follows 
mechanistic pathways involving intracellular uptake by M-cells of Peyer’s patches (Figure 
2, VI) or/and intercellular/paracellular uptake through the intestinal membrane [62]. By 
the intracellular pathway drug reaches the systemic circulation through the lymphatic 
system. This way enables nanocarriers to avoid the hepatic first-pass effect, thus 
increasing plasma drug concentration. For lipid-based nanocarriers containing self-
emulsifying agents, absorption can be driven by lipase-mediated chylomicron formation 
towards the lymphatic system [63]. The chylomicron formation also aids the absorption of 
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water-insoluble molecules as it enhances the dissolution and assimilation of lipophilic 
molecules [64]. 
Lipid-based nanocarriers can be transported through intracellular Peyer’s patches uptake 
and by the chylomicron formation, evading first-pass effect and targeting drugs to the 
lymphatic system with special relevance in lymphatic cancers and some infections 
therapy. 
 
3.4.2 Carrier-mediated transport 
 
Molecules transport across a membrane involving a protein is designated as carrier-
mediated transport (Figure 2, III). If the transport process requires energy it is named 
active transport (e.g. endocytosis, influx/efflux), and may involve transport against a 
concentration gradient. When the process is not driven by energy is defined as facilitated 
transport (e.g. phagocytosis), and is based on the concentration gradient of a substrate. 
Interaction of nanocarriers with the outer surface of the cells and cellular membranes 
leads to internalization into intracellular vesicles, and initiates the endocytosis process. 
This invagination of plasma membrane surrounding the nanocarriers can have different 
sizes, compositions and internal environment, accordingly to the internalization pathway 
(e.g. endosomes, phagosomes or macropinosomes). Endocytosis pathway is determined by 
the size, morphology and surface chemistry of the nanocarriers and, may also depend on 
the cell type. Phagocytosis, macropinocytosis, chlatrin-mediated, caveolin-mediated and 
clathrin/ caveolin-independent endocytosis are internalization mechanism described so 
far. Usually the internalization of nanocarriers in vesicles results in their degradation at 
the late endosomes (lysosomes containing enzymes and acidic pH) and, prevents them 
from reaching their target sites (cytoplasm, mitochondria, nucleus). Nanocarriers escape 
from endosome is challenging but can be achieved by using endosomolytic polymers (e.g. 
poly(amidoamine) or peptides to increase the intracellular delivery and avoid lysosomal 
degradation. Exocytosis of the vesicle contents is also a possible pathway for the excretion 
of nanocarriers from cells. Direct translocation of nanocarriers across the plasma 
membrane may occurs independent on the metabolic activity of the cells. This pathway 
named transduction is mediated by peptides known as cell penetrating peptides and is 
characterized by being energy- and receptor-independent [65]. 
Carrier-mediated transport is selective and may involve transporters through mechanism 
of active drug influx and efflux. More than 400 membrane transporters have been 
described. In carrier-mediated transport the physicochemical properties of the molecules 
and their potential affinity for various transport proteins play essential roles [66]. 
Nanocarriers coupled to affinity moieties that target GI surface markers (eg. ICAM-1, 
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cobalamin receptor), involved in transport, may improve BA. Enterocytes express various 
transporters on the apical and basolateral membranes conducting the influx (solute 
carrier, SLC family) or efflux (ATP-binding cassette, ABC family) of endogenous molecules 
and xenobiotics. Contrary to the passive transport process, the carrier-mediated transport 
is saturable, subject to inhibition, stereospecific and occurs in the specific cells expressing 
the transporter. 
 
3.4.3 Factors affecting nanocarriers absorption  
 
The rate and extent of oral drug absorption is influenced by physicochemical and 
biopharmaceutics factors. Physicochemical data is heterogeneous but indicates that 
ionization state, molecular weight and lipophilicity affect small molecules BA. 
Nanocarriers are design to enhance drug solubility and protect the encapsulated 
therapeutic agents from the extreme conditions found in the GI tract. Particle size, surface 
charge and chemical composition are essential parameters to consider in order to improve 
drug oral BA. 
The molecule’s ionization determines its dissolution rate and passive diffusion across the 
GI tract. Therefore, the pH value is a crucial parameter in oral drug absorption and 
dissolution [67]. Physiological aspects influence the pH, as the luminal secretions alter the 
local environment. At the luminal side the pH is acidic and can be as low as 2.3. While in 
the duodenum, the secretion of pancreatic bicarbonate and bile neutralizes the pH and, 
along the small intestine the pH progressively becomes alkaline. pH-sensitive 
nanocarriers can be design taking advantage of this specific feature of the GI tract. 
Accordingly, to their composition, drug release will occur under the intended pH and the 
body regions with physiological pH will not be affected [41].  
The particle size matters in orally drug delivered nanocarriers. Small particles (ca. 100 
nm) have been reported to exhibit higher absorption as compared to larger (ca. 500 nm) 
particles [64]. However, larger nanocarriers show longer retention periods in the Peyer’s 
patches facilitating transport to the lymphatic system.  
Surface charge and hydrophobicity also affect the oral BA and thus the nanocarriers 
interaction with the GIT. Nanocarriers with high hydrophobicity exhibited improved 
accumulation in the Peyer’s patches [64]. Contrary to size, nanocarrier charge is a crucial 
parameter for the interaction with intestinal in vitro models [68]. M cells uptake is highly 
affected by surface charge. Specific targeting to M-cells, e.g. lectin ligand, also improves 
cellular uptake [69]. Positively charged nanocarriers present higher cellular toxicity 
compared to negatively charged and may even lead to reactive oxygen species production, 
and mitochondrial damage [70]. Most probably, these effects are related to the 
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electrostatic interaction between the surface particles and cell membranes. In the 
intestinal membrane in vitro model, the receptor-mediated endocytic pathway plays a role 
in the internalization and transport of positively charged nanocarriers, while the lipid raft 
pathway mediates the uptake and transport of negatively charged nanocarriers [68]. 
The surface charge of nanocarriers alters upon absorption due to plasma protein 
adsorption. This phenomenon determines the biological nanocarriers fate, as it can lead to 
phagocytosis, long-term blood circulation or specific targeting. Protein adsorption on 
nanocarriers may reduce mean resident time and increases first-pass metabolism [71]. 
Oral drug delivery poses a significant challenge due to the short residence time of the 
formulations within the GI tract. Therefore, to increase the effectiveness of therapy, 
delivery systems with ability to adhere to the oral mucosa or target specific parts of the GI 
tract would be advantageous. Although the mechanisms governing oral absorption remain 
unknown, various strategies proved to be effective, for example, improvement of 
mucoadhesiveness, polymer coating and ligand-mediated targeting to epithelia. 
Polysaccharides and chitosan reinforce the mucoadhesion by interfering with the tight 
junctions thus enhancing absorption of the drug. Coating lipid-based nanocarriers with 
chitosan leads to inversion of surface potential from negative to positive, preventing the 
pH triggered aggregation of lipid nanocarriers in the stomach [31]. In fact, positively 
charged chitosan has a high affinity to bind with negatively charged mucin and mucosal 
surfaces [72]. Also, modification with tocopheryl polyethylene glycol 1000 succinate and 
pluronics could enhance oral absorption by inhibition of intestine efflux pumps, as P-
glycoproteins [73]. 
Nanocarriers taken from the GI tract can reach the systemic circulation or be cleared by 
the immune system. To improve oral BA nanocarriers recognition and elimination can be 
overcome by coating with hydrophilic polymers, such as PEG [74]. The impact of 
PEGylation in inhibiting lipid digestion, mediated by gastric and pancreatic lipases, is 
dependent on the molecular weight and the packing density of PEG molecules, as 
increasing the molecular weight and the packing density of PEG headgroups result on 
improved steric hindrance of digestive enzymes thus protecting the lipid core [75]. 
Ligand-mediated targeting to epithelia takes advantage of the specific receptors 
expression on the cell surface. Active targeting to M-cells, by receptor mediated 
phagocytosis, can be achieved using lectins [76]. The potential of transenterocytic 
phagocytic pathway has also been explored, targeting several receptors (eg. vitamins, 
carbohydrate and proteins) [69].  
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3.5 Nanocarriers Characterization: Issues and challenges  
 
Properly characterization of nanocarriers is a critical step to control product quality, 
stability and safety. Although it is not an easy work due to the complexity and diversity of 
these formulations. Parameters must be studied according to the type of nanocarrier 
chosen as well as the nature of the materials used. Despite the diversity of the nanocarriers 
available, there are basic common characterization techniques for particle size and shape, 
and the homogeneity of the system (polydispersity index). Accurate and sensitive 
techniques have already been used for these purposes, which are able to provide excellent 
qualitative and quantitative information [1]. 
The dynamic light scattering (DLS) is one of the most popular techniques used to estimate 
the size distribution of small particles in solution or suspension. The data obtained 
provide information about a population of nanocarriers in each sample solution, and not 
from each particle. Main strengths of DLS include: short experiment duration, 
noninvasive technique, able to measure diluted samples in a different wide range of 
concentrations and even small amounts of higher molecular weight species can be 
detected. Even though, the high accuracy of the technique can, sometimes, lead to a wrong 
interpretation of the data as the presence of even a small percentage of aggregates may 
interfere in the scattering intensity, increasing the size of measured particle. In the case of 
nanocarrier with poorly soluble drugs, proper dilution sometimes is not enough to 
solubilize unentrapped drug in suspension, and these particles are also measured, giving 
the false result of bigger nanocarriers. Besides the mentioned basic characterization 
parameters, there are some other critical that must be studied more deeply and carefully. 
Association efficiency together with drug loading and drug release kinetics are important 
not only for therapeutic purposes, as it dictates the rate of drug that may reach the site of 
action, but also should be well determined, without having super estimation or false 
results, which are common for insoluble drugs [77]. Furthermore, the physical state of the 
drug in the nanocarriers, i.e., in amorphous state or in crystal form, may be important as it 
directly influences drug loading in nanocarriers as well as the release characteristics of the 
encapsulated drug [77]. 
The next sections will address with more details these critical parameters and the possible 
issues that its determination may give rise to. 
 
3.5.1 Polymorphism and crystallinity 
 
Drug stability, solubility, dissolution, efficacy and, consequently, BA are parameters 
directly related to the physical state of the drug in nanocarriers. The drug may be
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encapsulated in a crystalline or amorphous state, which will depend on several parameters 
of the nanocarrier design. In addition, the crystalline form of the drug may change, 
leading to a formation of a polymorph of the drug. 
Polymorphs are chemically identical, although the different arrangement of the molecules 
lead to a different configuration of the crystal, which can vary from each other 
significantly in solubility and stability [78]. 
Several factors can alter the physical state of the drug for instance the use of the organic 
solvent as well as its type, the method of obtaining, and even some drying processes as 
lyophilization. Because most of the techniques applied to obtain nanocarriers with poorly 
soluble drugs use organic solvents, it is important to check if polymorphs of the drug have 
been already reported, and monitor this parameter during all the steps of the formulation. 
The assessment of the polymorphic form and the crystallinity of the drug may be 
performed using different techniques that may be correlated with each other, as 
differential scanning calorimetry (DSC), X-ray diffraction (XRD) and microscopy [78]. 
 
3.5.2 Drug association 
 
In general, poorly soluble drug encapsulation is influenced by several factors such as 
nature of the nanocarrier, matrix polymorphism, method of preparation, surfactants, and 
use of organic solvents to dissolve the drug [33]. As already mentioned, regardless the 
nature of the nanocarrier matrix used, the miscibility between the drug and the carriers 
must be well determined, since the higher is the affinity between both components, the 
higher seems to be the association efficiency, and lower is the ratio carrier/drug necessary 
to achieve suitable formulation [33]. Furthermore, the association of the drug inside 
nanocarriers is also dependent on the distribution and partition of the drug between the 
external phase, which is usually aqueous, and the matrix [33]. It has already been reported 
that poorly soluble drugs tend to precipitate in the external phase, when the method of 
preparation involves an oil-in-water emulsion, leading to low association efficiency [77]. 
The association efficiency may be determined by destroying the nanocarriers, with 
previous separation from the unentrapped drug (direct method); or measuring only the 
drug present on the external phase (indirect method). In both cases, the separation of the 
obtained nanocarriers should be done, despite the small size of these particles makes it 
difficult to separate the colloids and the dispersion medium and, for lipophilic drugs, the 
drug theoretically soluble is present as a precipitate, leading to an overestimation of the 
drug loading capacity. 
Basically two methods are used to measure association efficiency, namely centrifugation 
and ultra-filtration, depending on the nature of the material used. For instance, for 
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polymeric-based nanocarriers, it is common to use the centrifugation method as with high 
speeds of centrifugation they form a pellet, and the supernatant may be collected, despite 
the force used do perform the technique. On the other hand, ultra-filtration is often 
successfully used for lipid-based nanocarrier, as most of the lipids have low density and 
are not able to form pellet, at considerable high speed of centrifugation. This technique 
utilizes membranes with different molecular weight cutoffs that retain the nanocarriers, 
while the solubilized drug passes through the membrane [78]. None of the mentioned 
methods are completely suitable to estimate the association efficiency of poorly soluble 
drugs, as the presence of precipitated drug is common, turning this characterization one of 
the most difficult challenges during the design of the formulations. 
 
3.5.3 Drug release profile 
 
As already mentioned along this chapter, the solubility of the drug in aqueous medium 
may be indicative of its in vivo performance, as the precipitation of the drug reduces the 
total amount of drug absorbed, decreasing its BA. Thus, the best way to mimic in vitro the 
behavior of the drug solubilization upon oral administration is through a dissolution test, 
also called release profile in the case of nanocarriers. The in vitro release profile, if 
properly performed, can inform the rate by which the drug becomes available to be 
absorbed, in different conditions encountered in vivo such as different pH, the presence of 
digestion proteins and protein binding [79]. 
Some critical conditions must be established during the in vitro release assay in order to 
provide some predictive potential, such as the release media and sampling methods. The 
choice of the medium should simulate in vivo systems. Phosphate buffer solution (PBS) is 
the simplest and common medium used for this purpose, despite significant 
underestimation of the intestinal fluid environment [79]. Thus, serum-containing buffers 
may be a reasonable choice of release medium for mimicking a physiological fluid, 
especially for poorly water-soluble drugs, since they have a more complex composition 
that seems to affect solubilizing properties (e.g. fasted or fed state simulated intestinal 
fluids (FaSSIF and FeSSIF, respectively)) [79]. 
The first challenge to be solved during an in vitro drug release of nanocarriers containing 
poorly soluble drugs is to satisfy sink conditions, which is defined as the volume of 
medium at least three fold higher than the volume necessary to reach a supersaturated 
solution of drug. It means that, to obtain realistic results, suitable volume of release 
medium must be used, implying the use of very low concentration of formulation in the 
case of poorly soluble drugs, compromising sometimes the accuracy of the quantification 
analysis. With the use of simulated intestinal fluids is even more useful to achieving sink 
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conditions compared to PBS due to the solubilizing effects of the proteins. Likewise, this 
difficulty may be alleviated by concentrate the samples prior to analysis, or adding 
surfactants of co-solvents in the release medium to increase the drug solubility [80]. 
Besides the composition and the volume of the release media, it is important to select the 
more appropriate method, depending on the formulation to be studied. Centrifugation 
and dialysis are most widely used for this purpose, although both have critical limitations. 
The first method is based on the centrifugation of the samples at each time point, at high 
speeds to separate the nanoformulations from the free drug. The main disadvantages of 
this method are that the pressure generated during the centrifugation can force the release 
of the drug and, for lipophilic drugs, precipitation of drug in the pellet may occur. In 
addition, the compression of the pellet is often excessive, turning the resuspension 
difficult, or sometimes the separation is incomplete, leading to cumulative errors in 
measurement of the released drug [80]. 
In the dialysis, the nanocarrier suspension is placed inside a dialysis bag with a specified 
molecular weight cutoff, and the released drug molecules diffuse out of the bag, for further 
quantitative analysis. In this case, the major difficulty is to achieve real concentration of 
poorly soluble drugs in the receptor compartment due to premature precipitation of the 
drug inside the dialysis bag. 
 
3.5.4 Permeability assays 
 
One of the last steps during formulation design, but not less important, is the evaluation of 
its permeability characteristics in order to compare the in vitro absorption profile with 
pure drug. In face of all the challenges associated with the conception of drug delivery 
systems containing poorly soluble drugs, a significant increasing in the number of reports 
in this framework has been done, applying techniques from the most basic models 
including non-cellular-based (artificial membrane), cell or tissue based models (in vitro), 
to more complex and time consuming methods as in situ, in vivo intestinal perfusion, and 
in silico [4]. Nevertheless, the in vitro techniques are preferred as they are less laborious 
and less expensive as compared to in vivo animal studies, and can represent an alternative 
to animal use mainly during initial stages research. 
Currently, there are a variety of human immortalized cell lines that are able to easily grow 
into confluent monolayer models, which can mimic with good correlation with in vivo 
results the intestinal epithelium for transport studies. The commonly used cells for this 
purpose are endothelial cells (e.g. Caco-2 cells). Caco-2 cells differentiate both structurally 
and functionally into cells resembling mature enterocytes and have also been shown to 
express several transport systems of different molecules [81]. The successful application of 
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in vitro models to predict drug absorption across the intestinal mucosa depends on how 
closely they mimic the characteristics of the in vivo intestinal epithelium [4]. Thus, other 
cell lines were started to be used in co-cultures together with Caco-2 due to the need to 
develop models with greater predictability, that involves other mechanism of absorption, 
and have the ability to provide a more realistic mucus barrier [82]. In this context, several 
studies have been done applying co-cultures of Caco-2 and mucus secreting goblet cells 
(HT29) [83], or Caco-2 co-culture with Raji B lymphocytes, that has been developed to 
mimic the M cells [84]. 
Despite good correlations have been encountered between in vivo/in vitro values of 
permeability with these models, there are still several difficulties associated in the 
prediction of absorption of poorly soluble drugs, especially for drug belonging to BCS class 
IV. As already discussed, the absorption of these drugs are extremely influenced by 
physiological environment, as the presence of endogenous surfactants, as well as the 
presence or absence of food, which are factors very difficult to mimic in vitro. In addition, 
gastric emptying rate, GI transit rate and GI pH cannot be incorporated in the results 
interpretation [81]. 
Likewise, the limit of detection of analytical methods, together with the tendency for drug 
precipitate before permeation is one more obstacle during in vitro permeability assays for 
poorly soluble drugs, leading to uncertain results. Besides, it is common to find high levels 
of toxicity in many cell lines, which turns the concentration of drug in the sample even 
lower. One recent strategy to overcome the solubilization problem during in vitro 
permeability tests is the use of solubilizing agents (eg. poloxamers, Tritons), which may 
partially eliminate the detection limit challenge, turning possible the estimation of the 
permeability [85]. 
 
4. Conclusions  
 
Despite the vast and growing therapeutic application of poorly soluble drugs it was 
demonstrated that there are still severe issues regarding the development of oral dosage 
forms. Along the previous sections, it could be seen that the use of different systems either 
polymeric- or lipid-based has been studied as nanocarriers to improve oral BA of class II 
and class IV drugs. In this framework, the use of nanotechnology has been proven to be a 
promissory and efficient strategy to improve solubility, dissolution kinetics and oral BA of 
hydrophobic drugs. Few reports already describe in vivo assays with a significant 
enhancement of drug-loaded nanocarriers oral BA as compared to free drug. It was shown 
along this chapter that there are several different nanocarriers used for this purpose, with 
different features, which allows developing tailor-made nanotherapeutics for different 
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drugs. With rapid scientific and technological advances in nanosizing hydrophobic drugs, 
its potential can be vital for clinical applications. This whole field will thus require more 
attention in the future, in particular regarding to in-vitro–in-vivo correlations, in order to 
elucidate in detail all effects involved and to provide an adequate basis for appropriate 
carrier selection. 
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1. Experimental design 
 
Experimental design, also known as design of experiments (DoE), is the methodology used 
to systematically conduct and plan experiments aiming to extract the maximum amount of 
information with the lowest number of analyses [1]. 
Before the construction of an experimental design, is important to select the variables that 
will be investigated, the ones that can be changed independently of each other 
(independent variables) within the experimental domain. Experimental domain describes 
the experimental field that must be investigated and is defined by the minimum and 
maximum limits of the experimental variables studied, also called levels [2]. Lastly, the 
responses or dependent variables are the measured values of the results from 
experiments. 
 When the experimental variables and the responses have been defined the experiments 
can be planned and performed in such a way that a maximum of information is gained 
from a minimum of experiments [3]. The experimental designs are constructed with a 
specific set of experiments defined by a matrix composed by the different level 
combinations of the variables studied [2, 3]. The type of design is chosen depending on the 
proposed model and the objectives of the study, which may be screening, factor influence, 
optimization, among others [3, 4]. 
The experimental design tool was used along this entire thesis aiming to provide a rational 
and systematic development of the drug delivery systems. 
 
1.1 Empirical models 
 
The outcome of an experiment is usually dependent on the experimental conditions. It, 
therefore, can be described as a function f(x) which represents a reasonable description of 
the relationship between the experimental variables and the responses within a limited 
experimental domain [3]. 
Two types of models are mainly used to investigate the experimental system, namely 
linear and polynomial models. The polynomial model contains additional terms that 
describe the interaction between different experimental variables and are divided into 
second order interaction model or quadratic model. The last one can determine optimum 
(maximum or minimum) levels by the introduction of a quadratic term. For the different 
models, different types of experimental designs are needed [3]. 
The linear model is mathematically expressed by the following equation: 
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	" = $%	 $&'& + )*&+,  
 
where k is the number of variables, b0 is the constant term, bi represents the coefficients of 
the linear parameters, xi represents the variables, and ε is the residual associated to the 
experiments [2]. 
The next level of the polynomial model should contain additional terms, which describe 
the interaction between the different experimental variables. The second-order model for 
an interaction presents the following terms [2]: 
 	" = $%	 $&'& + $&-'&'-*,.&.- + )*&+,  
 
where bij represents the coefficients of the interaction parameters. 
Critical point (maximum, minimum, or saddle), can be determined by the introduction of 
quadratic terms [2] according to the equation presented below: 
 	" = $%	 $&'& + $&&'&/*&+, + $&-'&'-*,.&.- )*&+,  
 
1.2 Full factorial designs 
 
Full factorial is the design that has every possible combination of factors at the designated 
levels. There are Lk combinations of k factors at L levels [5]. The simplest design in the 2k 
series with only two factors, at two levels (“low” and “high”). This design is called a 22 
factorial design [6]. 
 
1.3 Screening: Plackett-Burman design 
 
A screening experiment is performed in order to determine the experimental variables and 
interactions that have significant influence on the result, measured in one or several 
responses [3, 7]. This kind of experimental design can be applied when many factors must 
be examined to identify which are the ones that may potentially influence one or more 
responses of interest, aiming to reduce the number of factors to be investigated in further 
experimentation [1]. Thus, minimizing the number of experiments while maximizing 
information is the ultimate goal [1]. 
Plackett-Burman design (PBD), are one of the most popular screening designs and are 
used to investigate n–1 variables in n experiments, in a multiple of four sample size, i.e., 
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4k observations with k = 1, 2, … n. Thereby PBD require fewer experiments than the highly 
fractionated factorial designs that include the same number of factors. The projective 
property of the PBD is that it allows an efficient separation of main effects and interaction 
for further studies [1, 7]. 
 
1.4 Box-Behnken design 
 
A Box–Behnken design (BBD) has three or more levels and can be applied to problems 
having three or more factors. There are no factorial or extreme points and the design 
requires 2k(k−1) + ncp (ncp = number of central points) [5]. In BBD, the experimental 
points are located on a hypersphere equidistant from the central point, which allows the 
efficient estimation of the first- and second-order coefficients of the mathematical model. 
These designs are, in this way, more efficient and economic than their corresponding 3k 
designs, mainly for a large number of variables [2, 8]. The construction of this design 
requires that all factor levels have to be adjusted only at three levels (−1, 0,+1) with equally 
spaced intervals between these levels [2]. 
 
2. Response Surface Methodology  
 
Response surface methodology (RSM) is a collection of mathematical and statistical 
techniques based on the fit of a polynomial equation to the experimental data obtained by 
experimental design. It must help to better understand the behavior of experimental 
collection aiming to make statistical previsions. It is useful when a response or a set of 
responses of interest are influenced by several variables, and allows to simultaneously 
optimize the levels of these variables to achieve the best system performance. For these 
purposes, linear or square polynomial functions are employed to describe the system 
studied and, consequently, to explore experimental conditions until its optimization [2]. 
The application of RSM implies in the following steps: (i) selection of independent 
variables that could potentially interfere on the system through screening studies, as well 
as the delimitation of the experimental domain; (ii) correct choice of the experimental 
design and performance of the experiments according to the selected experimental matrix; 
(iii) mathematic–statistical treatment of the obtained experimental data through the fit of 
a polynomial function; (iv) evaluation of the model’s fitness; (v) obtaining the optimum 
values for each studied variable [2]. 
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3. Solid Dispersions 
 
Solid dispersions are defined as a dispersion of the drug in an inert carrier or matrix at 
solid state, aiming to enhance the oral bioavailability of poorly water-soluble drugs by 
modulating drug release profile. It has been demonstrated that solid dispersion, may 
improve drug solubility by the reduction of particle size, which are generally molecularly 
dispersed in the matrix [9-11]. When the solid dispersion is exposed to aqueous media and 
the carrier dissolves, the drug is released as very fine colloidal particles due to the increase 
in the surface area [9-11]. This mechanism has been reported to be responsible for the 
bioavailability enhancement of poorly soluble drugs [9-11]. Several methods have been 
reported to prepare solid dispersions [9-11]. The kneading and solvent evaporation the 
most widely used due to their advantages.  
 
3.1 Kneading 
 
Kneading is perhaps the simplest technique to prepare solid dispersions in which the drug 
is dispersed in the carrier as microcrystals or in amorphous state. According to this 
procedure, the drug and the selected carrier are triturated together using a small volume 
of ethanolic (1:1 – w/w) solution to give a thick paste. The drug or at least the carrier used 
should be soluble in water or in ethanol.  
The obtained paste is kneaded for a pre-defined time, to disperse the drug into the carrier, 
and then the formulation is dried at medium temperature (40 – 60ºC) in an oven. The 
dried mass is pulverized and the particles are calibrated by passing through appropriate 
mesh sieve size. The solid dispersion powder obtained by this technique are physico-
chemically stable and can be easily formulated in a tablet dosage form by direct 
compression method [12]. 
 
3.2 Solvent evaporation 
 
Solvent evaporation processes consist in solubilizing both drug and carrier(s) in common 
solvents or in a mixture of solvent followed by solvent removal. Non-covalent molecular 
interactions between drug and carrier(s) during solvent removal are responsible for the 
formation of an amorphous product [9]. Solvent evaporation processes can be divided in 
four major groups depending on solvent removal conditions: (i) high temperature and 
normal pressure, (ii) high temperature and negative pressure, (iii) freeze-drying, or (iv) 
supercritical fluids [9]. 
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3.2.1 Freeze-drying 
 
Freeze-drying comprises freezing a solution/suspension of drug and carrier(s) followed by 
reducing the surrounding pressure to allow water and solvents in the sample to undergo 
solid–gas transition. In a freeze-drying process, drug and carrier(s) maintain their 
molecular dispersion structure observed upon dissolution [9]. 
 
4. Nanoparticles 
 
Nanoparticles are solid, colloidal particles consisting of macromolecular substances that 
vary in size from 10 nm to 1000 nm. Typically, the drug of interest is dissolved, entrapped, 
adsorbed, attached and/or encapsulated into or onto the matrix. Depending on the 
method of preparation nanoparticles, nanospheres, or nanocapsules can be achieved, and 
each of them present different properties and drug release characteristics [13]. 
The mechanism by which nanoparticles can improve drug solubility is based on the 
formation of a fine colloidal dispersion, at the same time that entraps the drug, providing 
a large surface area of absorption in the gastrointestinal tract [14]. Several nanostructures 
have been already used for this purpose namely lipid-, phospholipid- or polymer-based 
nanoparticles [15]. In this thesis, polymeric and solid lipid nanoparticles were developed. 
 
4.1 Polymeric nanoparticle 
 
4.1.1 Nanoprecipitation method 
 
The nanoprecipitation method is also called solvent displacement or interfacial 
deposition. In this method, there is an aqueous phase, generally containing a surfactant 
acting as stabilizer, and an organic phase, consisting of a solvent solution with the polymer 
and the drug. The solvent used for this method should be miscible with the aqueous phase. 
The nanoparticles are obtained as a colloidal suspension formed when the organic phase is 
added slowly and with moderate stirring to the aqueous phase. Several polymers have 
been reported to produce polymeric nanoparticles by nanoprecipitation method. In this 
thesis, the polymeric nanoparticles were based on Eudragit L100 (methacrylic acid - 
methyl methacrylate copolymer (1:1)) [16-18]. 
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4.2 Solid lipid nanoparticles 
 
Solid lipid nanoparticles (SLNs) consist of a physiological compatible solid lipid core and 
of an amphiphilic surfactant shell. The main characteristic of the lipid phase is that they 
remain in solid state at room temperature [19, 20]. 
SLNs can be prepared using a wide variety of lipids including fatty acids, glyceride 
mixtures or waxes, stabilized with selected biocompatible surfactants (non-ionic or ionic). 
Besides, SLNs presents low cytotoxicity due to their biodegradable and biocompatible 
lipid composition, and are feasible to scale-up with an associated low cost [19, 21]. 
 
4.2.1 Hot homogenization and ultrasonication technique 
 
Several methods to produce SLNs have been already described [22, 23]. In this thesis, we 
have used the hot homogenization and ultrasonication technique. In this method, the lipid 
and the drug are first melted above the melting point of the lipids (generally 5ºC) followed 
by the addition of aqueous phase heated to same temperature. Then, are emulsified by 
probe sonication. The ultrasonication is based on the mechanism of cavitation, which 
disperses the melted lipid to minute droplets [24]. The cooling of the nanoemulsions 
allows the crystallization of the lipids and subsequent formation of lipid nanoparticles.  
 
5. Formulations characterization 
 
5.1 Microscopy techniques 
 
The morphology of the formulation may be assessed by images obtained through 
microscopic techniques, such as scanning electron microscopy (SEM) and transmission 
electron microscopy (TEM). 
SEM allows to obtain three dimensional images of the surfaces of the formulations, in this 
case solid dispersions, and the respective physical mixtures. The samples are irradiated 
with an electron beam and the signals generated from the interaction of the electron beam 
with the sample comprise secondary electrons, backscattered electrons, characteristic x-
rays, and other photons which can be used to investigate different features of the sample 
surface [25]. 
On the other hand, TEM utilizes energetic electrons which cross the samples to provide 
morphologic and crystallographic information, in this work was used for the 
nanoparticles. The images are generated by the interaction between the samples and the 
energetic electrons in the vacuum chamber, which generates high-resolution, two-
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dimensional, black and white images [25]. 
 
5.2 X-Ray diffraction  
 
The X-ray diffraction (XRD) can be described as the reflection of a collimated beam of X-
rays incident on the crystalline planes of an examined compound. Typically, XRD, based 
on wide-angle elastic scattering of X-rays, is a tool for characterizing crystalline size, shape 
and lattice distortion by long-range order, but is limited to disordered materials [25]. 
The XRD technique represents the primary method for obtaining fundamental structural 
information on crystalline substances including the determination of crystal structures, 
evaluation of polymorphism and solvate structures, evaluation of degrees of crystallinity, 
and the study of phase transitions [26]. XRD techniques used to characterize solids 
include the analysis of single crystals or powders, this last case is also called X-ray powder 
diffraction (XRPD). In powder XRD, the typical output is a plot of intensity versus the 
diffraction angle (2θ). Such a plot can be considered a fingerprint of the crystal structure, 
and is useful for determination of crystallographic sameness of samples by pattern 
comparison. A crystalline material will exhibit peaks indicative of reflections from specific 
atomic planes. The same will be exhibited for all repeating planes with the same spacing. 
An amorphous sample, on the other hand, will exhibit a broad hump in the pattern called 
an amorphous halo [27].  
In this thesis, the XRD technique was employed to assess the degree of crystallinity of 
solid dispersions, compared to the pure drug. 
 
5.3 Dynamic light scattering  
 
The measurement of nanoparticles was conducted by dynamic light scattering (DLS) 
technique, which consists in the incidence of a laser beam through the sample with 
particles in suspension and that promotes a light scattering whose intensity fluctuations is 
measured by a detector. The fluctuations are caused by the random Brownian motion of 
the nanoparticles that can be faster in the case of small particles, or slower in the case of 
larger particles, according to the Stokes-Einstein equation. 
The polydispersity index can also be determined and describes the distribution width of 
the particle size (from 0 to 1) [25]. 
 
5.4 Electrophoretic light scattering  
 
The electrophoretic light scattering (ELS), commonly called zeta potential, is a physical 
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property which indicates the surface charge of the nanoparticles. The presence of charge 
on the particles surface affects the ion distribution the aqueous medium, resulting in the 
creation of an electrical double layer constituted by the charged surface and the counter- 
ions distributed in a diffuse way in the aqueous medium. This solvating layer is held to the 
surface, and in the edge of the layer (Stern layer) zeta potential can be measured. When an 
electric field is applied, charged particles in suspension are attracted towards the electrode 
of opposite charge. When the equilibrium is reached, the particles move with constant 
velocity, also known as electrophoretic mobility which can be correlated with the zeta 
potential [25]. 
The magnitude of the zeta potential gives an indication of the long-term stability of the 
colloidal dispersions. Nanoparticles in suspension will tend to suffer repulsion between 
them if they have a large absolute value of zeta potential and will be considered stable 
when this value is higher than |30| mV [76]. 
 
5.5 Differential scanning calorimetry  
 
Differential scanning calorimetry (DSC) is a technique able to study thermally induced 
transitions and particularly, the conformational transitions of biological macromolecules 
[28]. This thermal analysis has been frequently used to investigate the physical state, 
degree of crystallinity and polymorphism of compounds. Specifically, to lipid based 
nanosystems, it has been applied to evaluate crystal ordering of the lipid nanoparticles. 
The DSC thermal analytical technique measures how physical properties of a sample 
change, along with temperature against time, allowing to measure the heat capacity of a 
substance and the enthalpy variation (DH). During a change in temperature, DSC 
measures a heat quantity, which is radiated or absorbed by the sample based on a 
temperature difference between the sample and the reference material. The sample 
material is enclosed in a pan (generally aluminum pan) and an empty reference pan is 
placed on a thermoelectric disk surrounded by a furnace which is heated at constant rate 
[28, 29]. The energy is introduced simultaneously into the samples and the reference 
pans, so that temperatures of both cells are raised identically over time. The difference in 
the input energy required to match the temperature of the sample to that of the reference 
would be the amount of excess heat absorbed or released by the sample (during an 
endothermic or exothermic process, respectively). This difference is measured in terms of 
DH, calculated from the area under the transition peak [28, 29]. 
In this thesis, DSC measurements were performed to assess physical state of drug after 
production of either polymer- and lipid-based nanoparticles, and to identify potential 
chemical interactions between the drugs and other constituents of the formulation. 
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5.6 Fourier Transform Infrared spectroscopy 
 
Fourier transform infrared spectroscopy (FT-IR) is a technique which measures the 
vibrational frequency of specific chemical bonds, allowing the identification of 
functionalgroups present in the samples. By analyzing the absorption bands that is given 
in the infrared spectrum, it is possible to identify vibrational modes associated to the 
presence of specific molecules [25]. Moreover, infrared spectroscopy technique may allow 
to assess significant differences between crystalline and amorphous phases and hence are 
used to infer crystalline degree of the sample as the intensity of the vibrational bands is 
directly proportional to the concentration of the concerned phase [30]. 
FT-IR analysis was used to investigate the stability of the used drugs after preparation 
through the assessment of chemical interactions between drug and other excipients. 
Moreover, this tool could provide information about the influence of the process on the 
degree of crystallinity of the final formulations and the physical state of the drug in the 
systems. 
 
6. Drug quantification 
 
6.1 Spectrophotometry  
 
When light passes through or is reflected from a sample, the amount of light absorbed is 
the difference between the incident radiation and the transmitted radiation. 
The amount of light absorbed is proportional to the number of absorbing molecules 
through which the light passes, and may be expressed as either transmittance or 
absorbance. Although, for quantitative applications, absorbance values are most widely 
used as the relationship between absorbance and concentration, path length is normally 
linear, and is expressed following the Beer-Bouguer-Lambert law: 
 0 = )bc 
 
where A is the absorbance; e is the extinction coefficient related to the given substance; b 
is the path length (usually in centimeters) and c is the substance concentration. 
As e is characteristic of a given substance at defined set conditions, and c is always 
constant, in practice, these parameters are not used for quantitative analysis, instead a 
calibration curve for the substance to be analyzed is constructed using one or more 
standard solutions with known concentrations of the analyte. 
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The simple linear relationship between absorbance and concentration and the relative 
ease of measurement of ultraviolet-visible (UV-Vis) light have made UV-Vis spectroscopy 
is the basis for several quantitative analytical methods [31]. 
The UV-Vis spectrophotometry technique was applied to quantify the selected drugs in the 
developed drug delivery systems and to estimate the drug association in nanoparticles 
formulations. 
 
6.2 High-performance liquid chromatography  
 
The chromatographic technique is a separation technique based on the sample 
partitioning between a moving phase, in this case liquid, and a stationary phase, which is 
solid [27]. The high-performance liquid chromatography (HPLC) is currently the most 
suitable method for meeting most of the criteria for quantitative analysis in the 
pharmaceutical framework. It is a reliable quantitative precise and accuracy quantification 
method sufficient to allow for the determination of the drug and related substances 
simultaneously using a variety of detectors, with excellent reproducibility [26]. 
 The proposed combined therapy using different systems with two different drugs for the 
treatment of leprosy imply the development of a quantitative and sensitive HPLC method 
that could separate both drugs and the excipients used in the preparation of the 
formulations. The method was developed to quantify dapsone and clofazimine isolated or 
in combination in the different obtained drug delivery systems. Also, the developed 
method allowed to quantify the drugs in culture medium, from permeation studies using 
Caco-2 cell monolayer. 
 
6.3 Association efficiency and drug loading 
 
The association efficiency may be determined by destroying the nanoparticles, with 
previous separation from the unentrapped drug (direct method); or measuring only the 
drug present on the external phase (indirect method). In both cases, the separation of the 
nanoparticles should be done [32]. 
The separation of the nanoparticles may be done by centrifugation of ultra-filtration, 
depending on the nature of the material used. For polymeric nanoparticles, it is common 
to use the centrifugation method as the material characteristics allow to obtain pellets 
with reasonable centrifugation speeds, enabling to collect supernatant and quantify the 
non-entrapped drug. On the other hand, ultra-filtration is often successfully used for lipid 
nanoparticles. This method requires the use of membranes with a defined molecular 
weight cutoff that retain the nanocarriers, while the solubilized drug passes through the 
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membrane [32]. 
The indirect method was the main method used for association efficiency estimation, even 
though the direct method was applied for confirmation purposes. Centrifugation and 
ultra-filtration separation techniques were used for polymeric and solid lipid 
nanoparticles, respectively. The drug was quantified by UV-Vis spectroscopy. 
 
7. In vitro studies 
 
7.1 In vitro dissolution 
 
 In vitro dissolution tests are relevant for the prediction of in vivo performance as drug 
absorption after oral administration depend on drug release from the formulation and the 
dissolution under physiological conditions. The selection of appropriate dissolution 
conditions is important to the successful in vitro evaluation of oral solid dosages and must 
be designed to closely simulate the GIT environment [33, 34]. 
 General guidelines exist for the selection of dissolution media, volume, stirring rate, and 
temperature to be used with each type of apparatus. The selection of the dissolution 
testing conditions should be based on the ability to detect product variation, the stability 
changes, and the correlation with in vivo results in situations where these studies are 
performed [27]. For oral dosage forms, it is important that the dissolution medium ranges 
in pH from 1.2 to 6.8, even though, it is most important to simulated gastro-intestinal 
fluids. Sink conditions are desirable but not mandatory [33, 34], especially for the 
evaluation of solid dispersions where the theoretical solubility of an amorphous form is 
often predicted to be much higher than the experimentally observed value, and is 
important to assess the improvement on the drug dissolution profile [35]. 
In this thesis, the dissolution tests were performed to assess the drug dissolution profile 
and the solubility increment provided by the developed amorphous solid dispersions, by 
two different methods, which were compared to physical mixtures and pure drug. The 
assays were performed under pH 6.8 to simulate intestinal environment. 
 
7.2 In vitro release 
 
The in vitro release studies are commonly performed by two methods, depending on the 
nature of the carrier. Centrifugation and dialysis are the most widely used for this 
purpose. The first method is based on the centrifugation of the samples at each time point, 
at 20,000 xg to separate the nanoformulations from the free drug, for further 
quantification. This method is suitable for polymeric nanoparticles. In the dialysis, the 
nanoparticles suspension is placed inside a dialysis bag with a specific molecular weight 
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cutoff, and the released drug molecules diffuse out of the bag, for further quantitative 
analysis [36]. 
Both methods were applied is this thesis, depending on the testing formulation. 
 
8. Cell studies 
 
8.1 Cell viability  
 
Cell viability studies were conducted to assess the toxicity of nanoparticles, using different 
cell lines representative of the GIT. The MTT assay is a colorimetric assay used to access 
cell metabolism, measuring the activity of cellular enzymes that reduce the thiazolyl blue 
tetrazolium bromide (MTT) substrate to formazan, resulting in a dark purple color which 
is spectrophotometrically quantified [37]. 
 
8.2 In vitro permeability assays 
 
Permeability studies can be important to simulate the transport of nanoparticles through 
intestinal barrier. These assays are performed on 12-well transwell cells with Caco-2 
monolayers by seeding cells on membrane inserts for 21-23 days. The cells grow on the 
apical chamber until the monolayer achieves a transepithelial electrical resistance (TEER) 
value around 400 Ω.cm2 [38]. 
The permeability was carried out by adding diluted formulations in the apical side of the 
transwell system. At predetermined time intervals aliquots were sampled from the 
basolateral compartment and replaced with fresh culture medium. The amount of drug in 
the samples was analyzed by HPLC. The cumulative amounts of transported drug across 
the monolayers can be calculated from the concentrations measured in the basolateral 
compartment. The permeability profile may be expressed as apparent permeability 
(Papp), which is calculated following the equation: 
 01123456	143742$8986"	 :211 = 	;<;6 × 10×?% 
 
where, Papp is the apparent permeability coefficient (cm/sec), dQ/dt is the linear 
appearance rate of the compound on the receiver end based on its cumulative transport 
for 8 h (µg/sec), A is the surface area of the cell monolayer (cm) and C0 is the initial 
concentration of compound in the donor chamber (µg/ml) [39]. 
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 Chapter IV 
Progress beyond the state of the art 
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Chaves, L.L., et al., Rational and precise development of amorphous polymeric systems 
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1. pH-sensitive nanoparticles for improved oral delivery of dapsone: risk assessment, 
design, optimization and characterization. 
2. Optimization of solid lipid nanoparticles for clofazimine delivery: risk 
management, statistical design and physicochemical characterization; 
3. Development of PLGA nanoparticles loaded with clofazimine for oral delivery: 
assessment of formulation variables and intestinal permeability. 
In preparation: 
1. Polymeric nanosystems combination allows dapsone and clofazimine intestinal 
permeation 
Integrated discussion
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A. Rational and precise development of amorphous 
polymeric systems with dapsone by response surface 
methodology.3 
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1. Introduction 
 
Leprosy is a chronic infectious disease that continues to be a serious public health 
problem in several developing countries, caused by Mycobacterium leprae (M. Leprae) 
[1]. It is a slowly growing intracellular bacillus, transmitted from an infected person to 
others via their nasal secretions [2]. The disease affects peripheral nerves, especially 
Schwann cells, as well as skin and multiple internal organs such as the reticulo-
endothelial system, bones and joints, mucous membranes, eyes, testes, muscles, and 
adrenals [3]. Its clinical manifestations are related to the level of cell-mediated 
immunity of individual patients [1, 4]. The multidrug therapy consists in combinations 
of dapsone (DAP), rifampicin, and clofazimine to treat multibacillary leprosy (MB), 
while DAP in combination with rifampicin is usually used to treat paucibacillary (PB) 
leprosy [1]. 
Dapsone (4,4’-diamino-diphenylsulfone, DAP) is a bacteriostatic drug that acts by 
competitive inhibition of the enzyme dihydrofolate synthetase and dihydrofolate 
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reductase, key enzymes in the folate biosynthesis pathway in M. leprae [1, 5]. Despite 
its therapeutic potential, DAP is classified as a class II compound according to the 
Biopharmaceutics Classification System (BCS) [6], and its low solubility was found to 
result in a low therapeutic index and high microbial resistance [7]. Several approaches 
have been attempted in order to improve DAP water solubility, such as encapsulation 
into nanoparticles [8], inclusion complexes with cyclodextrins [9], nanoemulsion [10, 
11] and co-crystals [7]. However, these strategies are often confronted with few 
practical limitations and the desired bioavailability enhancement may not always be 
achieved [12]. In this framework, solid dispersion system is one of the promising 
methods to improve the aqueous solubility of poorly soluble drugs, especially for oral 
solid dosage forms. 
In these formulations, the drug dissolution rate may be improved by reducing the drug 
particle size to almost a molecular level and by modifying the drug crystallinity to 
generate a completely or partially amorphous state, increasing their saturation 
solubility in gastrointestinal fluids [13, 14]. 
 In the last few years, the International Conference on Harmonization Q8 guidelines, 
described the concept of Quality by Design (QbD) [15], which is getting great attention 
in pharmaceutical formulation development, focusing on the science of production, to 
construct a systematically quality in the final pharmaceutical product [12, 16]. It is 
widely known that formulation optimization can be implemented by the use of a 
combination of analytical approaches, such as design of experiments (DoE), response 
surface methodology (RSM), and optimization [17]. DoE is a structural and organized 
procedure for determination of critical factors that could affect the process or product 
in order to ensure their reliability and robustness [16, 18]. Likewise, RSM is applied to 
describe correlations between causal factors and response variables, enabling to 
improve understanding of the influence of different excipients and their interactions as 
well as predicting optimized formulations with the desired profile [18, 19]. 
Although the QbD concept seems promising, currently, few works have been developed 
in the field of solid dispersions on the importance of process and formulation factors 
[16, 18, 20, 21]. 
The present study aimed to develop DAP amorphous Polymeric Dispersions (PDs) by 
using DoE and RSM as optimization tools. For this purpose, a suitable carrier was 
chosen from an initial polymer screening, and the improvement on the equilibrium 
solubility was chosen as critical parameter. Additionally, it was determined the 
influence of PDs process in the selected polymer and also the influence of a third 
component on the drug equilibrium solubility. It was used two types of solvent 
evaporation methods (kneading and freeze-drying), due to their simplicity and 
New technologies for the improvement of leprosy MDT  
		
 118 
potential for scale-up, to manufacture PDs. The PDs were subsequently characterized 
regarding their crystallinity, morphology and molecular interactions. In vitro drug 
dissolution study was then performed with the formulations. 
 
2. Material and methods 
 
2.1  Material 
 
DAP was purchased from CHEMOS GmbH (Regenstauf, Germany). 
Polyethyleneglycols (PEG 1500, PEG 4000, PEG 8000 and PEG 20000), low molecular 
weight chitosan and Pluronic® F-68 were purchased from Sigma-Aldrich (St. Louis, 
USA); hydroxypropyl methylcellulose (HPMC; METHOCEL™ E5LV) was obtained 
from Colorcon Limited, UK. Polyvinylpyrrolidone (PVP K30) was obtained from Fluka 
(Buchs, Switzerland). Compritol® ATO 888 and Gelucire® 44/14 were gifted from 
Gatefossé (Saint-Priest, France) and inulin was kindly provided by Sensus (Roosendaal, 
the Netherlands). Ethanol (VWR chemicals), acetonitrile (VWR chemicals) and ultra-
pure water (MilliQ) were used in preparation of the solid dispersions.  
 
2.2 Methods 
 
2.2.1 Equilibrium solubility of DAP at different pH aqueous solutions 
 
Solubility studies of DAP were performed according to the shake flask method [22]. An 
excess amount of drug (± 20 mg) was weighed in test tubes containing 10 mL of ultra-
pure water, or selected buffer solutions, namely hydrochloric acid buffer pH 1.2, acetate 
buffer pH 4.5 and phosphate buffer pH 6.8 and 7.4 [23]. The samples were 
mechanically stirred in a thermostatic water bath at 37±1°C, for simulating 
physiological conditions [22], or 25 ±1°C for 48 h. Subsequently, the suspensions were 
filtered using paper filters (Whatman nº5), and quantified by spectrophotometry at 
291nm. All the experiments were conducted in triplicates. 
 
2.2.2 Screening of different polymeric carrier 
 
The effect of different carriers on the solubility of DAP was studied by formulating 
physical mixtures (PM) of DAP and several hydrophilic and hydrophobic carriers (PEG 
1500, PEG 4000, PEG 8000, PEG 20000, Pluronic F68, chitosan, inulin, 
Gelucire®44/14, Compritiol ATO 888; HPMC and PVP K30) at the ratio 1:1 and 1:5 
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(w/w). The equilibrium solubility was the parameter chosen (quality attribute) for the 
selection of the suitable carrier for the improvement of DAP solubility, which were 
performed similarly to the equilibrium solubility of DAP in ultra-pure water, at 37±1°C, 
for 48h.  
 
2.2.3 Preparation of physical mixture 
 
PM were prepared by weighing known amounts of DAP and the respective amounts of 
carriers, respecting the ratios studied which were merely mixed vigorously with a 
vortex during 5 minutes for complete homogenization. 
 
2.2.4 Preparation of solid dispersions 
 
2.2.4.1 Kneading Method 
 
Kneaded (KN) PDs were prepared with DAP: polymer ratios of 1:1, 1:3 and 1:5 (w/w). 
Accurately weighed quantity of polymer and drug were mixed with a mortar and a 
pestle, with sufficiently amount of a hydro-alcoholic solution (50:50 water/ethanol), 
which was dripped while the mixture was kneaded until the obtaining of a smooth and 
homogeneous mass. Finally the mass was dried in an oven at 60 °C for 2h and then 
passed through a #100 sieve. The PD were then stored in desiccator. 
 
2.2.4.2  Freeze-drying method 
 
Firstly, known amounts of DAP and PVP K30 were dissolved in acetonitrile and water 
respectively, respecting the ratios studied (1:1, 1:3 and 1:5 (w/w)). The solutions were 
maintained in magnetic stirring during 48h, for the complete solvent evaporation and 
better interaction drug-polymer. The final solutions were then frozen at -84ºC for 24h. 
The samples were freeze-dried (Lyoquest ECO, Telstar) using a condenser temperature 
of -65ºC and pressure of 0.5 mbar, during 48h, in order to obtain a dry cake. The 
samples were stored in desiccator for a complete drying.  
 
2.2.5 Design of experiments 
 
The experiments were carried out following a full factorial design to optimize and 
evaluate the effect of material attributes on the equilibrium solubility of DAP PDs 
obtained by two different methods (kneading and freeze-drying) and the respective PM. 
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A two factor, three level (32) design were performed in order to explore response 
surfaces and constructing second-order polynomial models with STATISTICA 10 
(Statsoft Inc, USA). The factors studied were the amount of polymer and the influence 
of a surfactant as a third component in the formulation. The levels and factors are given 
in Table 1. The response adopted was the equilibrium solubility after 48h, at 25ºC. The 
ANOVA analysis of the experimental data was performed by RSM. The polynomial 
model given by Eq. (1) was applied as the response function.  
 @ = 0%	 + 0,A, + 0/A/ + 0BA,A/ + 0CA,/ + 0DA// 
Where: 
Y = dependent variable (equilibrium solubility) 
X1 = Amount of polymer (mg) PVP K30; 
X2 = Amount of surfactant (mg) Pluronic F68; 
X1X2 = represent the interaction term; 
Xi2 = quadratic terms; and 
Ai = polynomial coefficients. 
 
The effects of the factors were considered significant when the ANOVA results 
indicated a significance level higher than 5% (p < 0.05). 
 
Tables 1. Independent variables and their corresponding levels of PD preparation. 
Variables Levels 
-1 0 +1 
X1 200 mg 600 mg 1000 mg 
X2 0 8 mg 20 mg 
 
 
2.2.6 Solid dispersions characterization 
 
2.2.6.1 X-Ray diffraction 
 
The X-ray power diffraction (XRD) data were collected with a PANalytical Empyrean 
X-ray diffractometer equipped with a Cu-Kα monochromatic radiation source. The 
scanning angle ranged from 2 to 60° in 2θ steps of 0.26° and a counting time of 5 
s/step.  
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2.2.6.2 Scanning electron microscopy 
 
The surface morphology of PM, KN and FD PDs were observed by scanning electron 
microscopy (SEM) on a FEI Quanta 400 FEG SEM from FEI (Hillsboro, Oregon, USA). 
The powder samples were also observed were mounted onto a metal stubs and vacuum-
coated with a layer of gold/palladium prior observation in microscope. 
 
2.2.6.3 Fourier transformed-infrared spectroscopy (FT-IR) 
 
FT-IR spectroscopy was used to investigate the physicochemical interactions occurring 
PM, KN and FD PDs. The IR spectra were obtained using the PerkinElmer® (Spectrum 
400) equipped with an attenuated total reflectance (ATR) device and zinc selenite 
crystals. The samples were transferred directly to the ATR compartment, and the result 
was obtained by combining the 16 scans. The spectra were recorded between 4000 and 
600cm-1 with a resolution of 4 cm-1. 
 
2.2.6.4 In vitro drug release  
 
The in vitro dissolution profiles of DAP, PMs and PDs were conducted using the USP 
paddle apparatus for all the samples. The samples were dropped into 900 mL of 
phosphate buffer pH 6.8 maintained at a temperature of 37°C ± 0.5 °C and stirred at a 
speed of 100 rpm for 60 min. A 5 mL aliquot of the sample was withdrawn at 5, 10, 15, 
30, 45, 60 min and further replaced with same volume of dissolution medium kept at 
the same temperature. Samples were filtered and analyzed by spectrophotometry at 291 
nm.  
 The release profiles were assessed by calculating the similarity factor f2 for each 
sample pair, according to the Eq. 2 [24, 25]. 
 
f2=50	×	9GH 	 	1 + 	 1/5 J- − L- 	/		M-+,
	D ×	100 	 
 
 
Where n is the number of dissolution points, Rj and Tj are the reference and test 
dissolution values at time t. Two dissolution profiles are considered similar when the f2 
value is 50–100 [26]. 
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3. Results and discussion 
 
3.1 Equilibrium solubility of DAP in different pH 
 
The values of DAP solubility determined at different pH, are present in Fig. 1. The 
observed behavior of solubility dependence on pH was due to the chemical 
characteristics of DAP, and the presence of amino groupings. At lower pH (1.2), the 
major micro-species of the drug is with both amino group protonated, which increase 
the solubility of the drug. On the other hand, as the pH increases, the solubility 
decreases, once at pH 4.5, 6.8 and 7.4 the drug maintain its molecular structure. 
 Moreover, it was observed that at physiological temperature (37ºC) the solubility was 
almost two fold higher. 
 
 
Figure 1. Effect of temperature and pH on the solubility of DAP (n=3). 
 
Drug permeation occurs mainly in the small intestine, and depends on several 
physiological and physical-chemical parameters concerning pharmaceutical dosage 
[27]. 
Despite the high protonation of DAP at lower pH leading to its high solubility, the 
luminal pH of the small intestine, where the majority of the drug is absorbed, ranges 
between 5.5 and 7.0. At these range of pH DAP molecule is almost totally unionized 
(pKa 2.41) which may lead to recrystallization in the lumen, hindering permeation rate 
[28]. 
 
3.2 Screening of different carrier 
 
Various carriers were used to evaluate the enhancement of DAP solubility, in two 
different ratios, in order to observe the tendency of DAP solubility with the amount of 
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the carriers. The equilibrium solubilities of the different DAP PMs in ultra-pure water 
are shown in Fig. 2.  
 
 
Figure 2. Effect of different carriers on the equilibrium solubility of DAP in water at 
37ºC, (n=3).  
 
Due to the hydrophobic characteristics of Gelucire 44/14 and Compritol ATO 888, it 
was expected that DAP solubility would not increase merely by preparing PM. These 
type of carriers are non-swellable lipophilic material, presenting a surface activity of 
self-emulsifying properties. Thus it is necessary to first melt the carriers and then 
disperse drug. Generally, hydrophobic carriers tend to promote sustain the release of 
the drug [29, 30], which is not the purpose of this work. 
The PM with carbohydrates carriers (inulin and chitosan) did not show great potential 
in the increment of solubility of the DAP. Hydrophilic systems, i.e., polymeric matrices, 
are the most used to develop PDs [30]. Among the hydrophilic polymers tested (PEGs, 
HPMC and PVP K30), only the PVP K30 was found to significantly influence DAP 
solubility, and this increment seems to be proportional to the amount of polymer used. 
On the other hand, HPMC provided a slight decrease on DAP solubility inversely 
proportional to the amount of polymer, probably due its gelling properties, leading to 
drug association. Moreover, PEGs did not demonstrate any positive effect on DAP 
solubility, and a positive correlation between the concentration of PEG and the 
molecular weight was observed on DAP solubility. Despite the extensive use of PEGs in 
PDS, the decrease in DAP solubility in PM suggests that the interaction between the 
drug and the polymer should be studied deeper. 
The use of PVP K30 to formulate PDs was previously proposed [16, 18, 31-33]. The 
mechanism by which it leads to increased equilibrium solubility is due to wetting and 
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decreased surface tension effects [32, 33]. In addition, due to the amorphous 
characteristic of PVP, the system became partially crystalline, which is more favorable 
to be completely amorphous when formulating PDs, where the drug has a better chance 
to be molecularly dispersed in the carrier [29], especially when there is a possibility of 
hydrogen interactions between the carrier and the drug [30]. 
Based on the results, the PVP K30 was the polymer that seems to be most suitable to 
increase DAP solubility, which solubility increases as the amount of PVP increases. It is 
expected that applying different processes to obtain PDs, better results may be 
achieved. Therefore, PVP K30 was chosen as polymer model for further studies. 
Recent studies have shown that during the accelerated dissolution of binary PDs, an 
unavoidable supersaturation of drug and its consequent recrystallization may occur. In 
this context, the properties of the carrier can be tailored to the needs of the system, e.g., 
stabilization of a solid solution or improvement of the dissolution rate [34]. The 
inclusion of surfactants as a third component in the PDs may help to avoid drug 
recrystallization and to stabilize the systems [35, 36]. It was already reported that the 
use of Pluronic® may maintain solution concentrations that were higher than the 
equilibrium solubility of crystalline drug due to solubilizing effect and surface activity 
of these polymeric surfactants [20]. 
 
3.3 Optimization and evaluation of PDs by Design of Experiments and 
Response Surface Methodology 
 
RSM is a collection of mathematical and statistical techniques based on the fit of a 
polynomial equation to the experimental data, which must describe the behavior of a 
data set with the objective of making statistical previsions. Before applying the RSM 
methodology, it is first necessary to choose an experimental design that will define 
which experiments should be carried out in the experimental region being studied [37]. 
DoE, on the other hand, is an optimization technique that aims to evaluate all the 
potential factors simultaneously, systematically and speedily, and can be applied for 
process or products [38]. Together they are useful tools during formulation design, and 
has been applied successfully during the optimization of PDs [16, 18, 20, 39, 40]. 
In order to promote further solubility of DAP, a novel ternary PDs system consisting of 
DAP, PVP and Pluronic F68 were investigated through DoE. PDs systems were 
obtained by kneading (KN) and freeze drying (FD) methods, in order to evaluate the 
influence of the process. 
The experimental results with the respective observed responses of the dependent 
variables are shown in Table 2. The maximum equilibrium solubility after 48h varied 
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between 100.9 and 192.7 µg/mL for PM, from 198.2 and 459.7 µg/mL for KN and from 
344.2 and 994.6 for FD solid dispersion. The highest value of equilibrium solubility was 
obtained from the sample 7 of the FD PD, being also the formulation that originated 
higher solubility values using KN. All the values obtained from FD solid dispersions 
were higher than those obtained from KD, proving that this method was more efficient 
in the improvement of DAP solubility. Likewise, in all the cases, the influence of the 
Pluronic F68 as a third component of solid dispersions was not positive, according to 
the results of equilibrium solubility.  
 
Table 2. Equilibrium solubility obtained from physical mixtures (PM), and PDs o 
tained by kneading (KN) and freeze-drying (FD) 
 
Based on these results, the process inputs and the response variables were related using 
a quadratic equation with statistical analysis through STATISTICA 10 software. X1 
represent amount of PVP K30 and X2 represent the amount of Pluronic F68. The 
results of the regression coefficients of the obtained equations, the R squares calculated 
and the Fcalculated for each model are shown in Table 3. As observed, all the F calculated 
were much higher than the Fcritic (9.02) with 95% of confidence, proving that the models 
are statistical significant, and could be used to achieve a suitable input values. The 
larger the coefficient is, the higher is the influence of the material attribute on the 
response. It can be inferred from Table 3 that the PVP K30 as material attribute have a 
significant effect on the equilibrium solubility of DAP in all the techniques used. 
With the equations obtained, 3D responses surface plots were obtained, as shown in 
Fig. 3. The RSM models shows correlations coefficient (R2) of 0.989 for PM, 0.989 for 
KN and 0.999 for FD method, which prove that the models obtained are very well 
correlated. The qualities of the models were evaluated by plotting correlation plots 
(predicted data vs experimental data) and residual plots (residual vs experimental 
Sample Independent Variable Dependent Variables 
X1 X2 Physical 
mixture (PM) 
µg/mL 
Kneading (KN) 
µg/mL 
Freeze Dried (FD) 
µg/mL Real 
(mg) 
Coded Real 
(mg) 
Coded 
1 
2 
3 
4 
5 
6 
7 
8 
9 
200 
200 
200 
600 
600 
600 
1000 
1000 
1000 
-1 
-1 
-1 
0 
0 
0 
+1 
+1 
+1 
0 
8 
20 
0 
8 
20 
0 
8 
20 
-1 
0 
+1 
-1 
0 
+1 
-1 
0 
+1 
150.2 ± 7.9 
144.2 ± 10.8 
134.7 ± 55.8 
166.2 ± 10.5 
172.4 ± 16.5 
100.9 ± 10.3 
189.8 ± 8.1 
192.7 ± 11.2 
190.4 ± 12.1 
252.3 ± 11.5 
198.2 ± 4.9 
198.3 ± 7.8 
315.6 ± 5.8 
249.7 ± 3.5 
253.0 ± 12.5 
459.7 ± 4.4 
399.4 ± 9.8 
329.1 ± 9.0 
408.5 ± 22.6 
344.2 ± 22.0 
353.1 ± 21.7 
502.4 ± 18.2 
380.0 ± 30.1 
355.1 ± 21.0 
994.6 ± 47.7 
835.0 ± 22.8 
515.4 ± 48.5 
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data) (Fig. 4). It could be seen that all the models show high predictability coefficients, 
with few outliers, mainly for FD process, thus the predicted values for the three models 
were reasonably similar to the experimental data. In addition, the residual plots 
provided a better visual comprehension of the capability of the models, since all the 
data were widely scattered in predicting DAP solubility, as all of the points are tightly 
distributed along the horizontal axis (Fig. 4b,d,f). Thus, they can be judged as suitable 
models, with no trend in the data. These data reflect greater robustness in the freeze-
drying process, since all the process parameters may be controlled, which is of great 
value to the scale-up stage. 
 
Table 3. Regression analysis for responses for physical mixtures (PM), and PDs 
obtained by kneading (KN) and freeze-drying (FD) 
Reg. Coefficients PM p-value KN p-value FD p-value 
Intercept. 213.225 - 446.254 - 692.565 - 
X1 (L) -0.378 0.0521 -0.878 0.0770 -1.844 0.0028 
X1 (Q) 0.0006 0.0090 0.0016 0.0099 0.004 0.0002 
X2 (L) -2.299 0.5904 -18.230 0.1808 -10.551 0.1983 
X2 (Q) -0.258 0.2095 0.786 0.1753 0.438 0.2050 
X1.X2 0.002 0.4872 -0.006 0.4682 -0.0207 0.0198 
R2 0.989 0.989 0.999 
Fcalculated 56.63 408.67 3287.90 
 
The influence of the amount of PVP K30 in the FD process was more relevant, 
comparing to KN and PM, confirmed by the values of the intercept of the equations 
obtained, which are the arithmetic means responses of all the runs [39], i.e., in all the 
FD PDs, the equilibrium solubility was higher than the others. In addition, for all the 
processes the quadratic coefficient had positive effect on the responses, indicating that 
the effect of the PVP on the equilibrium solubility is more important at higher amounts. 
On the other hand, the linear term of the amount of PVP had a negative impact for the 
freeze drying process. It can be explained by the fact that the freeze drying process itself 
is able to improve DAP solubility, and small amount of PVP would not influence on the 
response, and even lead to a decrease on the final result, only being advantageous if 
used in higher concentrations. 
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Figure 3. Response surface plot showing the effect of the amount of PVP K30 and 
Pluronic F68 on the equilibrium solubility of DAP from physical mixtures (PM), and 
PDs obtained by kneading (KN) and freeze-drying (FD). 
 
 
Figure 4. Predicted vs experimental data plots (top) and residual plots (bottom) for 
data obtained by RSM where: a and b are from PM, b and c are from KN, e and f are 
from FD. 
 
 
Moreover, the amount of Pluronic F68 influenced negatively, i.e., decreased the 
positive effect of PVP K30, once the regression coefficient of X1.X2 was also relevant, but 
with negative signal. It was expected that the addition of a surfactant may increase the 
equilibrium solubility of DAP, as already described in other studies. Although, due to 
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the amphiphilic structure of Pluronic F68, which has the properties to self-assemble 
into micelles in aqueous solution when the concentration was above the critical 
micellar concentration, DAP might be entrapped by micelles formed, which may 
become an obstacle to the further solubilization after the 48h [34]. Thus, for further 
characterization, sample 7 of the FD PD was chosen.  
 
3.4 Solid dispersions characterization 
 
For the characterization of the solid dispersions, sample 7 was selected, according to 
the results of the formulation optimization. 
 
3.4.1 X-Ray diffraction 
 
The XRD patterns of PDs indicate changes in its crystalline structure. The 
diffractograms of DAP, PVP K30, and PDs obtaining by kneading and freeze drying 
method are depicted in Fig. 5. The crystalline character of DAP is explicit in the XRD, 
reflected in the intense peaks between 10º and 30 º [9], while the PVP K30 is 
completely amorphous, with complete absence of peaks. Regarding the PDs, it could be 
seen that the kneading method did not generate a completely amorphous material, 
although the intensity and some peaks is decreased, and in some cases, disappeared. 
On the other hand, in the freeze dried PDs XRD patterns, it was not found any 
characteristic peak of DAP, which indicates that the material is completely amorphous, 
due to a strong intermolecular interaction between the drug and the polymer, better 
explained in the further characterization, and due to the influence of the lyophilization 
process itself, already described in the literature, responsible to produce amorphous 
material, with very low density [32].  
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Figure 5. X-ray diffractograms of dapsone (DAP) and PVP K30 raw material; physical 
mixtures (PM), and PDs obtained by kneading (KN) and freeze-drying (FD). 
 
 
3.4.2 Scanning electron microscopy 
 
The Fig. 6 shows SEM images of DAP, PVP K30, PM, and PDs obtained by kneading 
and freeze dried process. The crystalline profile of DAP and the amorphous character of 
PVP K30, with rounded shapes, are well defined. In the SEM images of PM, the drug 
interacts only superficially, while in the images obtained from KN PD, the particles 
present new shapes, not spherical, where the drug appear to be inserted in the 
polymeric matrix, in its crystalline form. This phenomenon is able to improve the drug 
solubility due to a higher interaction between the drug and the PVP K30, leading to a 
decrease of the superficial tension. 
In the case of the FD PD, the images show irregular particles with flake-like 
appearance, which is typical of freeze-dried materials [32, 41]. In these images it was 
not possible to identify the crystals of DAP neither the rounded shapes of PVP K30. 
Instead, a homogeneous distribution was observed, wherein the drug appears to be 
dispersed within the polymer. This homogeneous matrix reflects the best results 
obtained during the formulation optimization, once in this case the interaction between 
the drug and the polymer was at molecular level, which facilitate the dissolution 
process. 
 
 
 
New technologies for the improvement of leprosy MDT  
		
 130 
 
Figure 6. Representative scanning electron microscope (SEM) images of PVP K30 (a), 
and DAP raw material (b); physical mixtures (PM) (c,d), and PDs obtained by kneading 
(KN) (e,f), and freeze-drying (FD) (g,h). 
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3.4.3 Fourier transformed-infrared spectroscopy (FT-IR) 
 
In the FT-IR spectra from DAP (Fig. 7), it can be observed a band at 3300–3400 cm-1 
corresponding to the stretch of the amine group (N-H), and peaks corresponding to 
bend vibration of –NH2 groups between 1590 and 1550 cm-1. The bands at 1143 and 
1180 cm-1 are ascribed to the symmetric and asymmetric vibrations of the sulfone group 
(-SO2) [42]. PVP contains an amide carbonyl on the pyrrolidone monomer, which is a 
strong hydrogen bond acceptor [43]. The –C=O group of PVP is considered to be the 
most favorable site for interaction due to the steric constraints on the N atom [44]. The 
spectra of the PVP starting material showed, among others, important bands at 2955 
cm−1 (C–H stretch) and 1665 cm−1 (C=O) [32]. 
Regarding the PDs, compared to the PM, it could be seen that the region corresponding 
to the N-H bonding showed a lower intensity and hypochromic shift, especially in the 
case of FD, which can be explained by hydrogen bond between the drug and PVP K30 
at a molecular level. Moreover, the broadening of the stretching region could be 
attributed to changes in the crystal structure, particle shape and size [45]. 
Intermolecular interactions in the amorphous solids can directly affect their molecular 
mobility [46] causing changes in the oscillating dipole of the molecules, which may lead 
to changes in the frequency and bandwidth of interacting groups in the spectrum [47]. 
Thus, drug–polymer interactions in PDs can be explored using IR spectroscopy, 
whereby the presence of specific interactions is often used to infer miscibility. Specific 
interactions between the drug and polymer are usually hydrogen bonding [48]. 
Additionally, amorphous systems may involve a weakening or strengthening of 
hydrogen bonds thus leading to decrease in band intensities, due to the general 
diffusion and broadening [46]. 
DAP molecule contains considerable potential moieties for intermolecular interactions 
via −NH2 and −SO2− functional groups [46, 49]. The –SO2 group has a strong electron 
withdrawing nature, although this phenomenon may lose its electron-accepting 
capability due to the presence of aromatic ring directly bonded, which lead to a 
stabilization of its electrons at the neighborhood. On the other hand, the −NH2 group 
becomes much more susceptible to donate protons, which is probably the most 
available site for hydrogen bonding. 
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Figure 7. FT-IR spectra (a) and detailed N-H stretching region (3700–3000 cm−1) (b) 
of DAP, PVP K30, physical mixture (PM), kneaded (KN) PD, and freeze-dried (FD) PD. 
 
 
3.4.4 In vitro drug release  
 
The release profiles of DAP from PDs in comparison with DAP powders and PMs is 
depicted in Fig. 8. DAP powder exhibited a poor dissolution rate with 41% of drug 
dissolved after 30 min. PM presented a slight improvement in the dissolution 
properties in comparison with the pure drug. These results suggested that PVP itself 
might act as a weak solubilizer in PMs, contributing to the limited increase in drug 
dissolution, as well as in preventing drug aggregation [34]. Nevertheless, it was evident 
that PDs exhibited faster dissolution rates than DAP powders and corresponding PMs. 
The drug release from PD formulations were considerably increased, indicating a fast 
and burst release of DAP in dissolution media, since more than 75% of drug was 
released in first 10 minutes, when compared to the pure drug, which dissolution was 
very slow, less than 10% in the same period of time. 
The dissolution rate improvement of the drug in the PDs may be attributed to the high 
hydrophilicity of the PVP, smaller particle size and consequently larger surface area 
(especially in freeze-dried PDs) and decreasing in drug crystallinity [33, 45]. 
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Figure 8. Dissolution profiles of dapsone (DAP) raw material, physical mixtures, and 
PDSs obtained by kneading (KN) and freeze-drying (FD) processes, and the similarity 
factors between all the formulations and pure drug. 
 
 
The similarity factor, f2 has been used by the FDA for the comparison of dissolution 
profiles. f2 values between 50 and 100 to indicates similarity between two dissolution 
profiles and f2 values of 100 for two identical profiles [25]. From the results, none 
similarity was observed between the dissolution profiles of pure drug, PM and both PDs 
formulation, since all the correlations provided f2 values below 50 (Table 5). This 
corroborates with the morphological and crystallinity differences observed within FD 
and KN samples. Despite the burst effect in the drug release profile, the dissolution in 
the first 10 min was faster for FD dispersions compared with the KN samples. This 
phenomenon may be attributed to the very wettable and needle shaped particles, in 
addition to a completely amorphous powder obtained by freeze drying method, which 
not can be obtained from the kneading process, from which was obtained a partially 
crystalline powder, as observed from the XRD and SEM analysis. Accordingly, the 
particle size and particle shape of the PDs powders may be considered as the main 
cause of the drug release rate enhancement, since in all formulations the amount of 
PVP was the same, so its hydrophilic character did not interfere for differentiate the 
profiles [32, 45]. 
Despite the freeze-drying process has improved DAP solubility and immediately 
released the drug, and the fact that this process can be easily scale-up with low losses, 
the kneading process also provided satisfactory results considering the simplicity low-
cost of the technique. 
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4. Conclusion 
 
In this study, QbD was successfully applied for pharmaceutical development of DAP 
PDs, through the application of DoE and RSM as tools. A full-factorial design was 
developed to investigate the effect of the variables (amount of PVP K30 and amount of 
Pluronic® F68) on the equilibrium solubility of the PM, KN and FD PDs. 
Implementation of response surface plot and regression correlation analysis revealed 
the relationship between the variables and the responses. It was observed that the 
solubility of DAP increased directly with the increase in amount of PVP K30, which was 
not observed with the addition of Pluronic® F68. This phenomenon was more evident 
for the formulations obtained by the freeze-drying method. These findings could be 
explained by the improved wettability caused by the highly hydrophilic polymer PVP, 
mainly by particle size reduction, by the conversion of the crystalline form to the 
amorphous form and by the molecular interactions between drug and polymer in 
resultant dispersions, as supported by the FT-IR spectra. 
Results show that the PDs preparation method had a significant effect on the 
dissolution performance of DAP. Of the two processes studied, freeze-drying was more 
effective in producing PDs with higher dissolution rates than kneading. Although, 
despite the substantial differences between them from a manufacturing perspective, 
both solvent evaporation techniques used were able to improve DAP solubility and 
immediately released the drug. Freeze-drying can be advantageous in terms of 
dissolution enhancement but the associated production costs should be considered 
before applying this technology.  
The combination of preliminary studies and experimental design performed in the 
present study together with image and spectral analysis represent one step towards 
DAP PDs formulation development on the basis of Quality by Design, and showed 
increased prediction efficiency during the optimization procedure. 
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ABSTRACT 
 
Aim: To optimize the production of pH-sensitive dapsone (DAP) nanoparticles based 
on Eugradit L100 (NPs-EL100-DAP) for oral delivery. Materials & methods: NPs-
EL100-DAP were optimized using a Plackett–Burman design and a Box-Behnken 
design. The physicochemical properties of the obtained nanoparticles were monitored 
by microscopy, dynamic light scattering, UV-visible and Fourier-Transform Infrared 
spectroscopies, differential scanning calorimetry, in vitro release assays, and examined 
for cytotoxicity and permeation across intestinal barrier. Results: The in vitro release 
assay of NPs-EL100-DAP confirmed the nanoparticles’ pH sensitivity and the ability to 
deliver DAP at intestinal environment. NPs-EL100-DAP demonstrated enhanced 
intestinal interactions in comparison to free DAP, across Caco-2 monolayers. 
Conclusion: These studies demonstrate the potential of NPs-EL100-DAP as a 
therapeutic platform for oral treatment of leprosy. 
 
 
Key words: Eudragit L100, Caco-2 cell, leprosy, Box-Behnken design, Plackett–
Burman design, in vitro release assay  
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1. Introduction 
 
The oral route is still considered the safest and most convenient route of drug 
administration, as it provides higher patient compliance compared to other routes [1]. 
On the other hand, factors like low aqueous solubility, rapid metabolism of drug in the 
gastrointestinal tract (GIT) and low mucosal permeability commonly limit its in vivo 
performance [2]. Many approaches have been reported to overcome the limitations 
associated with drugs administered orally, especially regarding poorly soluble drugs. 
The main strategies are based on the reduction of drug particle size and increasing the 
dissolution rate. Among the emerging strategies, the use of nanoparticles as drug 
delivery systems has been shown to be a promising tool due to their powerful 
advantages by providing an enhanced safety and efficacy of the drugs, promoting 
targeted and/or prolonged delivery, and offering improved stability of drug against GIT 
chemical/enzymatic degradation [3]. 
Besides, recent studies have demonstrated the advantages of the use of stimuli-
responsive systems as pH-sensitive nanoparticles for targeted intestinal delivery of 
drugs, avoiding undesired gastric absorption, preventing potential degradation in the 
stomach environment which may lead to the formation of toxic compounds, and 
ensuring the drug release in the intestine [2, 4, 5]. 
Several polymers have the ability to protect the drug against the action of the stomach 
enzymes and acidic gastric fluids [6], remaining intact in low pH environments, and 
dissolving at higher pH conditions [5]. Eudragit L100 (EL100) which is an anionic 
copolymerization product of methacrylic acid and methyl methacrylate, is an enteric 
pH-dependent copolymer, which is soluble above pH 6, thus being commonly used for 
the preparation of enteric solid dosage forms [4-8]. 
Dapsone (4,4′-diaminodiphenylsulfone) (DAP) is a sulfone group drug with unique 
properties as its dual antimicrobial and anti-inflammatory therapeutic activity. It has 
been used as the drug of choice in the multidrug therapy of leprosy due to its 
bacteriostatic action against Mycobacterium leprae, inhibiting the synthesis of the folic 
acid via competition with p-aminobenzoate [9, 10]. However, severe side effects as 
hemolytic anemia and peripheral neurophathy have been reported after oral 
administration [10]. The systemic effects are related to the occurrence of toxic 
metabolic products, although relevant digestive problems such as nausea, vomiting, 
and stomatitis may occur. Besides, the clinical use of DAP is limited due to its 
physicochemical properties namely water low solubility, being classified as a Class II 
agent according to the biopharmaceutical classification system, which leads to an 
inadequate oral bioavailability [9]. 
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The aim of this study was to screen and optimize the production of pH-sensitive 
Eudragit L100 DAP loaded nanoparticles (NPs-EL100-DAP) by evaluating the variables 
that affect the selected critical parameters. First, a Plackett–Burman screening design 
(PBD) was used to identify the main factors affecting NPs-EL100-DAP, followed by a 
Box-Behnken design (BBD) which was applied to optimize formulation parameters of 
the nanoparticles. Further, the optimized nanoparticles were characterized regarding 
particle size distribution, polydispersity index (PDI), association efficiency (AE), 
morphology and in vitro dissolution testing under different pH conditions (pH 1.2 and 
6.8). Cell viability of the obtained formulations was also assessed with three different 
cell lines, in order to evaluate the toxicity of the particles when in contact with gastric 
(MKN-28) and intestinal (Caco-2 and HT29-MTX cells). Finally, the in vitro 
permeability of NPs-EL100-DAP through Caco-2 monolayers was performed in order 
to monitor the performance of the developed system. 
 
2. Materials and methods 
 
2.1 Materials  
 
DAP was purchased from CHEMOS GmbH (Regenstauf, Germany); Pluronic® F-68, 
and polyvinyl alcohol (PVA) were purchased from Sigma–Aldrich (St. Louis, USA); 
poly(methacrylic acid-co-methyl methacrylate) 1:1 (Eudragit® L100, Evonik Roehm 
GmbH, Darmstadt, Germany), ethanol (VWR chemicals, Carnaxide, Portugal) and 
acetone (JGMS, Odivelas, Portugal) were used to produce the nanoparticles. 
Caco-2 and MKN28 cell lines were purchased from the American Type Culture 
Collection (ATCC, Wesel, Germany) (passage number 35 - 55); HT29-MTX cell line was 
kindly provided by Dr. T. Lesuffleur (INSERM U178, Villejuif, France). Dulbecco’s 
Modified Eagle Medium (DMEM), Roswell Park Memorial Institute (RPMI), fetal 
bovine serum (South America origin), Pen-Strep (penicillin, streptomycin) and 
Trypsin-EDTA were all obtained from Gibco (Paisley, UK). Thiazolyl blue tetrazolium 
bromide (MTT) was obtained from Sigma–Aldrich. 
 
2.2 Eudragit L100 nanoparticles preparation 
 
Dapsone-loaded Eudragit L100 nanoparticles (NPs-EL100-DAP) were prepared via the 
nanoprecipitation method, previously described [4, 11], with slight modifications. 
Briefly, known amounts of Eudragit L100 and DAP were co-dissolved in a mixture of 
ethanol-acetone (1:1), in defined volumes, according to the experimental design. The 
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organic solution was subsequently slowly dripped (0.5 mL min-1) in the aqueous phase 
containing the surfactant (PVA 1% (w/v)), previous acidified to pH 3 to promote the 
polymer precipitation. The final solution was maintained under magnetic stirring at 
350 rpm (RT 15 Power IKAMAG Multiposition Magnetic Stirrer, Staufen, Germany) 
and room temperature until complete solvent diffusion. The particles were centrifuged 
using an Allegra X-15R centrifuge (Beckman Coulter), at 11,200 xg for 30 min, and the 
supernatant was discarded. This procedure was performed three times with acidified 
water (pH 3) to eliminate non-encapsulated drug. The resultant particles were freeze-
dried for 48 h, using a LyoQuest 85 plus v.407 Telstar freeze dryer (Telstar® Life 
Science Solutions, Terrassa, Spain). 
 
2.3 Experimental design 
 
2.3.1 Preformulation screening: Plackett-Burman 
 
A Plackett-Burman design (PBD) was performed to screen and evaluate the process and 
formulation parameters that may influence the desired profile of the nanoparticles, 
allowing to evaluate a wide number of variables at the same time with good level of 
accuracy. Moreover, this experimental design aimed to select the main effects for the 
subsequent studies. The design was constructed with seven factors and eight 
experiments, using the STATISTICA 10 (StatSoft®, Dell Software, Round Rock, TX, 
USA) software. The parameters studied were chosen on the basis of preliminary 
investigation and on the literature. All the non-studied variables such as the type of 
polymer (EL100), organic solvent (ethanol:acetone, 1:1 v/v) and solvent evaporation 
method (magnetic stirring at 300 rpm, room temperature) were kept constant. The 
selected dependent variables were: particles size (Y1), polydispersity index (Y2) and 
association efficiency (Y3). The independent variables were: (X1) volume of aqueous 
phase; (X2) type of surfactant; (X3) surfactant concentration (w/v); (X4) ratio 
polymer/drug; (X5) polymer concentration (w/v); (X6) volume of organic phase; and 
(X7) method of preparation (coded and real levels in Table S1). 
 
2.3.2 Optimization: Box-Behnken Design 
 
After the assessment of the critical parameters by the PBD, a three factor-three level 
Box-Behnken Design (BBD) was applied to optimize the nanoparticle formulation, with 
15 runs including 3 replicates of the central point. The selection of factors (independent 
variables) and their respective levels were based on the PBD results. All the other 
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variables not used in the BBD were maintained constant, namely volume of aqueous 
phase (10 mL); type of surfactant (PVA); surfactant concentration (1%, w/v) and 
method of nanoparticle production (nanoprecipitation). 
The data was analyzed by the regression coefficient of each response, following the 
equation: 
 @ = $% + $,A, + $/A/ + $BAB + $,/A,A/ + $,BA,AB + $/BA/AB + $,,A,/ + $//A// + $BBAB/ 
 
Where Y is the response, b0 is the intercept representing the mean of the results while 
b1 to b33 are the associated coefficient; X1, X2 and X3 are the independent variables, 
reassigned as ratio polymer/drug (X1); polymer concentration (X2); and volume of 
organic phase (X3). The combination of factors and quadratic terms are expressed as 
XiXj and Xi² respectively. 
The polynomial equations were statistically examined through the analysis of variance 
(ANOVA) and the factors were considered significant when the values of p of the 
regression coefficients were < 0.05. The correlation coefficients (R2) and lack of fit were 
also obtained in order to predict the accuracy of the models. Graphical correlations 
between two independent variables and a single response were depicted in 3D 
responses surface plots, and optimum values for each variable were assessed based on 
the desirability profile. In order to evaluate the robustness of the developed models, the 
desired particle was obtained in triplicated as a check-point, where the magnitude of 
the error between observed and predicted values was evaluated following the equation: 
 N82O	 % = |predicted	value	– 	observed	value|G$O43a4;	a29b4 ×100 
 
2.4 Nanoparticles characterization 
 
2.4.1 Particle size and polydispersity index 
 
The mean particle size as well as the polydispersity index (PDI) were analyzed using a 
ZetaPALS, Zeta Potential Analyzer (Brookhaven Instrument Corps, Holtsville, NY, 
USA), at 25ºC with a light incidence angle of 90º. The fresh particles were properly 
diluted with ultrapure water until reaching a suitable concentration (Kcps 300-500), 
and the obtained value is the representation of multiples runs (n=6).  
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2.4.2 Association efficiency 
 
For the determination of drug association in the different formulations of the 
experimental design, nanoparticles were diluted 5 times with acidified ultrapure water 
(pH 3) and centrifuged at 11,200 g for 30 min. Absorbance of supernatant was 
measured at 391 nm, which corresponds to DAP maximum absorption wavelength, by 
UV-VIS spectroscopy (Jasco V-660, Easton, MD, USA). The percentages of association 
efficiency (AE) was calculated based on the following equation: 
 0c = 8586829	27Gb56	Gd	e0: − 34fGa434;	e0:8586829	27Gb56	Gd	e0: ×10 
 
2.4.3 Fourier-Transform Infrared 
 
The spectra of DAP, NPs-EL100 and NPs-EL100-DAP were obtained in order to 
evaluate possible chemical interactions between DAP and the excipients used to 
formulate the nanoparticles. The Fourier-Transform Infrared (FT-IR) spectra were 
obtained using the PerkinElmer® Spectrum 400 (Waltham, MA, USA) equipped with 
an attenuated total reflectance (ATR) device and zinc selenite crystals. The samples 
were transferred directly into the ATR compartment, and the result was obtained by 
combining the 16 scans. The spectra were recorded between 4000 and 600 cm−1 with a 
resolution of 4 cm−1. 
 
2.4.4  Morphology 
 
The morphology of the optimized nanoparticles was examined employing transmission 
electron microscopy (TEM, JeolJEM-1400, JEOL Ltd., Tokyo, Japan). Images were 
obtained after dropping diluted colloidal dispersions over a grid followed by negative 
staining with uranyl acetate. The grid was exposed at the accelerating voltage of 60 kV. 
 
2.4.5 Differential scanning calorimetry 
 
Differential scanning calorimetry thermograms of DAP, EL100, NPs-EL100 and NPs-
EL100-DAP were obtained aiming to evaluate the physical changes in DAP crystallinity 
before and after the production process. The thermal analysis was performed using a 
DSC 200 F3 Maia (Netzsch, Selb, Germany). 
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Accurately weighted samples (1-2 mg) were poured into aluminum pans and 
hermetically sealed. An empty pan was used as reference. The samples were scanned 
from 30 to 250 ºC, at 10 ºC/min. Nitrogen gas was used as purge gas, at 40 mL/min. 
 
2.4.6 In vitro drug release 
 
In vitro DAP release profile from the optimized nanoparticles was evaluated using the 
dialysis bag diffusion [12-14] method, in two different pH conditions, 1.2 and 6.8, to 
simulate gastric and intestinal physiological conditions, respectively. The assay was 
carried out in sink conditions.  
Briefly, 1 mL of unwashed colloidal dispersions (containing the equivalent of 750 µg.ml-
1 in DAP) was placed into dialysis bag with a molecular weight cutoff of 3,500 Da. The 
dialysis bags were immersed into 40 mL of dissolution media, and stirred magnetically 
(RT 15 Power IKAMAG Multiposition Magnetic Stirrer, Staufen, Germany) at 350 rpm 
and 37.0 ºC ± 0.5ºC. The dialysis bag was the donor compartment, and at regular 
interval times, 200 µL of the outside dissolution media were withdrawn and replaced 
by the same amount of fresh media. Subsequently, the samples were read 
spectrophotometrically in a microplate reader (SynergyTM HT, Biotek, Winooski, VT, 
USA), at specific wavelengths (288 nm for pH 1.2 and 291 for pH 6.8) for each different 
dissolution media. The release profile was evaluated during 2 h, for the pH 1.2, and 
during 6 h for the pH 6.8, in order to simulate the transit time of the particles in 
stomach and small intestine, respectively [15, 16]. The experiment was performed in 
triplicate (n = 3) for each pH condition.  
 
2.5 Cell studies 
 
Caco-2 and HT29-MTX cell lines were cultured in DMEM, and MKN-28 cells were 
cultured in RPMI, both medium supplemented with 10% (v/v) of fetal bovine serum 
(FBS), and 1% (v/v) penicillin-streptomycin. Cells were grown in a humidified 
incubator at 37 ºC, 5% CO2 and 95% relative humidity, and the cells were detached 
using a trypsin solution when reaching 80% confluence. 
 
2.5.1 Cell viability  
 
Cell viability assays were performed using the MTT assay with Caco-2, HT29- MTX and 
MKN-28 cell lines in order to evaluate the effect of NPs-EL100 and NPs-EL100-DAP 
along the GI tract. The three types of cells were seeded in 96-well microplates at a 
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density of 5 x 104 cells per well for Caco-2 and HT29-MTX; and at 105 cells per well for 
MKN-28. 
The nanoparticles suspensions and free DAP were tested in a concentration-dependent 
range (25 – 400 µg mL-1 in relation to DAP concentration) prepared in culture medium. 
Free DAP samples were prepared from a stock solution in DMSO, and properly 
dilutions were performed immediately before the assays, so that the maximum 
concentration of DMSO did not exceed 4% (v/v). 100 µL of each sample were incubated 
for 24 h with Caco-2 and HT29-MTX cell lines, and during 4 h for MKN-28. After each 
time of incubation, the samples were replaced with 100 µL of MTT solution (5 mg mL-
1), and incubated for more 2 h. Then, the MTT solution was withdrawn, and the purple 
crystals were solubilized in 100 µL of dimethyl sulfoxide. The optical density of the 
solution was measured at a wavelength of 570 nm in a SynergyTM HT Multi-mode 
microplate reader (BioTek Instruments Inc., Winooski, VT, USA). Untreated cells were 
taken as control with 100% viability and cells exposed to 4% (v/v) DMSO used as 
control for free DAP. The MTT test was performed in triplicate and results were 
expressed as mean values ±SD. The cell viability (%) in relation to control cells 
(untreated cells) was calculated by Eq. (3):  
 ?499	a82$8986"	(%) = 0 f499O	85fb$264;	i86ℎ	dG37b9268G50 f499O	85fb$264;	i86ℎ	fb96b34	74;8b7×100 
 
2.5.2 DAP permeation across Caco-2 monolayers 
 
For the permeability studies, Caco-2 cells were seeded on 12-well Transwell inserts 
(Corning Transwell Clear, pore size 3 µm, area 0.33 cm2) at a cell density of 105 cells 
cm-1. The cells were grown in supplemented DMEM, and the culture medium was 
added to both apical and basolateral compartments, with changes every other day, 
during 21-23 days, until the monolayer achieve suitable initial transepithelial electrical 
resistance (TEER) values. The tightness of the Caco-2 monolayer was measured as 
TEER across the Caco-2 cell monolayer using a Millicell1-ER system (Millipore 
Corporation, Bedford, MA), equipped with a pair of chopstick electrodes that inserted 
into the apical medium. The TEER at the beginning of these studies was higher than 
400 Ω cm2, indicating an intact monolayer; TEER values were also obtained after 
completion of flux experiments at 6 h. The resistance measurement of the medium 
without cells was considered as blank. The permeability was carried out by adding 0.5 
mL of culture medium containing the equivalent of 100 µg.mL-1 of DAP (as NPs-EL100-
DAP or unloaded DAP) in the apical side of the cell monolayer. The samples were 
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incubated for 6 h, and at predetermined time intervals (1, 2, 3, 4 and 6 h), 0.5 mL were 
sampled from the basolateral compartment and replaced with fresh culture medium. 
The amount of DAP in the samples was analyzed by HPLC according the section 3.5. 
The experiments were carried out in triplicate. The cumulative amounts of DAP 
transported across the monolayers were calculated from the concentrations measured 
in the basolateral compartment. The apparent permeability (Papp) was calculated as 
described elsewhere [17]. 
 
2.6 Dapsone determination by high-performance liquid 
chromatography 
 
The quantification of DAP in cell culture media was performed by high-performance 
liquid chromatography (HPLC) with UV detection. The HPLC system (Jasco) 
comprised a high-pressure pump (PU-2089), an autosampler (AS-2057) and a diode 
array detector (MD-2015) programmed for peak detection at 280 nm, controlled by 
ChromNAV software. A reversed phase Kinetex® core-shell C18 column (250 x 4.1 mm, 
5 µm particle size, 100 Å; Phenomenex, Torrance, CA, USA) was used as stationary 
phase. Elution was performed in gradient mode using as mobile phase a mixture of 
aqueous acetate buffer (final concentration 50 mM, pH 4.8) and acetonitrile, at a flow 
rate of 1 mL min-1. The selected gradient started with 30% (v/v) of acetonitrile, which 
was maintained up to 3 min. From 3 to 5.5 min, the contribution of acetonitrile was 
rapidly changed to 80% (v/v). This composition was maintained up to 7.5 min, after 
which the initial conditions were re-established and held during 5.5 min more to assure 
column equilibration. Hence, the total run time was 13 min. The injection volume was 
20 µL. Standard dapsone solutions were prepared at 0.5, 1, 2.5, 5, 7.5, 10, 15 and 20 µg 
mL-1 in culture medium containing 40% (v/v) of acetonitrile and 50 mM acetate buffer, 
pH 4.8. To prepare the samples for HPLC analyses, 200 µL of each sample was added 
to 160 µL of acetonitrile and 40 µL of acetate buffer 500 mM, pH 4.8, to final 
concentrations of 40% (v/v) and 50 mM, respectively. The mixtures were vortexed and 
centrifuged at 18,000 × g for 10 min at room temperature. After centrifugation, 
supernatants were collected and analyzed by HPLC. 
 
2.7 Data analysis 
 
The statistical analysis of the experimental design was performed using STATISTICA10 
(StatSoft®) software. GraphPad Prism software (version 6, GraphPad Software, La 
Jolla, CA, USA) was used for statistical comparisons of the results to control for the 
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cytotoxicity studies. Statistical analysis of the results was performed using student 
(unpaired) t-test and one-way ANOVA test. All the other results were presented as 
mean and standard deviation (SD). The differences were assumed statistical significant 
when p < 0.05 (95% confidence level). 
 
3 Results and discussion 
 
3.1 Experimental design 
 
3.1.1 Preformulation screening: Plackett-Burman  
 
During the development of nanoparticles formulations, it is crucial to define at first the 
suitable method of preparation, and then set and control production conditions, 
especially for polymeric nanoparticles in which several steps of the method of 
preparations may affect the characteristics of the obtained nanoparticles [18]. 
Plackett-Burman designs are screening models that involve a large number of factors 
and relatively few runs [19]. Because PBD are fractional factorial designs, the number 
of runs needed to investigate main effects is equal to 2n or multiples of 4 and therefore 
can be used to identify critical factors with a reasonable number of experimental runs 
and good degree of accuracy. Therefore, they are very useful to set or eliminate 
variables in further investigations [20]. Based on these facts, it is essential to perform 
preliminary studies in order to screen several critical parameters during the 
development of polymeric nanoparticles as: (i) drug solubility in the organic phase, 
which may influence the drug loading; (ii) the miscibility of the organic solvents with 
the aqueous phase considering the choice of the nanoprecipitation method; (iii) 
inclusion of a suitable stabilizer to prevent the aggregation of the nanosuspensions; (iv) 
the ratio polymer/drug as well as their concentration in the nanosuspension, which are 
important to both drug loading and stability of nanosuspensions [19]. Other important 
parameters were fixed as the type of polymer (EL100) due to its specific pH sensitivity; 
and the organic solvent used (ethanol:acetone - 1: 1 v/v) due to its miscibility with 
water and ability to solubilize of both drug and polymer. The obtained responses for the 
prepared formulations are expressed in Table 1. 
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Table 1. Layout and observed responses of Plackett–Burman screening design 
batches 
*X1: volume of aqueous phase; X2: type of surfactant; X3: surfactant concentration (w/v); 
X4: ratio polymer/drug; X5: polymer concentration (w/v); X6: volume of organic phase; X7: 
method E= emulsion N = nanoprecipitation. 
 
The results of the PBD are shown as a standardized Pareto chart (Figure 1), which 
consists of bars with a length proportional to the absolute value of the estimated effects, 
divided by the standard error [21]. The graphs evidence the p-values of the 
independent variables, which were considered to have significant effect when the 
values were < 0.05, with 95% of confidence [21]. As the design was constructed with 
continuous and categorical variables, the analysis was performed separately to obtain 
standardized estimated effects.  
The categorical variables did not statistically influence the responses, on the contrary of 
the continuous variables (Figure 1). The response that suffered major alterations was 
the size (Figure 1A). Concerning the size, the concentration of the polymer in the 
organic phase (X5), the volume of the organic phase (X6) and the ratio polymer/drug 
(X7) seemed to have a significant effect, in this order. The positive sign for the 
concentration of polymer in the organic phase reveals that the size tends to increase 
with the increase of the amount of polymer in the solution; on the contrary the opposite 
effect was observed for the other two significant variables (volume of organic phase and 
ratio polymer/drug), that presented negative sign. All the other variables as volume of 
aqueous phase (X1), type of surfactant X2), concentration of surfactant (X3) and method 
of nanoparticle preparation (X7) were considered insignificant, with 95% of confidence, 
and were fixed at level -1 for the subsequent studies. 
The PBD allowed to reduce the number of variables from seven to three, namely: 
concentration of polymer in the organic phase (X5); volume of organic phase (X6) and 
ratio polymer/drug (X7), which were selected for further optimization studies.  
Independent variables Dependent variable 
batch X1 X2 X3 X4 X5 X6 X7 Size 
(nm) 
PDI AE 
(%) 
1 10 mL  PVA 0.1%  1:5 0.5% 2 mL N 198.3 0.146 81.9 
2 20 mL  PVA 0.1% 1:1 1.0% 2mL E 133.3 0.085 82.2 
3 10 mL Pluronic 0.1%  1:1 0.5% 4 mL E 341.0 0.300 93.6 
4 20 mL Pluronic 0.1% 1:5 0.5% 2 mL N 173.6 0.151 75.1 
5 10 mL PVA 1% 1:5 0.5% 2 mL E 168.5 0.150 68.9 
6 20 mL PVA 1% 1:1 0.5% 4 mL N 273.8 0.166 81.8 
7 10 mL Pluronic 1% 1:5 1.0% 2 mL N 137.6 0.143 94.2 
8 20 mL Pluronic 1% 1:5 1.0% 4 mL N 156.4 0.167 82.4 
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Figure 1. Pareto charts showing the significance of continuous (over) and categorical 
(down) variables for (A-B) particle size, (C-D) polydispersity index, and (E-F) 
association efficiency. (p values = 0.05)  
 
3.1.2  Optimization: Box-Behnken design 
 
After the preliminary investigation through the PBD model, a deeper investigation was 
performed with the most significant factors, to optimize the nanoparticles production 
conditions, using a three-level, three-factor BBD, which requires a minimum number of 
experiments when three factors are considered, as compared to others designs [1]. 
According to the previous sections the selected parameters were reassigned as follows: 
the polymer/drug (X1); the concentration of the polymer in the organic phase (X2); and 
the volume of the organic phase (X3). The levels of the selected independent variables 
were chosen based on previous knowledge (Table 2). All the other variables were 
maintained constant, as described in the section 3.2.1. The responses (dependent 
variables) studied were the particles size (Y1), the polydispersity index (PDI, Y2) and the 
association efficiency (AE, Y3). The experimental values of the 15 formulations 
generated by the BBD were obtained (Table S2). 
  
A 
B D
B 
C E 
F 
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Table 2. Summary of the coded levels of the Box-Behnken design; including the levels 
of the optimized formulation, the desirable parameters used for the optimization, and 
the comparison between predicted and observed values for the considered responses 
 
The mathematical correlation between the factors coefficients and their p values were 
analyzed via regression analysis, for each response, and are expressed in Table 3.  
 
 
Table 3. Summary of the regression analysis for the considered responses Y1–Y3 
 
 
 Particle size (Y1) PDI (Y2) AE (Y3) 
 Coeffficient p-Value Coeffficient p-Value Coeffficient p-Value 
β0  192.067 0.000 0.191 0.000 37.214 0.000 
X1  -4.688 0.373 -0.004 0.639 -7.092 0.003 
X12  13.996 0.011 0.001 0.914 -0.290 0.771 
X2  27.613 0.002 0.035 0.005 2.691 0.090 
X22  -0.054 0.211 0.002 0.662 -3.274 0.018 
X3  8.275 0.145 0.011 0.194 4.186 0.022 
X32  -6.167 0.006 -0.011 0.086 -0.142 0.887 
X1.X2  -13.650 0.100 -0.030 0.035 -0.112 0.953 
X1.X3  -9.475 0.221 -0.004 0.696 0.883 0.647 
X2.X3  -5.975 0.418 -0.037 0.016 -7.264 0.010 
R2  0.945 0.913 0.937 
 
The factors were considered statistically significant, with 95% of confidence level, when 
p values are less than 0.05. The response variables were fitted to different regression 
models, in which the best fitting was considered. The polynomial equations were 
statistically validated using ANOVA and were considered statistically significant when 
F was higher than Fcritic for all responses [1]. The mean values of the obtained response 
corresponded to the intercept of the model. The magnitude and the sign of the 
polynomial coefficients, expressed in Table 3, indicate synergistic or antagonistic effect, 
Independent variables Dependent 
variables 
 Coded Levels Y1 = Particle size 
(nm) 
 Low 
Level 
(-1) 
Medium 
Level 
(0) 
High 
Level 
(+1) 
Y2 = PDI 
X1 = ratio polymer/drug 1:1 2:1 3:1 Y3 = AE (%) 
X2 = concentration of organic 
phase (w/v) 
0.5 % 1 % 1.5 %  
X3 = volume organic phase 1 mL 2 mL 3 mL  
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when the signs are positive or negative, respectively. Moreover, effects of the change of 
more than one factor at a time, or quadratic relations of the terms are studied by 
evaluating the regression coefficients of Xn.Xm and Xn2 respectively. 
 
3.1.2.1 Effect on particle size 
 
The combination of level factors of the BBD result in a range of particle sizes between 
135.0 nm (F2) and 253.8 nm (F12). According the regression analysis, the ratio 
polymer/ drug (X1) and the concentration of the polymer in the organic phase (X2) 
showed to be statistically significant for the particle size. For X1 only the quadratic 
coefficient was statistically relevant, which suggest a non-linear response with the 
change in ratio polymer/drug. The positive sign of the coefficient suggests that the 
particle size increase with the increasing of the values of the levels of X1. i.e., when the 
amount of polymer in the medium is higher than the amount of drug, the particle size 
seems to increase. Similarly, the linear coefficient of X2 has a positive sign, suggesting 
that the particle size increases with the increasing of polymer concentration in the 
organic phase. Both facts are expectable as, the polymer density in each drop during the 
particles preparation by the nanoprecipitation is higher when the levels of these 
variables increase, thus resulting in larger particles [22]. These effects are summarized 
in the response surface graph (Figure 2).  
Moreover, the organic solvent volume (X3) significantly influenced the particle size in a 
negative way, i.e., the higher is the volume, the smaller seem to be particles.  
 
3.1.2.2 Effect on polydispersity 
 
The PDI values obtained from the 15 formulations ranged from 0.129 (F1) to 0.268 
(F10), indicating a narrow distribution. Based on the regression analysis, the 
simultaneous modification of the ratio polymer/drug (X1) and the concentration of the 
polymer in the organic phase (X2) showed to be statistically significant (p < 0.05). The 
negative sign means that the combination of the variables may influence the decreasing 
of the PDI value. As observed in Figure 2 the PDI values decrease with the decreasing of 
the concentration of polymer in the organic phase together with the decreasing of the 
ratio polymer/drug, as the optimal values are closer to the levels -1 for both variables. 
Similarly, to the particle size, the density of the polymer in the organic phase may 
promote the aggregation of the particles due to the supersaturation of the polymer 
when the solvent drops get in contact with the aqueous phase, leading to the formation 
of precipitates.  
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Simultaneous changing of the volume (X3) and concentration (X2) of organic phase also 
promoted significant changing in PDI values. In fact higher concentrations of solute 
increases the viscosity of the organic phase, making difficult the formation of particles 
from the solvent dripping, leading to particles with high dispersity index [23]. 
 
3.1.2.3 Effect on drug association efficiency 
 
The AE obtained from the formulations varied from 21.6% (F6) to 50.8% (F3). 
According to the results of the regression analysis the ratio polymer/drug (X1), the 
concentration of polymer in organic phase (X2), the volume of the organic phase (X3), 
statistically influenced the AE rate (p < 0.05). Besides X2 seemed to influence the AE in 
a non-linear way as only quadratic effect was significant. The negative sign before X1 
regression coefficient revels an inverse relation between polymer/drug ratio and AE. 
Similar results have already been reported [24].  
On the other hand, the positive sign of X3 indicates that the AE increases with the 
increasing of the volume used during the nanoparticle preparation. This could be 
explained by the higher degree of DAP solubilization with the increasing of the relation 
organic to aqueous phase, retarding the solvent diffusion in the media, which may 
maintain DAP solubilized and viable to be entrapped. 
 
 
Figure 2. Response surface models showing the influence of the independent variables 
on the selected responses particles size (Y1) (A), PDI (Y2) (B) and AE (Y3) (C). 
3.1.3 Validation of de obtained models 
 
For the optimization, specific values of the responses were selected as particle size (Y1) 
was below 200nm; minimum PDI (Y2); and maximum AE (Y3). The high R2 of all the 
B C A 
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models (Table 3) indicate good correlation between the experimental and predicted 
results. Three-dimensional response surface graphs were plotted, for the significant 
variables in each response, in other to better understand the behavior of the dependent 
variables. 
The optimized nanoparticles were designed using the desirability function of the 
STATISTCA10 (StatSoft®) software, in which each response is associated with its own 
partial desirability function. The point possessing the highest value for desirability is 
termed as optimum. Based on the desirability analysis, the optimized formulation was 
achieved with the ratio polymer/drug 2:1 (0); with polymer concentration in organic 
phase of 0.5% w/v (-1) and volume of organic phase of 3 mL (+1). 
The optimal nanoparticles were selected and prepared as checkpoint to validate the 
model. The predicted values for all the responses were closer to the observed, with 
deviation/bias < 6.5% which characterize the robustness and high extrapolative ability 
of prediction of the mathematical models. 
 
3.2 Characterization of the optimized nanoparticles  
 
3.2.1 Particle size, polydispersity index and association efficiency 
 
After optimization based on the desirable profile, the check point formulation was 
formulated in triplicated. Unloaded EL100 nanoparticles were also prepared. The mean 
of particle size measurements for NPs-EL100-DAP was 198 ± 6 nm and for NPs-EL100 
was 185 ± 9 nm, which were in good agreement. PDI values were considered suitable 
(0.200 and 0.179 for NPs-EL100-DAP and NPs-EL100, respectively). The AE of NPs-
EL100-DAP was 47.9% ± 4.8, which was considered a good value, considering loading 
capacity of the developed system. 
 
3.2.2 Fourier-Transform Infra-Red studies 
 
The FTIR spectra of DAP optimized freeze-dried NPs-EL100 and NPs-EL100-DAP 
nanoparticles are shown in Figure 3. The FTIR spectrum of NPs-EL100 presents 
characteristics bands of the polymer Eudragit L100 mainly in the region between 3500-
3000 cm-1 and in 1740-1695 cm-1 which correspond to –OH, and C-O stretching 
vibrations, respectively. The spectrum of NPs-EL100-DAP is the superposition of the 
FTIRspectra of NP-EL, with the presence of characteristic peaks of DAP  
(1590-1550 cm-1), (Figure 3), indicating the presence of DAP [25].  
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In the DAP spectrum, it can be observed: band at 3300-3400 cm-1 corresponding to the 
stretch of the amine group (N-H); and, characteristic band of the bending vibration of 
NH2 group between 1590-1550 cm-1. Bands regarding the symmetric and asymmetric 
vibrations of the sulfone group (-SO2) in 1143 and 1180 cm-1 respectively were also 
found [9]. 
 
Figure 3. FTIR spectra of (A) DAP, NPs-EL100 and NP-EL100-DAP, and (B) detail of 
the spectra in the region between 2000-1400 cm-1. 
 
3.2.3 Differential scanning calorimetry studies 
 
DSC thermograms of DAP, EL100, NPs-EL100 and NPs-EL100-DAP are shown in 
Figure 4. The thermograms of NPs-EL100-DAP did not sow the endothermic event 
corresponding to the melting of DAP, indicating that the drug is present in the system 
in the amorphous phase, and may be homogeneously dispersed in the polymer matrix. 
In addition, the simple superposition of the NPs-EL100 and NPs-EL100-DAP, suggest 
that no interaction between the drug and the nanoparticles constituents occurred. The 
thermogram of DAP shows two endothermic events, the first at 83ºC corresponding to 
a polymorphic transition of DAP, and the second at 179°C corresponding to the melting 
of DAP [1, 26]. The thermogram of EL100 shows an endothermic event at 210ºC which 
could be attributed to the film formation of EL100.  
A B 
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Figure 4. DSC thermograms of DAP, EL100, NPs-EL100 and NPs-EL100-DAP. 
 
3.2.4 Morphology assessment 
 
The morphology of NPs-EL100 and NPs-EL100-DAP are shown in the Figure 5. The 
TEM micrographs show that the particles were spherical in shape, with homogeneous 
distributions, and no morphological differences between unloaded and drug loaded 
nanoparticles was found. The size of the particles seemed to be in accordance to the 
values obtained by the DLS measurements.  
 
 
Figure 5. TEM images of NPs-EL100 and NPs-EL100-DAP. Scale bar 200 nm 
 
3.2.5 In vitro drug release assays 
 
The in vitro drug release from the optimized NPs-EL100-DAP was evaluated using the 
dialysis bag diffusion technique. Two different pH conditions (1.2 and 6.8) were 
B A 
200nm 200nm 200n
m 
200n
m 
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assessed to mimic stomach (2 h, pH 1.2) and intestinal (6h, pH 6.8) physiological 
conditions, respectively. 
The cumulative percentage of drug released from the NPs-EL100-DAP for each pH are 
represented in the Figure 6. According to the release profile, it could be seen that 
during the 2 h in acidic conditions, only 30.7% ± 3.2% crossed the diffusion membrane, 
which may help to reduce DAP side-effects on the gastric mucosa. Considering the AE 
of the optimized NPs (about 50%) it is possible to infer that most of the released DAP 
on gastric fluid corresponds to the non-entrapped DAP, proving that, in fact, the 
highest amount of drug remains entrapped within the NPs. 
 
Figure 6: In vitro release profile of DAP from NPs-EL100-DAP in different pH 
conditions. 
In intestinal mimetic environment, pH 6.8, the NPs-EL100-DAP revealed a different 
release profile. A biphasic profile was observed with approximately 80% of DAP was 
released within the first hour, followed by a sustained release reaching up to 100%. The 
fast DAP release of the drug at pH 6.8 may be explained by the high loading capacity of 
the nanoparticles and the fast dissolution of the polymer in more alkaline pH 
conditions (6.8) (Figure 6). In fact, the swelling behavior of EL100 and the erosion 
phenomenon have been already reported [2, 5, 6, 25]. 
According to the results, the developed drug delivery system was able to retain the DAP 
in acidic environment (pH 1.2), during the initial 2 h, and release the drug immediately 
when the pH changes close to neutral values (pH 6.8) suggesting that the optimized 
nanoparticles could overpass the stomach environment (acidic) considering the transit 
time, and reach the intestine (pH 6.8) where the drug may be delivered and then be 
available to be absorbed, avoiding possible acid hydrolysis in the stomach. Usually, 
drug release profile depends on the specific properties of the polymer, on the drug 
loading and polymer/drug ratio. Cetin and co-workers have described for a fast drug 
release from Eudragit nanoparticles releated to more water uptake, swelling ratio, 
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and/or polymer degradation [6]. Moreover, an increasing in the drug release has been 
observed as a function of polymer/drug ratio [6, 27]. 
 
3.3 Cell studies 
 
3.3.1 Cell viability assessment 
 
Following the promising pH-triggered release of DAP under gastro-intestinal 
conditions, in vitro biocompatibility of the NPs-EL100 systems were analyzed in MKN-
28, Caco-2 and HT29-MTX cells. The rationale for selecting different cell lines was 
related to their importance as suitable models mimicking the different cell-types of the 
GI tract (e.g., stomach, enterocytes and mucus secreting cells) and, therefore, relevant 
in the oral route of administration [28, 29]. In addition, the aim of this study was to 
evaluate if the nanoparticles were able to protect the GIT membranes from any adverse 
effect of DAP alone. 
The effects of NP-EL100, NPs-EL100-DAP and free DAP on the cell lines MKN-28, 
Caco-2 and HT29-MTX are shown in Figure 7. According to data, during the period of 
24 h, NPs-EL100-DAP showed cell viabilities higher than 80%, thus it did not present 
significant reduction on cell viability in the up to 400 µg mL-1 in DAP, for the cell lines 
Caco-2 and HT29-MTX. Similar results were observed with unloaded nanoparticles 
(Figure 7A and 7B). For the gastric cell line MKN-28, cell viability values for the tested 
samples were higher than 75% after 4 h, at all the tested concentrations (Figure 7C). 
Same results were found for free DAP. The absence of cytotoxicity of the NPs-EL100-
DAP in both intestinal cells and in most of the tested concentrations in MKN-28 cells 
could be attributed to EL-100 biocompatibility [30]. Moreover, the polymeric-based 
system probably avoided instant delivery of DAP to the cellular media which might 
attribute to the sustained release and consistent diffusion of drug from the nanoparticle 
(Figure 6). 
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Figure 7. Cell viability of the intestinal and gastric cells exposed to the NP-EL100, 
NPs-EL100-DAP and free DAP, assessed by the MTT assay. The viability of Caco-2 (A), 
HT29-MTX (B) and MKN-28 (C) cells after 24 (A and B) and 4 h (C) incubation with 
different dapsone concentrations (free or loaded in NPs) at 37 °C and equivalent 
polymeric concentration. Data expressed as the average ± standard deviation (n=5, of 
three different assays). 
 
3.3.2 DAP permeation across Caco-2 monolayer 
 
The in vitro bioassay with Caco-2 cells monolayer has been widely used as model to 
predict drug permeability and have been well correlated with in vivo absorptions in 
humans [29]. Thus Caco-2 monolayer assay was conducted to analyze the permeability 
of DAP as loaded in NPs-EL100 formulation and as free drug. The tested concentration 
was selected according to the cytotoxicity assays, which was 100 µg mL-1 of DAP 
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equivalent to 200 µg mL-1 in polymer concentration in the NPs-EL100-DAP 
formulations.  
The cells monolayer integrity was evaluated by TEER analysis throughout the 
experiment, and no cellular lesion which changes TEER values was detected (data not 
shown). In the beginning of the experiment the initial TEER values were higher than 
400 Ωcm2, as recommended for absorption studies [31]. The addition of the studied 
samples did not affect these values until the end of the experiment (6 h). 
As can be observed in Figure 8, the permeation profile of NPs-EL100-DAP in 
comparison to free DAP presented different trends. The polymeric-based nanoparticles 
were able to significantly enhance the DAP permeation across the intestinal cells (ca. 
55% of the initial amount), as compared to free DAP, suggesting that the presence of 
pharmaceutical adjuvants helped in the permeation process. Given the physicochemical 
characteristics of the NPs-EL100-DAP, cellular interaction might occur by endocytic 
and transcytosis processes. Additionally, the DAP release from NPs-EL100 observed in 
the in vitro studies (Figure 6) is in accordance with these results, where a steady 
permeability profile and improved permeability resulted in significant differences in 
the apparent permeability values (Fig 8B). The small droplet size of the polymeric 
nanoparticles enables better adherence to the membrane during transport of the drug 
and optimizes intestinal absorption and permeation [32]. The low water solubility of 
free DAP may be related with the reduced amounts of DAP obtained in the basolateral 
chamber, reaching about 30 % of the initial amount within 6 h. The DAP rapidly 
precipitates in the medium which hampers its permeation across the monolayer from 
the apical to the basolateral side. The cumulative permeated amount of DAP across the 
Caco-2 cells monolayer up to 6 h is shown in Figure 8A. A significant permeability 
enhancement of DAP was observed for the NPs-EL100-DAP formulation after 6 h of 
contact with Caco-2 cell monolayers (**p<0.05), when compared to free DAP. 
Therefore, dapsone, a class II drug, when incorporated in a polymeric-based 
nanoparticle, behaves as a class I drug according to the Biopharmaceutics Classification 
System, due to its higher solubility and higher permeability, with a Papp of 23.5 × 10-6 
cm/sec [33]. Accordingly, both the dose required and the subsequent adverse effects 
can be reduced, with improved absorption and permeability. In this work, a polymeric-
based nanoparticle of EudragitL100 was used and its properties allowed a higher 
permeability coefficient of DAP that the obtained with other nanoemulsion systems 
previously described [32, 34, 35]. 
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Figure 8. In vitro cumulative permeability profile and Papp coefficient of DAP (open 
circles) and NPs-EL100-DAP (clack squares) across the Caco-2 cells monolayer. The 
experiments were conducted from the apical-to-basolateral direction in culture 
medium at 37 °C. Data sets were compared to free DAP (*p < 0.05, **p < 0.01). Error 
bars represent mean ± s.d. (n ≥ 3). 
 
4 Conclusions 
 
In this study, pH-sensitive NPs-EL00-DAP was successfully developed and 
characterized after the identification of most critical variables, through PBD and the 
optimization employing a three-level, three-factor BBD. The ratio polymer/drug, the 
concentration of polymer in the organic phase and the volume of the organic phase 
were found to be the most significant variables that affected the formulations 
properties. The experimental design strategies allowed to understand the main 
formulation and process parameters that affected the selected responses namely 
particle diameter, PDI and AE. The optimized formulation was achieved based on the 
desirability profile and presented low bias compared to the predicted values for these 
responses. 
FTIR and DSC analysis confirmed the association of DAP and the absence of 
interactions; TEM micrographs revealed the spherical morphology of the nanoparticles 
and supported the results obtained from the DLS analysis. The in vitro drug release at 
different pH conditions confirmed the pH sensitivity of NPs-EL00-DAP, being able to 
provide enhanced drug delivery at intestinal environment. No toxicity was observed in 
Caco-2, HT29-MTX and MKN-28 cell lines up to 400 µg.mL-1 of DAP. Thus, the 
protection property of the EL100 from acidic environment showed to be promising to 
delivery strategy at the site of absorption, as 2-fold enhanced permeability was 
observed when DAP was incorporated within NPs-EL100 in comparison to free DAP. In 
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fact, the application of NPs-EL100 to deliver DAP, a class II drug, increased its 
solubility and permeability, resulting in a class I drug behavior. 
The present study demonstrated the potential of NPs-EL00-DAP as a therapeutic 
platform, although further studies using clinical relevant models should be pursued to 
assess its efficacy for treatment of diseases as leprosy. 
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5 Supplementary material 
 
Selected independent variables performed during Plackett-Burman design and their 
respectives low (-1) and high (+1) coded and real levels. 
 
Table S1: Independent variables with the respective levels.  
Factor Factor significance Level (-1) Level (+1) 
X1 Vol. of aqueous phase (AP) 10 mL 20 mL 
X2 Type of surfactant PVA Pluronic® F68 
X3 Surfactant concentration (w/v) 1% 0.1% 
X4 Ratio polymer/drug* 1 : 1 1 : 5 
X5 Polymer concentration (w/v) 0.5% 1% 
X6 Vol. organic phase (OP) 2 mL 4 mL 
X7 Method Nanoprecipitation (N) Emulsion (E) 
*the amount of drug was always adjusted to the ratio polymer/drug based on the 
concentration of polymer in the organic phase. 
  
New technologies for the improvement of leprosy MDT  
		
 167 
Experimental values of the 15 formulations generated by the Box-Behnken design with the 
selected independent variables namely (X1) the ratio polymer/drug; (X2) concentration of the 
polymer in the organic phase and (X3) volume of organic phase. The levels of the selected 
independent variables were chosen based on previous knowledge. All the other variables were 
maintained constant, as described in the section 3.2.1. The dependent variables studied were the 
particles size (Y1), the polydispersity index (PDI, Y2) and the association efficiency (AE, Y3).  
 
 
Table S2: Formulation composition and the effects of different formulation variables on the 
dependent variables. 
*X1 = ratio polymer/drug (-1 = 1:1; 0 = 2:1; +1 = 3:1); X2 = concentration of organic phase (-
1 = 0.5%; 0 = 1.0%; +1 = 1.5%); X3 = volume of organic phase ( -1 = 1 mL; 0 = 2 mL; +1 = 3 
mL); Y1 = particle size; Y2 = PDI; Y3 = AE. 
 
  
Formulation Independent variables Dependent variables 
X1 X2 X3 Y1 
(nm) 
Y2 
 
Y3 
(%) 
F1 -1 -1 0 138.4 0.129 42.9 
F2 1 -1 0 135.0 0.165 28.2 
F3 -1 1 0 221.4 0.241 50.8 
F4 1 1 0 163.4 0.159 35.7 
F5 -1 0 -1 162.3 0.181 36.3 
F6 1 0 -1 193.2 0.198 21.1 
F7 -1 0 1 199.3 0.213 43.4 
F8 1 0 1 192.3 0.213 31.7 
F9 0 -1 -1 184.0 0.107 26.4 
F10 0 1 -1 250.7 0.268 44.0 
F11 0 -1 1 211.0 0.200 48.8 
F12 0 1 1 253.8 0.215 37.3 
F13 0 0 0 182.5 0.191 34.7 
F14 0 0 0 183.8 0.194 26.3 
F15 0 0 0 181.0 0.154 35.8 
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C. Optimization of solid lipid nanoparticles for 
clofazimine delivery: risk management, statistical design 
and physicochemical characterization.5 
 
                                                   
5 Submitted 
New technologies for the improvement of leprosy MDT  
		
 170 
Optimization of solid lipid nanoparticles for clofazimine delivery: risk 
management, statistical design and physicochemical characterization 
 
Luíse L. Chavesa, Sofia Limaa,b, Alexandre C.C.Vieiraa, Domingos Ferreirac, Bruno 
Sarmentob,d,e, Salette Reisa 
 
aUCIBIO, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, 
Universidade do Porto, Porto, Portugal 
bCESPU, Instituto de Investigacão e Formação Avançada em Ciências e Tecnologias da 
Saúde and Instituto Universitário de Ciências da Saúde, Gandra, Portugal 
cUCIBIO, REQUIMTE, Laboratório de Tecnologia Farmacêutica, Faculdade de 
Farmácia, Universidade do Porto, Portugal 
dI3S, Instituto de Investigacão e Inovação em Saúde, Universidade do Porto, Portugal 
eINEB – Instituto de Engenharia Biomédica, Universidade do Porto, Portugal 
 
 
ABSTRACT 
The aim of this work was to develop solid lipid nanoparticles (SLNs) loaded with 
clofazimine (CLZ) (SLNs-CLZ), towards drug bioavailability improvement and 
reduction of its intrinsic high toxicity. Initially, risk assessment of the process and 
product variables was conducted, helping to select the starting conditions of the pre-
formulation. The identification of drug crystals allowed the implementation of control 
actions during nanoparticles characterization. A spectrophotometric method for the 
quantification of CLZ in SLNs was developed, validated and showed to be accurate, 
precise, efficient, specific and sensitive with low limits of detection and quantification. 
A Box-Behnken design was constructed and the relations between the independent 
variables in the selected responses could be understood. The optimized SLNs-CLZ with 
suitable particle size (PS), zeta potential (ZP), association efficiency (AE) and drug 
loading (DL) parameters for oral delivery. The optimized SLNs-CLZ were also 
characterized by Fourier transformed infra-red spectroscopy (FTIR) and differential 
scanning calorimetry (DSC). The optimized SLNs-CLZ presented values of 230 nm, -
34.28 mV, 72% and 2.39 % of PS, ZP, AE and DL respectively. FTIR confirmed the 
presence of the drug and the absence of chemical interactions, while DSC thermograms 
indicated the amorphous state of CLZ. The storage stability studies ensured the 
stability of the systems over a period of 12 weeks at 4ºC. In vitro cytotoxicity studies 
evidenced no significant effect of both drug-load and unloaded SLNs on MKN-28 
gastric cells and on intestinal cells, namely Caco-2 and HT29-MTX cells up to 25 µg 
mL-1 in CLZ. Free CLZ solutions exhibited IC50 values of 16.3 and 20.3 µg mL-1 for Caco-
2 and HT29-MTX cells, respectively. It can be concluded that the optimized system was 
developed considering important variables for the formulation of poorly soluble drugs. 
The optimized SLNs-CLZ represent a promising platform to orally deliver CLZ. 
 
 
Key-words: leprosy, Box-Behnken design, cytotoxicity, UV-Vis quantification  
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1. Introduction 
 
Clofazimine (CLZ) is an antibiotic and anti-inflammatory drug, classified as a 
riminophenazine agent [1, 2]. It has been recommended for decades by the World 
Health Organization for the therapy of multibacillary leprosy. In addition, recent 
studies have revived its application in the treatment of multidrug-resistant tuberculosis 
[1, 2]. 
Despite its clinical approval, it is a highly hydrophobic drug (logP > 7) [1], virtually 
insoluble in water [2]. This particular feature of CLZ result in a limited absorption 
(about 40%) due to its extremely high hydrophobicity, associated with a very large 
volume of distribution and elimination half-life of more than 70 days, as the cells act as 
drug reservoirs [3]. After long-term administration, the consequent bioaccumulation of 
CLZ results in yellowish and reddish skin pigmentation, abdominal pain and 
cardiotoxicity [1].  
CLZ has three amine groups, which may be protonated and charged at acidic pH, 
increasing its solubility. Therefore, in the gastrointestinal tract, CLZ may form 
supersaturated solutions, as it passes from the stomach (pH 1 - 3) [4] to more alkaline 
environment of the intestine leading to in vivo drug precipitation [2]. In fact, it is 
already reported that CLZ can form complexes with intracellular membranes, and 
precipitate as crystal aggregates, being phagocytized by the mononuclear phagocyte 
system [2]. This phenomenon may be correlated with the undesired and toxicological 
effects, often resulting in patients’ treatment noncompliance [5]. 
Several strategies are commonly applied to improve poorly soluble drugs solubility 
namely prodrug formation, salt formation [6], complexation with cyclodextrins [3] or 
other macromolecules [7, 8], formulation of amorphous dispersions [9], use of co-
solvents or surfactants [10], formulation of liposomes [11] and nanosuspensions [12]. 
Although many types of nanoparticles are available for oral delivery, lipid nanoparticles 
and especially solid lipid nanoparticles (SLNs), have shown to be one of the most 
promising delivery systems to improve the oral bioavailability of hydrophobic drugs, 
due to its high lipid content [13]. 
SLNs consist of a physiological compatible solid lipid core and of an amphiphilic 
surfactant shell. The main characteristic of the lipid phase is that they remain in solid 
state at room temperature [14, 15]. The mechanism by which SLNs can improve the 
solubility of poorly soluble drugs is based on the formation of a fine lipid dispersion, at 
the same time that entraps the drug, providing a large surface area of absorption in the 
gastrointestinal tract [16]. Besides the traditional advantages of the colloidal systems 
such as improved physical stability, protection of drug from in vivo degradation, 
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controlled drug release, possibility to specific targeting, SLNs are feasible to scale-up 
with an associated low cost [13, 14]. 
Despite the great number of works applying different technologies to improve CLZ 
solubility, the encapsulation into lipid nanoparticles have not been described, yet. The 
aim of this work was to develop SLNs loaded with CLZ (SLNs-CLZ) to improve CLZ 
bioavailability and to decrease its associated toxicity, using a rational development. The 
design of the SLNs-CLZ was carried out by first assessing the risks associated with 
product and process parameters during SLNs production, with further application of a 
Box-Behnken design aiming to better underwent the influence of different factors on 
selected responses. The optimized formulations were physicochemically characterized 
by dynamic light scattering, Fourier transformed infra-red spectroscopy, differential 
scattering calorimetry, and, also the storage stability and the in vitro cytotoxicity were 
assessed. 
 
2. Materials and methods 
 
2.1  Materials 
 
Clofazimine (CLZ) was purchased from Hangzhou Heta Pharm & Chem Co. The solid 
lipids Precirol ATO 5 Cetyl Palmitate, Compritol 888 ATO, Precirol ATO 5, Gelucire 
43/01, were kindly provided by Gattefossé (Saint-Priest, France). Softisan 142 was 
purchased from Cremer Care (Hamburg, Germany); Witepsol E85 from Sasol 
(Johannesburg, South Africa), and stearic acid was from Merck & Co., Inc. (Whitehouse 
Station, NJ, USA). Tween® 80 was purchased from Sigma-Aldrich Co. (St Louis, MO, 
USA). All other chemicals used in the study were of analytical grade. Caco-2 and 
MKN28 cell lines were acquired from the American Type Culture Collection (ATCC, 
Wesel, Germany) (passage number 35 - 55); while, HT29-MTX cell line was kindly 
provided by Dr. T. Lesuffleur (INSERM U178, Villejuif, France). Dulbecco’s Modified 
Eagle Medium (DMEM), Roswell Park Memorial Institute (RPMI), fetal bovine serum 
(FBS), Pen-Strep (penicillin, streptomycin) and Trypsin-EDTA were all obtained from 
Gibco (Paisley, UK). Thiazolyl blue tetrazolium bromide (MTT) was obtained from 
Sigma–Aldrich (St Louis, MO, USA). 
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2.2 Methods 
 
2.2.1  Preparation of SLNs 
 
All the formulations of the experimental design were prepared by the hot 
homogenization followed by ultrasonication method, as previously described [15]. 
Briefly, the selected amounts of Precirol ATO 5 and CLZ (Table 1) were both heated to 
75°C to solubilize the drug in the lipid matrix. Further, the aqueous phase containing 
the established amount of surfactant (Tween® 80) (Table 1) was pre-heated in water 
bath at the same temperature. The 6 mL of aqueous phase were added into the lipid 
phase and homogenized using a probe sonicator (VCX130; Sonics & Materials, Inc., 
Newtown, CT, USA), at 70% of amplitude for 5 min. The colloidal dispersion obtained 
was rapidly cooled down in an ice bath. Placebo SLNs were prepared similarly, without 
the addition of CLZ. When appropriate, the formulation was freeze-dried for 48h, 
under vacuum (0.5 mBar), and -55ºC using a LyoQuest 85 plus v.407 Telstar freeze 
dryer (Telstar® Life Science Solutions, Terrassa, Spain).  
 
2.2.2 Risk assessment of critical variables 
 
To identify the potential risks and determine the cause-effect relationship between 
potential formulation and process parameters, an Ishikawa fishbone diagram was 
constructed. This approach was conducted based on prior knowledge, experiment trials 
and literature review [17-19]. The key parameters identified as Critical Quality Attribute 
(CQA), which may affect nanoparticles performance in vivo, were particle size, 
polydispersity index (PDI), zeta potential (ZP), association efficiency (AE) and drug 
loading (DL) [20, 21].  
 
2.2.3  Development and validation of a spectrophotometric method for 
CLZ quantification 
 
An UV-Vis spectrophometric method was developed and validated regarding linearity, 
detection limit, quantification limit, precision, accuracy, specificity and robustness [22] 
using an ultraviolet-visible spectrophotometer (Jasco V-660, Easton, USA). The stock 
solution was prepared by accurately weighing 5 mg of CLZ with further dissolution in 
50 mL of DMSO. The solution was sonicated in water bath for 10 min up to complete 
solubilization. The linearity was investigated using CLZ stock solutions in HCl 1 M at 
different concentrations ranging from 0.125 to 1.5 µg mL-1 of CLZ, in triplicated. The 
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limit of detection (LoD) and limit of quantification (LoQ) were determined from 
angular coefficient (b) obtained from the linear equation of the standard curve, and 
from the standard deviation of five blank samples (S) (LoD = 3.3(b /S); LoQ = 10(b /S) 
[22]. Precision was evaluated regarding intermediate precision (assays on different 
days) and repeatability (different assays on the same day) which were determined with 
six scans of the CLZ standard solution. Precision levels were calculated by the relative 
standard deviation percentage (RSD %) from the analytical curves. Accuracy (recovery) 
was determined by preparing CLZ solutions with unloaded SLNs supernatants. Briefly, 
known volume of fresh SLNs was diluted with ultrapure water (20 times) and 
centrifuged at 4,000 xg for 10 min, using AmiconÒ filters devices. The supernatant was 
diluted (1:1) with HCl 2 M, to reach final HCl concentration of 1 M, and this solution 
was used to prepare the samples by adding the CLZ stock solutions to obtain 0.25, 0.50 
and 0.75 µg mL-1 (the equivalent of 50, 100 and 150% of the test sample - 0.5 µg mL-1). 
The samples were analyzed and concentrations were recalculated from the calibration 
curve. Assays were performed in triplicated. Specificity was evaluated by obtaining UV-
Vis spectra of CLZ samples and supernatant of centrifuged SLNs using AmiconÒ filter 
device, with different dilutions, between 350-700 nm. Robustness of the method was 
evaluated by reading the test samples (0.5 µg mL-1) after 4 h, and by preparation the 
samples from a HCl 1 M acidified from other pH (1.2 and 6.8) solutions. 
 
2.2.4  Screening of starting conditions 
 
2.2.4.1 Selection of the lipid 
 
The selection of the lipid was based on the solubility of CLZ in different biocompatible 
lipids commonly used to formulate SLNs, namely Cetyl Palmitate, Compritol 888 ATO, 
Precirol ATO 5, Gelucire 43/01, Softisan 142 and Witepsol E85 and stearic acid. Briefly, 
a known amount of physical mixtures (PM) of each type of lipid and CLZ (10:1, w/w) 
were heated at 100°C and then left at room temperature (25°C) until solidification. The 
presence of drug crystals in the molten mixtures was observed and chosen as parameter 
for the choice of the lipid. 
 
2.2.4.2 Preformulation studies 
 
Before the construction of an experimental design, screening studies were conducted to 
assess the critical parameters (e.g. amount of lipid, amount of surfactant, time and 
amplitude of sonication) which should be controlled and studied during the 
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formulation design. For these purpose, preliminary SLNs formulations with CLZ using 
the selected lipid (Precirol ATO 5) were obtained according to section 2.2.1.  
 
2.2.5 Experimental design 
 
2.2.5.1 Box-Behnken design 
 
In order to assess the correlation between the responses and the factors during the 
development of SLNs-CLZ, maximizing the experimental efficiency with the minimum 
number of experiments, a three-level, three-factor Box-Behnken design (BBD) was 
applied. 
The selected independent variables were (X1) the amount of lipid, (X2) the amount of 
surfactant and, (X3) the amount of drug. These parameters and their lower (-1), 
medium (0) and higher (+1) values were selected based on previous screening studies 
for each variable. Other parameters were set as fixed levels. The studied responses 
were: Y1 = mean particle diameter, Y2 = PDI, Y3 = zeta potential (ZP), Y4 = association 
efficiency (AE), and Y5 = drug loading (DL). The results were studied using analysis of 
variance (ANOVA), and regression analysis (supplementary material). 
The best-fitting experimental model (linear, two-factor interaction, quadratic, and 
cubic models) was statistically evaluated according to multiple correlation coefficient 
(R2) provided by STATISTICA 10 software (StatSoft®, Dell Software, Round Rock, TX, 
USA). The effects of the obtained models were assessed by analyzing the statistical 
significance of the coefficients using ANOVA (p-value 0.05).  
 
2.2.5.2 Optimization and validation assays 
 
The optimization of the formulation was performed assuming the values obtained after 
studying the desirability profile tool of STATISTICA10 software. The constraints 
parameters were to: reach particles with 250 nm of diameter, minimize PDI, reach 
charge around -30 mV, and maximize AE and DL, all simultaneously. Three-
dimensional response surface plots were obtained for each response in order to better 
understanding the correlation between the factors. 
To evaluate the reliability of the models, the optimized nanoparticle was used as check 
point for the validation, in which the predicted values of each response were compared 
to the experimental by calculating the % bias. The linear correlation and residual plots 
between observed and predicted responses were obtained. The optimized nanoparticles 
were used for the subsequent characterization. 
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2.2.6 Characterization of the optimized SLNs-CLZ 
 
2.2.6.1 Mean particle size, PDI and zeta potential  
 
The mean particle size as well as the PDI were analyzed by dynamic light scattering 
(DLS) using a ZetaPALS, Zeta Potential Analyzer (Brookhaven Instrument Corps, 
Holtsville, NY, USA), at 25ºC with a light incidence angle of 90º. 
Before measurement, the formulation was filtered with a nitrocellulose 3 µm pore size 
filter (Merck Millipore, Billerica, MA, USA),) aiming to exclude the unentrapped 
precipitated drug. Further, the filtrated nanoparticles were properly diluted with 
ultrapure water until reaching a suitable concentration for the measurement, that is, 
Kcps around 500. The obtained values of particle size and PDI were representative to 
the mean of 6 runs. The zeta potential of the samples was analyzed by electrophoretic 
light scattering (ELS) using the Smoluchowski mathematical model. The filtered 
nanoparticles were measured in a folded capillary electrophoresis cell, at 25º. The 
obtained value represents the mean of multiple runs (n=10). 
 
2.2.6.2 Association efficiency and drug loading 
 
The quantification of entrapped drug within the SLNs was carried out based on 
methodologies already reported [23]. Briefly, fresh optimized formulation was filtered 
through 3 µm nitrocellulose membrane filter (Merck Millipore, Billerica, MA, USA) to 
retain unentrapped drug crystals which were undissolved. The drug retained in the 
filter was recovered with HCl 1 M, and the amount of free CLZ was measured by UV-Vis 
spectrophotometer (Jasco V-660, Easton, MD, USA) at 528 nm. The amount of soluble 
drug in the aqueous phase was determined by the ultrafiltration method. Briefly, SLNs-
CLZ was properly diluted in ultrapure water, then transferred into Amicon® Ultra-4 
Centrifugal Filter Devices (Millipore, Billerica, MA, USA), and centrifuged using an 
Allegra X-15Rcentrifuge (Beckman Coulter, Brea, CA, USA) at 4,000 xg for 10 min. 
After centrifugation, the samples were acidified with HCl until reaching the 
concentration of 1 M, and the free CLZ was detected by spectrophotometer at 528 nm. 
Standard curves were obtained in HCL 1 M and the supernatant of the aqueous phase 
solution obtained after Amicon filter centrifugation, used to determine the CLZ 
concentration. The results are expressed as mean ± standard deviation (n=3). Drug 
loading (DL) expresses the percent of drug to total lipids and excipients. Association 
efficiency (AE) was calculated following the equation:  
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0c = 8586829	27Gb56	Gd	;3bH	 − ;3bH	3462854;	85	d89643	3	l7 + 	;3bH	OG9b$94	85	2mb4GbO	1ℎ2O48586829	27Gb56	Gd	;3bH ×100 
 en = 	 8586829	27Gb56	Gd	;3bH − 34fGa434;	;3bH6G629	i48Hℎ6	Gd	525G12368f94O ×100 
 
2.2.6.3 Fourier transform infrared spectroscopy (FTIR) 
 
FTIR spectra of CLZ, Precirol ATO5 and CLZ physical mixture (PM), and freeze-dried 
SLNs and SLNs-CLZ were using a PerkinElmer® Spectrum 400 (Waltham, MA, USA) 
equipped with an attenuated total reflectance (ATR) device and zinc selenite crystals. 
The samples were transferred directly to the ATR compartment, and the result was 
obtained by combining the 16 scans. The spectra were recorded between 4000 and 600 
cm-1 with a resolution of 4 cm-1. 
 
2.2.6.4 Differential scanning calorimetry (DSC) 
 
DSC thermal analysis of CLZ, Precirol ATO 5, PM and freeze-dried SLNs and SLNs-CLZ 
and were performed using a DSC 200 F3 Maia (Netzsch, Selb, Germany). Briefly, 
accurately weighted samples (1 - 2 mg) were poured into aluminum pans and 
hermetically sealed. An empty pan was used as reference. The samples were scanned 
from 30 to 300 ºC, at 10 ºC/min of flow rate. Nitrogen gas was used as purge gas, at 40 
mL/min. The melting point (peak maximum), was calculated using the (NETZSCH 
Proteus® Software – Thermal Analysis – Version 6.1) software provided for the DSC 
equipment. 
 
2.2.6.5 Storage stability studies 
 
The storage stability of the SLNs-CLZ nanoparticles was assessed by conducting a study 
for a period of 12 weeks, at 4ºC. At each time point, the formulation was characterized 
regarding particle size, PDI, zeta potential, AE and DL. The results were compared to 
the first day of production.  
 
2.2.7 Cell- SLNs interaction studies 
 
Caco-2 and HT29-MTX cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% (v/v) of fetal bovine serum (FBS) and 1% (v/v) of 
penicillin-streptomycin. Gastric MKN-28 cells were cultured in RPMI 1640 culture 
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medium, with 10% (v/v) FBS and 1% (v/v) of penicillin-streptomycin. Cells were grown 
in a humidified incubator at 37 ºC and 5% CO2 atmosphere and 95% relative humidity. 
To detached the cells, a 0.25% (/w/v) trypsin-EDTA solution was used when cells’ 
confluence reached 80% 
The potential cell cytotoxicity of SLNs, SLNs-CLZ and CLZ pure drug was evaluated 
against Caco-2, HT29-MTX and MKN-28 cells lines using the 3-(4, 5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. Separately, each cell 
line was transferred into 96-well plates, at a density of 5 x 104 cells per well for Caco-2 
and HT29-MTX and 105 cells per well for MKN-28 cells. The plates were incubated for 
18- 24 h for cell attachment. Further, the culture media was removed and the wells 
were incubated with 100 µL of culture media containing different concentrations of 
SLNs, SLNs-CLZ and CLZ (6.25 – 50 µg mL-1 equivalent of CLZ). For CLZ pure drug, 
the samples were prepared from a stock solution in DMSO, and appropriate dilutions 
were done to reach maximum of 4% (v/v) of DMSO in the well, immediately before the 
beginning of the assay. Each sample was incubated during 24 h for Caco-2 and HT29-
MTX cell lines; and during 4 h for MKN-28. After the incubation period, the samples 
were removed and replaced by 100 µL of MTT solution (5 mg mL-1), and incubated for 
additional 2 h. Further, the MTT solution was removed and 100 µL of DMSO was 
added into each well to solubilize the formazan crystals. The optical density of the 
solution was measured at 570 and 650 nm wavelengths using SynergyTM HT Multi-
mode microplate reader (BioTek Instruments Inc., Winooski, VT, USA). Untreated cells 
were taken as positive control with 100% viability and cells incubated with 4% (v/v) 
DMSO used as control for free CLZ. The MTT test was performed in triplicate and 
results were expressed as mean values ±SD. The cell viability (%) in relation to control 
cells (untreated cells) as follows: 
 ?499	a82$8986"	(%) = oe	570 − 630	634264;	f499Ooe570 − 630	b5634264;	f499O ×100 
 
2.2.8 Statistical analyses 
 
All results were expressed as mean ± SD (n=3). The method validation was carried out 
using ANOVA, regression analysis, and T student test. Data obtained from the 
experimental design were analyzed by ANOVA and multiple correlation coefficient 
using STATISTICA10 (StatSoft®) software. GraphPad Prism software (version 6, 
GraphPad Software, USA) was used for statistical comparisons of the results to control 
for the cytotoxicity, through student (unpaired) t-test and one-way ANOVA test. The 
differences were assumed statistical significant when p < 0.05 (95% confidence level). 
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3. Results and discussion 
 
3.1 Risk management: cause-effect relationship 
 
In the Quality by Design (QbD) approach, the formulation by design involves the 
identification of potential risks that may affect the product quality [24]. In this 
framework, the Ishikawa diagram is a qualitative tool to explore systematically the 
causes and sub-causes that may produce an effect [20]. 
To design an Ishikawa diagram the parameters involved in the production of 
nanoparticles, such as the materials, the process and the characterization should be 
considered according to their possible influence along the following lines. In the 
nanotechnology framework, higher values of AE and DL are essential to reach suitable 
drug concentration in the site of absorption with improved yield and low amount of 
excipients. Particle diameter influences the uptake mechanism by the cells. On the 
other hand, the surface charge is an important indicator of long-term stability and 
biocompatibility of the colloidal suspensions [20]. 
Lipid-based nanocarriers seem to be an appropriate system to load poorly soluble 
drugs as they can solubilize such compounds. There is a variety of biocompatible 
materials available that have been used to improve oral bioavailability of drugs. On the 
other hand, lipid nanocarriers are not universal platforms to delivery poorly soluble 
drugs since lipophilic drugs do not necessarily display a high solubility in lipid phase. 
Besides, the partition of the drug between aqueous and oil phase should be taken into 
consideration to maximize AE and DL [25, 26]. Regarding the methods of production, 
several methods have been reported to produce SLNs such as high-shear 
homogenization, high-pressure homogenization and ultrasonication. The correct 
selection of the method is a critical step for obtaining of particles with suitable diameter 
and narrow size distribution [27]. 
Furthermore, properly characterization of SLNs is a critical step to control product 
quality, stability and safety. The particle size and PDI are important parameters to be 
controlled, and the DLS technique is the most used for this purpose which can provide 
excellent qualitative and quantitative information [23, 28]. In the case of 
nanoformulations with poorly soluble drugs, proper dilution sometimes is not enough 
to solubilize unentrapped drug, leading to a super estimation of the particle size due the 
drug precipitation [28-30]. In addition, AE and DL should also be well determined 
without having super estimation or false results, which are common for insoluble drugs 
[31]. Direct or indirect drug quantification methods have been reported to determine 
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the entrapped drug. For lipophilic drugs, the drug theoretically soluble is present as a 
precipitate, leading to an overestimation of the drug loading capacity [32]. 
In this context, the relationship between potential factors affecting the development of 
SLNs and the targeted quality attributes namely particle size, polydispersity index, zeta 
potential, association efficiency and drug loading were established by constructing a 
cause-and-effect Ishikawa diagram (Figure 1). Figure 1 shows the Ishikawa diagram 
illustrating the effect of product and process parameters on the targeted product 
quality profile. Based on prior knowledge and preliminary experiments formulation, 
the process variables were expressed as risk factors [33, 34]. 
 
 
Figure 1. Ishikawa cause-and-effect diagram in the development of SLNs-CLZ. 
 
The first step considered crucial for the development of SLNs-CLZ was the 
development of a suitable and reliable analytical method for CLZ quantification. 
Further, process and product variables were assessed by an initial risk management 
using the aforesaid tool. The study has suggested that factors, as amount lipid, amount 
of surfactant, and amount of drug were found to strongly influence the risk associated 
with the selected effects that where attributed as critical. On the other hand, process 
parameters such as amplitude and time of sonication showed overall medium risk 
associated. Based on this preliminary evaluation, formulation factors were selected to 
perform an optimization experimental design. 
 
3.2 Development and validation method for CLZ quantification 
 
The very low water solubility of CLZ is not only an issue during the design of new 
formulations, but also a challenge to have a proper quantification method, which 
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requires a minimum amount of organic solvent, and enough sensibility to quantify low 
drug concentrations [35]. 
Few methods for the determination of CLZ in biological fluids [36-38] and 
pharmaceutical preparations [39] are reported in the literature. Even though, the 
reported techniques, are time consuming and costly, and in the case of UV-Vis 
methods, are present lack of sensitivity and requires high levels of toxic organic 
solvents. Thus, the development and validation of a simple and, sensitive and accurate 
UV-Vis spectrophotometric method would be highly useful for the analysis of CLZ in 
bulk nanoformulations. 
CLZ is present as reddish crystals, and in an aqueous media almost all the drug 
precipitates. Despite CLZ poor water solubility, it has three sites of protonation [2], 
which make it soluble in acidic pH, becoming a purple solution (data not shown). 
Spectra for CLZ with different concentrations of HCl were obtained in the range 
between 350 and 700 nm. Figure 2A shows CLZ pH dependence, as the pH of the 
medium decreases, the maximum wavelength of the spectra shifts to higher values. 
However, as the pH of the medium increases, the spectra exhibit a different behavior, 
as the CLZ structure is at molecular conformation resulting in lower intensities of 
absorbance (Figure 2A). This behavior allows to reach very low detection limits. The 
minimum concentration of solvent to obtain spectra of protonated CLZ in the visible 
region was studied. HCl 1 M was selected for the method validation, which provided a 
maximum wave length of 528 nm. Linearity of the method was obtained in a range 
concentration of 0.125–1.5 µg mL-1 (Figure 2B). Least square regression (R2) showed a 
good correlation coefficient (r=0.9995) and the equation obtained was: absorbance = 
0.0735 [CLZ] + 0.00006. The LoD and LoQ were 0.0141 µg mL-1 and 0.0471 µg mL-1 
respectively.  
 
 
Figure 2. UV-Vis absorption spectra of (A) CLZ samples in different HCl 
concentrations; (B) calibration curve in the concentration range of 0.125 – 1.500 µg 
mL-1. in 1 M HCl; and (C) superposition of CLZ sample and SLNs drug-free supernatant, 
evidencing the selectivity of the method for CLZ. 
A B C 
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The relative standard deviation (RSD%) for repeatability, inter-day precision and 
second analyst analysis were less than 5% (3.8%, 3.2% and 1.3% respectively) 
indicating reasonable result. The mean percentage of recoveries for the three tested 
concentrations reached RSD values below 5% (1.82, 1.84 and 0.39% for 0.250, 0.500 
and 0.750 µg mL-1, respectively) demonstrating good agreement between added and 
quantified amounts of CLZ, and that small changes in CLZ concentrations could be 
accurately determined. The selectivity of the method was assessed by analyzing the 
interference of nanoparticles constituents in CLZ quantification. Figure 2C shows that 
the SLNs supernatant did not interfere with the absorption spectra of CLZ at 528 nm. 
The robustness of the method was assessed by evaluating the stability of the sample 
after 4 h, and samples preparation in HCl 1 M from already buffered solution. The 
results show that there were no significant differences between samples read 
immediately after preparation, and 4 h after performance of unpaired T test (p > 0.05, 
with 95% of confidence level). ANOVA statistical analysis were performed to compare 
samples obtained from different pH (1.2, 4.5 and 6.8), and once more no significance 
was found, with 95% of confidence level. 
 
3.3 Screening of starting conditions 
 
3.3.1 Selection of the lipid 
 
The correct selection of the lipid during the development of SLNs influences their 
ability to carry the drug and may warrant high values of association efficiency. 
Moreover, proper melting point of the lipid is essential to maintain the solid state of the 
particles at room temperature [40, 41]. 
Among the tested lipids, a more homogenous dispersion of CLZ was observed with 
Precirol ATO 5, suggesting that this lipid might be able to maximize the association of 
CLZ in SLNs. The melting temperature was also considered for the selection of the 
lipid, as it is preferable for storage and process reasons to have lipids with melting 
point above 50ºC. Most of the tested lipids were unable to completely dissolve CLZ and, 
presented a low phase transition temperature (below 50ºC), thus were not considered 
suitable for SLNs-CLZ production. Compritol 888, cetyl palmitate, stearic acid and 
Precirol ATO 5 were the lipid with higher melting point. As Precirol ATO 5 was able to 
visually better disperse CLZ, it was selected for the pre-formulation studies. 
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3.3.2 Pre-formulation studies 
 
Preliminary studies were considered essential to develop SLNs-CLZ since many factors 
may strong influence the final performance of the nanoformulation. As discussed 
before, parameters regarding process and formulation, in addition to methods for the 
characterization must be well defined and controlled.  
In this context, a step-by-step study was performed, in which three formulations at a 
time were obtained (Table 1), and the subsequent formulations were prepared after 
evaluation of the results of the previous step. Visual aspect, particle size and PDI were 
the parameters that were evaluated. 
Based on prior knowledge and literature review, 10 mg of CLZ, 250 mg Precirol ATO 5, 
and 90 mg of Tween® 80 were selected as the constituent of the SLNs. These values 
were selected considering the ratio lipid:surfactant as well as the ratio lipid:drug. 
Regarding the process variables, amplitude and time of sonication was assessed at two 
different levels (90 and 70%; 5 and 10 min, respectively). 
 
Table 1. Formulation and process parameters of preliminary SLNs-CLZ and their 
characterization (particle size and PDI) 
 
 
The initial three formulations (F1, F2 and F3) presented very high values of size (Table 
1) (higher than 400 nm) and values of PDI below 0.2. Besides, the higher percentage of 
sonication amplitude provided particles with lower sizes (F2) but increasing sonication 
time to 10 min (F3) did not produced smaller SLNs. Thus, 90% was set as fixed variable 
for the subsequent step. Less amount of lipid (200 mg) with different amount of 
Tween® 80 (40 and 60 mg), were studied in the second step (F4, F5 and F6 on Table 1) 
intending to observe the influence on the particle size and PDI values. Sonication time 
was also tested (5 and 10 min). It could be inferred that the amount of surfactant had a 
  Amount of 
Lipid (mg) 
Amount of 
Surfactant (mg) 
Time 
(min) 
Amplitude 
(%) 
Mean 
particle 
size 
PDI 
Step 
1 
F1 250 90 5 70 528 0.148 
F2 250 90 5 90 486 0.116 
F3 250 90 10 90 576 0.148 
Step 
2 
F4 200 60 10 90 537 0.163 
F5 200 60 5 90 615 0.202 
F6 200 40 10 90 553 0.313 
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negative impact on the PDI (higher values, F5) while the time of sonication had a 
positive impact on particle size (Table 1, F4). Even though, once more the particles 
presented sizes above 400 nm. 
It is already reported that the reduction in particle size result in increasing surface area 
of the particles, which seems to prolong the residence time of SLNs in the GI tract and 
enhance their contact with epithelial membranes, possibly leading to enhanced oral 
absorption [42]. Thus, particles with diameter much higher than 250 nm are not 
suitable for our aims. 
Therefore, further investigation of nanoparticles dispersion was performed by 
analyzing the range of the size populations. The histograms of the DLS analysis (Figure 
3) revealed that all the tested formulations presented two very distinct populations, one 
in the nanometer scale, and another much bigger, in the micrometer range. It could be 
inferred that due to the very poor solubility of CLZ, precipitated crystals of non-
entrapped drug were interfering in the DLS analysis. This phenomenon was increasing 
the mean particle size of the formulation, providing an unrealistic result. To solve this 
issue, we decided to filter the subsequent formulation with a 3 µm pore size filter, to 
retain drug crystals, aiming to have more realist results regarding particle size (data not 
shown). 
 
 
Figure 3. Histograms of size distribution of the preliminary formulations in terms of 
intensity (F1-F6). 
 
3.4 Experimental design  
 
After a preliminary assessment of the significance of the screened factors, an 
experimental design was constructed with the identified variables that may influence 
the critical attributes of the SLNs. In this context, (X1) amount of lipid, (X2) amount of 
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surfactant and (X3) amount of drug were used to explore individual and synergic effects 
on the particle size, PDI, zeta potential, AE and DL. 
The lower (-1), medium (0), and higher values (+1) for the factors were set out 
according to preliminary studies and literature research. A three-level, three-factor 
BBD was applied to optimize SLNs, allowing maximizing the experimental efficiency, 
with a minimum number of experiments. 15 formulations were prepared and analyzed 
regarding the adopted responses. The experimental design included three replicates of 
the central point aiming to estimate the experimental error and accurately test the fit of 
the model. The data obtained are expressed in Table 2. 
The effects of the factors coefficients were evaluated via regression analysis for each 
independent variable, which were considered statistically significant when p values 
were less than 0.05, with 95% of confidence level. Because all the PDI values were 
below 0.2, which is considered to be a homogeneous dispersion, this response was not 
statistically evaluated. 
 
Table 2. Formulation composition and obtained responses of 15 different formulation 
obtained from Box-Behnken design 
 
Formulation  Independent variables Dependent variables 
X1 (mg) X2 (mg) X3 (mg) Y1 (nm) Y2 Y3(mV) Y4 (%) Y5 (%) 
F1 250 60 7 208 0.127 -28.04 67.8 1.88 
F2 350 60 7 236.5 0.158 -32.31 61.9 1.26 
F3 250 100 7 169 0.174 -23.17 67.0 1.85 
F4 350 100 7 195 0.158 -23.62 62.4 1.57 
F5 250 80 4 198.1 0.164 -30.88 70.8 1.10 
F6 350 80 4 227.1 0.169 -29.08 83.0 0.94 
F7 250 80 10 204.3 0.165 -25.73 62.4 2.26 
F8 350 80 10 221.2 0.156 -21.78 81.7 2.02 
F9 300 60 4 203.3 0.193 -27.18 62.7 0.81 
F10 300 100 4 187 0.168 -38.28 77.4 0.97 
F11 300 60 10 220.7 0.154 -29.61 75.0 2.39 
F12 300 100 10 177.5 0.154 -24.65 69.5 2.24 
F13 300 80 7 227.2 0.155 -32.09 71.2 1.63 
F14 300 80 7 219.7 0.194 -29.93 80.6 1.87 
F15 300 80 7 219.7 0.147 -28.52 74.7 1.61 
X1= amount of lipid, X2 = amount of surfactant, X3 = amount of drug, Y1= particle size, 
Y2= PDI, Y3= zeta potential, Y4 = AE and Y5=DL 
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The polynomial equation generated after fitting in second-order quadratic models 
showed good correlations (R2) after multiple linear regression analysis for all the 
responses (Table 3), with insignificant lack of fit. Moreover, the significance of the 
obtained models was tested by ANOVA, and tested by evaluating p values. All the 
mathematical models were considered precise in the prediction of the respective 
response as all the p values where 0.05. 
 
Table 3. Summary of the regression analysis of the independent variables Y1–Y4 
  Particle size (Y1) Zeta potential (Y2) AE (Y3) DL (Y4) 
Coefficient p-Value Coefficient p-Value Coefficient p-Value Coefficient p-Value 
β0 203.975 0.000 -27.861 0.000 70.121 0.000 1.681 0.000 
X1 12.908 0.015 -0.308 0.691 0.868 0.671 -0.190 0.044 
X12 1.131 0.421 -1.614 0.075 1.860 0.269 0.015 0.653 
X2 -18.375 0.008 1.748 0.121 0.723 0.721 0.053 0.327 
X22 8.906 0.016 -0.083 0.875 3.513 0.104 0.043 0.270 
X3 0.708 0.704 3.008 0.046 -1.238 0.555 0.704 0.003 
X32 3.631 0.084 -0.042 0.937 -1.341 0.389 0.002 0.953 
X1.X2 -0.625 0.800 0.955 0.399 0.337 0.900 0.089 0.248 
X1.X3 -1.075 0.555 1.309 0.176 5.236 0.088 0.077 0.187 
X2.X3 2.625 0.229 -2.463 0.061 1.187 0.551 -0.037 0.441 
 R² = 0.993 R² = 0.975 R² = 0.940 R² = 0.995 
 
3.4.1 Effect on mean particle size 
 
The size of the nanoparticles is an important parameter to control during the 
nanoparticles formulation as it seems to influence on in vivo distribution, biological 
fate, toxicity and drug loading capacity [20].  
The obtained values of particle size from the formulations generated by the BBD ranged 
from 169.0 nm (F3) to 236.5 nm (F2), with a mean size (β0) of 204.0 nm. According to 
the regression analysis, the amount of lipid (X1) and the amount of surfactant (X2) 
seemed to statistically influence on SLNs particles size, as they presented p values 
<0.05, with 95% of confidence level. The positive sign of X1 coefficient reveals that the 
size increases with the increasing of the amount of lipid. On the contrary, the negative 
sign before the coefficients shows that the higher is the amount of surfactant (X2) the 
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smaller are the particles. Also, significance of the X2 quadratic coefficient evidences a 
nonlinear relation of the response (particle size) with the changing of the values levels.  
 
3.4.2 Effect on zeta potential 
 
The zeta potential is the measurement of electric charge present on the surface of the 
particles. This parameter is associated with the colloidal dispersion stability so that 
generally, the greater the zeta potential the more likely the suspension is to be stable 
due to the charged particles repel one another, overcoming the tendency to aggregate. 
It is currently admitted that zeta potentials of |30| mV are required for full electrostatic 
stabilization [18]. 
Zeta potential measured from the 15 formulations ranged from -21.78 mV (F8) to -
38.28 mV (F10). Only the amount of drug (X3) seemed to affect the surface charge of 
the nanoparticles (p value 0.046), with 95% of confidence level. The positive sign of the 
coefficient means that the zeta potential increases with the augment of the amount of 
CLZ. Zeta potential expressed as negative values, so that the higher is the value, the 
closer it is to the neutral. 
In this case, it seems that the excess of CLZ may neutralize the surface charge of the 
nanoparticles, as it may be localized in the outer portion of the nanoparticle, thus 
influencing the surface charge. 
 
3.4.3 Effect on drug association efficiency 
 
The eassociation efficiency (AE) is one of the most critical attribute when designing 
nanoformulations as high values of AE improves formulation yield. This fact is even 
more important when the drug present severe adverse side effect, as is the case of CLZ. 
The drug entrapment inside nanoparticles depends on the solubility of drug into the 
solid lipid and on the O/W partition of the drug. 
The AE values of all the 15 formulations are shown in Table 2. In general, all the 
formulations presented satisfactory AE values, ranging from 61.9% (F2) to 83.0% (F6), 
with mean value (β0) of 70.121%. The regression analyses evidenced that none of the 
variables influenced statistically the percentages of drug association. Considering the 
high values and narrow range of AE percentages, this result may not be considered as 
negative since the used selected levels for all the variables originated suitable 
formulations in terms of AE.  
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3.4.4 Effect on drug loading 
 
During the development of any nanoformulations, high values for DL are preferred as it 
means less carrier materials and excipients will enter the patient’s body, leading to 
lower risks of toxicity [13]. 
The DL obtained from the 15 formulations ranged from 0.81% (F9) to 2.39% (F11). The 
regression analysis of the model showed that the DL statistically alters with the 
changing of (X1) the amount of lipid, and (X3) the amount of drug, with 95% of 
confidence level. The negative sign of X1 coefficient demonstrate the inverse relation 
between amount of lipid and DL, i.e., the DL decreased with the increasing of the 
amount of lipid. The opposite is observed with the increasing of the amount of drug, as 
the sign is positive. The result is in accordance with the mathematical equation for the 
calculation of DL (section 2.2.6). 
Although this result seems to be obvious, it is not a rule, mainly in the case of very 
poorly water soluble drugs as CLZ. The DL is a parameter related to the distribution of 
the drug between lipid and aqueous phase, which is determined by the drug’s solid-
state nanocarrier matrix [13]. If the amount of lipid is not enough to solubilize the 
selected amount of drug, thus this relation would be not so predictable. In this case, 
this critical step was overcomed by evaluating previously the solubility of CLZ in 
Precirol ATO 5 during the pre-formulation studies. 
 
3.4.5 Optimization of SLNs-CLZ 
 
After the evaluation of the relationships between factors and responses by the 
polynomial equations, the optimization of the formulation was carried out. Three-
dimensional response surface analyses were plot to provide a graphical representation 
of the behavior of each response with the simultaneous changing of two factors at a 
time, maintaining non-used variables fixed at their middle level (Figure 4). 
Furthermore, the optimization of SLNs-CLZ was carried out using the desirability 
function of the STATISTICA10 software [43]. This approach is a useful tool to 
overcome the difficulties of multiples or opposite optimal values for the different 
responses, as each response is associated with its own partial desirability function. The 
optimal nanoparticles had to satisfy the selected requirements for each dependent 
variable, namely nanoparticles with size closer to 250 nm, zeta potential closer to -30 
mV, maximum AE and DL. The optimal calculated levels are expressed in Table 4. 
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The qualities of the models were assessed by plotting predicted versus of the 
experimental data (supplementary material), confirmed by the low mean percentage of 
bias (Table 4). 
The validation of the models was performed by formulating the optimized formulation 
with (X1) 300 mg of lipid, (X2) 60 mg of surfactant and (X3) 10 mg of CLZ. The check 
point responses were then estimated by the mathematical models and the experimental 
data were compared with the predicted. The lower magnitude of the bias reveals good 
correlation of the models, and is an indicative of the robustness and high explorative 
predictive ability of the mathematical models. 
 
Table 4. Summary of the coded levels of the Box-Behnken design; the levels of the 
optimized formulation, the desirable parameters used for the optimization, and the 
comparison between predicted and observed values for the considered responses 
Factors Coded Levels  
Optimized  
Independent variables 
Low Level 
(-1) 
Medium Level 
(0) 
High Level 
(+1) 
X1 = Amount of Lipid (mg) 250 300 350 300 mg 
X2 = Amount Surfactant (mg) 60 80 100 60 mg 
X3 = Amount of Drug (mg) 4 7 70 10 mg 
Dependent variables  Constrains Predicted Observed  Bias* 
Y1 = Particle size Optimum  
(250 nm) 
233 nm 230 nm 1.45 
Y2 = Zeta potential < -30 mV -32.59 mV -34.28 mV 4.93 
Y3 = Association efficiency Maximum 69% 72% 3.93 
Y4= Drug Loading Maximum 2.44% 2.32 5.23 
*Bias (%) = |predicted-observed|/observed x 100 
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Figure 4. Response surface plots evidencing the influence of the independent 
variables on the selected responses particles size (Y1) (A), zeta potential (Y2) (B), AE 
(Y3) (C-D) and DL (E) (Y4). 
 
 
3.4.6 Characterization of the optimized SLNs-CLZ 
 
3.4.6.1 Measurement of mean particle size, PDI and zeta potential 
 
The particle size, PDI and zeta potential of the optimized SLNs-CLZ were measured in 
triplicated. The obtained nanoparticles presented particles size of 230.0 ±8.3 nm which 
was very closer to the desired value of 250.0 nm; suitable PDI (0.149 ± 0.010) below 
0.200 and zeta potential closer to -30 mV (-34.28 ±2.80). Unloaded SLNs were also 
prepared and values of 216.8± 16.5, 0.166 ± 0.020 and -32.23 mV for particle size, PDI 
and zeta potential respectively, evidencing that particles were quite similar. 
 
3.4.6.2 Association efficiency and drug loading 
 
The determination of AE and DL of SLNs-CLZ was performed in triplicated and the 
obtained values were 71 ± 1.8% and 2.39 ± 0.1% respectively. The obtained results were 
considered satisfactory taking in account the issues during the pre-formulation studies 
namely the very poor solubility of CLZ in aqueous phase and either in the molten lipid. 
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3.4.6.3 SLNs-CLZ characterization by Fourier transform infrared 
spectroscopy  
 
The FTIR spectra of CLZ, PM, SLNs and SLNs-CLZ are shown in Figure 5. Both SLNs 
and SLNs-CLZ displayed typical bands at 2820 cm-1 and 1705 cm-1 relative to C- H and 
C = O (carbonyl) stretching of glyceryl units, respectively. The spectrum of CLZ present 
characteristic bands of N−H bending frequency at 1550−1620 cm−1, and another 
regarding C=N stretching at 1625 cm-1 [6]. Unknown peaks were not found in the 
spectra, confirming that there is no chemical interaction between CLZ and SLNs 
constituents. Due to the amorphous state of entrapped CLZ, the intensity of 
characteristic peaks may be decreased and/or overlapped by others belonging to the 
major constituents of SLNs-CLZ.  
 
 
Figure 5: FTIR spectra of CLZ, SLNs and SLNs-CLZ. 
 
3.4.6.4 Assessment of CLZ physical state in the SLNs by differential 
scanning calorimetry 
 
Differential scanning calorimetry (DSC) studies were conducted to study the physical 
state of CLZ in the nanoparticles and identify potential Precirol ATO5-CLZ interactions 
during the production process of obtaining, in addition to evaluate the behavior of the 
lipid phase.  
The thermograms of CLZ, Precirol ATO 5, PM, SLNs and SLNs-CLZ can be observed in 
Figure 6. The endothermic event of CLZ at 224 ºC was not observed in SLNs-CLZ, 
which suggests that CLZ is encapsulated in amorphous form in nanoparticle 
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formulation. Similar results were observed with Precirol ATO 5 and poorly soluble 
compounds [44, 45]. Furthermore, no additional unknown peaks were found, 
indicating no incompatibility between Precirol ATO 5 and CLZ. 
Precirol ATO 5 thermograms shows an endothermic event at 58ºC with a shoulder at 
62 °C, characteristic of the diffuse melting in complex glycerides due to the presence of 
different polymorphs (Figure 6) [46]. This phenomenon was not observed in both load 
and unloaded nanoparticles, which may suggest that the lipids undergo some 
polymorphic changes to less ordered structures during particle preparation allowing 
better incorporation of the drug in the lipid matrix [47]. 
In PM, the onset temperature of this event shifted to lower temperature, indicating that 
the presence of CLZ in crystalline form interfered in the lipid melting. This shifting in 
Precirol ATO onset melting temperature was not observed for both SLNs and SLNs-
CLZ. On the other hand, onset temperatures values of lipid transition for both SLNs 
and SLNs-CLZ were quite similar suggesting that the presence of the drug did not alter 
the lipid conformation, probably because it is well dispersed. These findings were 
already reported to Precirol ATO and other compounds [46]. 
Moreover, in the PM thermogram no endothermic event was found around 224ºC, 
suggesting that CLZ was solubilized in the molten lipid which may be considered a 
positive interaction between lipid and drug due to the suitable solubility of CLZ in the 
selected lipid. 
 
 
Figure 6. DSC thermograms of CLZ, physical mixture (PM), Precirol ATO 5, SLNs and 
SLNs-CLZ. 
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3.4.6.5 Storage stability studies 
 
The physical stability of the optimized SLNs-CLZ was evaluated regarding particle size, 
PDI, zeta potential, AE and DL, upon storage of the colloidal suspensions at 4ºC, 
during 12 weeks. Changes in particle size and PDI are indicators of formulation 
instability and the surface charge is commonly related to the aggregation of the 
particles [18].  
Figure 7 show the results obtained after each time point measurement for the tested 
parameters. At the end of the study, no aggregation or color change were found after 
visual observations. Moreover, the initial characteristics were maintained, with no 
significant changes (p > 0.5). Particles size varied about 30 nm from the initial values 
and PDI was always bellow 0.2. The colloidal suspensions remained with negative 
values closer to -30 mV, which indicate stable dispersion due to the electric repulsion 
between the particles It was observed that the SLNs did not release CLZ over time, as 
the AE and DL values were practically constant (Figure 7). This can be considered a 
positive result since is common to observe drug expulsion after lipid crystallization 
upon storage [18]. Overall, the developed SLNs-CLZ were stable when stored at 4ºC for 
12 weeks. 
 
 
Figure 7. Storage stability at 4ºC assessed as (A) particle size and PDI, (B) Zeta 
potential, (C) drug content of SLNs-CLZ expressed as AE and DL (mean ± SD, n=3). 
 
3.4.7 In vitro cell viability studies 
 
SLNs-CLZ development aims oral drug delivery in leprosy therapy. Thus, different cell 
lines were selected as suitable models mimicking the different cell-types of the GI tract 
(e.g., stomach, enterocytes and mucus secreting cells) [48, 49]. Caco-2, HT29-MTX 
(intestinal model cells) and MKN-28 (gastric model cell) cell viability studies were 
conducted with SLNs and SLNs-CLZ optimized formulations, in addition to CLZ free 
drug solutions. 
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The studies were performed with different concentrations of nanoparticles 
corresponding to 6.26 to 50 µg mL-1 in CLZ, equivalent to 0.25 - 2 mg mL-1, in relation 
to the amount of lipid phase, during 24 h for Caco-2 and HT29-MTX, and 4 h for MKN-
28. Cytotoxicity studies were also carried out with CLZ solutions at concentration range 
of 1.56 – 50 µg mL-1. The obtained results show that for Caco-2 cells, only the highest 
tested concentration of SLNs-CLZ (50 µg mL-1 in CLZ, 2 mg mL-1 in lipid) presented cell 
viability statistically different from the control (Figure 8). Unloaded nanoparticles were 
considered safe as at all tested concentrations the viability of the cells was superior to 
80%. For HT29-MTX and MKN28 cell lines, neither SLNs nor SLNs-CLZ presented 
statistical significance when compared to the control. These results show that the 
nanoparticles were not toxic for the studied cell lines when compared to free CLZ 
solutions. In fact, for all the intestinal cell lines exposure to free CLZ lead to significant 
reduction on the cell viability, and the IC50 values determined were 16.3 and 20.3 
µg.mL-1 for Caco-2 and HT29-MTX, respectively. No significant effect on the MKN-28 
cell viability was observed (Figure 8). Moreover, the high toxicity of CLZ has been 
already reported [50]. Upon prolonged oral administration CLZ seems to forms 
intracellular insoluble drug precipitates, leading to high concentration 
bioaccumulation, being easily associated with unwanted side effects as reddish skin 
pigmentation, abdominal pain and cardiotoxicity [1].  
Based on the exposed results, the successful incorporation of CLZ in SLNs, with the 
drug in its amorphous state, may prevent drug crystallization and the formation of 
precipitates in vitro and in vivo. In this context, the nanoformulations seems to have 
an elevated potential to delivery CLZ, decreasing the undesired effect, by protecting the 
surrounding cells from the toxic effects of the drug. 
 
 
Figure 5. Cell viability of (A) MKN-28, (B) HT29-MTX and (C) Caco-2 cell lines 
upon exposure to SLNs (dark grey), SLNs-CLZ (light grey), and CLZ (dark grey). Data 
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expressed as the average ± standard deviation (n=5, for each three independent assays) 
(*p value <0.05 in relation untreated cells). 
 
4. Conclusion 
In the present study, the risk management during the development of SLNs-CLZ 
helped to identify the main critical variables, through the Ishikawa cause-and-effect 
diagram, which allowed the construction of an experimental design for further 
optimization. The studding of the starting conditions namely the selection of the best 
lipid and other formulation and process variables allowed to identify the presence of 
drug precipitates, and to implement control actions during nanoparticles 
characterization. Moreover, the intended analytical method was found to be accurate, 
precise, efficient, specific and highly sensitive due to the lowest LoD and LoQ, being 
suitable for the quantification of CLZ in SLNs.  
A BBD was successfully obtained and the relations between the independent variables 
in the selected responses could be understood. The optimized SLNs-CLZ was achieved 
based on the desirability profile, which presented suitable parameters after 
characterization, namely particle size, zeta potential, AE and DL. FTIR confirmed the 
presence of the drug and the absence of chemical interactions, while DSC 
measurements indicated the amorphous state of CLZ. The stability studies ensured that 
the developed SLNs are stable over a period of 12 weeks at 4ºC. In vitro cytotoxicity 
studies evidenced that the optimized SLNs-CLZ are not toxic at the teste concentration 
range, on the contrary of the CLZ solutions that presented low IC50 for Caco-2 and 
HT29-MTX cell lines. 
Based on the obtained results, it can be concluded that the optimized system was 
carefully developed, considering important variables when formulation poorly soluble 
drugs and SLNs-CLZ is a promising platform to deliver CLZ with reduced associated 
effects. 
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ABSTRACT 
The use of polymeric nanoparticles as delivery systems is a promising tool to overcome 
drawbacks related to low aqueous solubility of drugs, which limit their in vivo 
bioavailability. The aim of this study was to assess critical factors during formulation 
design of clofazimine (CLZ) loaded in PLGA nanoparticles (NPs-CLZ) through a 
Plackett–Burman design (PBD). A screening PBD was constructed with twelve 
formulations involving six variables among process and formulation parameters and 
the selected responses were particle size, polydispersity index (PDI), association 
efficiency (AE) and drug loading (DL). The formulation was achieved based on the 
desirability tool, and the obtained NPs-CLZ formulation was characterized regarding 
morphology, physicochemical properties and in vitro cellular studies. Particle size, PDI, 
AE and DL were found to be 211 ± 3 nm, 0.211 ± 0.009, 70 ± 5% and 12 ± 1 %, 
respectively. Fourier transformed infra-red spectroscopy confirmed the absence of 
chemical interactions between CLZ and other nanoparticles constituents, while 
differential scanning calorimetry thermograms indicated the amorphous state of CLZ 
and transmission electron microscopy revealed the spherical shape of the particles. In 
vitro release profile of CLZ from NPs-PLGA showed a slow pattern of drug release. 
Cytotoxicity studies towards intestinal cells revealed that NPs-CLZ did not show CLZ 
toxicity on Caco-2 and HT29-MTX cells compared to free CLZ solutions. It can be 
concluded that experimental design can streamline the formulation of poorly soluble 
drugs, deploying suitable vehicles with enhanced properties. The optimized NPs-CLZ is 
a promising platform for oral delivery of CLZ. 
 
 
Key words:  Caco-2 cell monolayer permeation assay; Plackett–Burman design, 
PLGA nanoparticles; poorly soluble drug 
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1. Introduction 
 
Leprosy is a chronic infectious disease caused by Mycobacterium leprae (M. leprae), 
which is a slowly growing intracellular bacillus that affects mainly peripheral nerves, 
especially Schwann cells, and skin [1]. Its clinical manifestations are related to the host 
immune response and bacillary cell loading, being classified as lepromatous (high 
bacillary load) or tuberculoid (low bacillary load). The actual proposed treatment is 
classified according to the number of skin lesions namely multibacillary (more than 6 
lesion) or paucibacillary (2-5 lesions) [2]. Current therapy consists in a multidrug 
combination of dapsone, rifampicin, and clofazimine, depending on disease 
manifestation [1]. 
Clofazimine (CLZ), is an antibiotic and anti-inflammatory drug and, as other 
riminophenazines is effective against both slowly and rapidly growing mycobacteria, as 
well as most other Gram-positive bacteria [3].  The very high hydrophobicity (logP > 7) 
of CLZ result in a very limited absorption (about 40%) after oral administration [4-6], 
which lead to an increasing in the administered doses to reach appropriate 
pharmacokinetic levels and to guarantee the therapeutic effects [4]. Besides, its low 
solubility CLZ is associated with bioaccumulation in the body’s fatty tissue, resulting in 
a 70 days half-life in humans, causing skin pigmentation, abdominal pain and 
cardiotoxicity [4-6]. In fact, it is already reported that CLZ may originate in vivo drug 
precipitation, forming complexes with intracellular membranes, and precipitate as 
crystal aggregates, which is further phagocytized by the mononuclear phagocyte system 
[7, 8]. 
Several approaches have been reported to improve CLZ solubility namely salt 
formation [9], complexation with cyclodextrins [4] or other macromolecules [6, 10], 
formulation of amorphous dispersions [11], use of co-solvents or surfactants [12], 
formulation of liposomes [13] and nanosuspensions [14]. 
In recent years, the encapsulation of poorly soluble drugs into nanoparticles have been 
gaining attention to improve drug bioavailability due to nanoparticles permeation 
through the interstitial spaces in tissue which may enhance drug cellular uptake [15]. 
Furthermore, nanoparticles may offer protection against gastrointestinal degradation, 
provide improved circulation half-life and possibility to active and passive targeting to 
specific intestinal cells, reducing systemic undesired effects [16]. The application of 
polymer based nanodelivery systems are being promising platforms for this purpose 
due to their ability to prolong drug release, increase drug bioavailability, decrease drug 
degradation and reduce drug toxicity [17, 18]. The copolymer poly(lactic-co-glycolic 
acid) (PLGA) is one the polymers widely used in this context as it is biocompatible, 
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biodegradable and safely administrable [19]. Moreover, it has a particular 
advantageous   to promote controlled and sustained drug delivery [19]. 
Despite different works have tried to improve CLZ solubility and bioavailability, the 
encapsulation PLGA nanoparticles has not been already described. The aim of this 
work was to develop polymeric PLGA nanoparticles loaded with CLZ (NPs-CLZ) aiming 
to improve CLZ intestinal absorption and decrease its associated toxicity. For these 
purpose, NPs-CLZ were produced after assessment of Placket-Burman screening 
designs formulation responses. The obtained NPs-CLZ were physical-chemically 
characterized regarding particle size distribution, polydispersity index (PDI), 
association efficiency (AE), in addition morphological studies, and in vitro drug release 
assays. Cell viability of the obtained formulations was also assessed with two different 
cell lines (Caco-2 and HT29-MTX), aiming to evaluate the toxicity of the particles when 
in contact with intestinal cells. Finally, the in vitro permeability of NPs-CLZ through 
Caco-2 monolayers was performed to assess the performance of the developed system 
in an intestinal model. 
 
2. Materials anda methods 
 
2.1. Materials  
 
CLZ was purchased from Hangzhou Heta Pharm & Chem Co. Poly (lactic-co-glycolic 
acid) (PLGA) (50:50 Purasorb® PDLG 5002A) was a kind gift from Purac Biomaterials 
(Gorinchem, The Netherlands). Polyvinyl alcohol (PVA) was purchased from Sigma–
Aldrich (St. Louis, USA) and acetone obtained from JGMS (Odivelas, Portugal). 
Caco-2 cell line was purchased from the American Type Culture Collection (ATCC, 
Wesel, Germany) (passage number 35 - 55) and HT29-MTX cell line was kindly 
provided by Dr. T. Lesuffleur (INSERM U178, Villejuif, France). Dulbecco’s Modified 
Eagle Medium (DMEM), fetal bovine serum (FBS, South America origin), penicillin- 
streptomycin mixture (Pen-Strep) and trypsin-EDTA 0.25% (w/v) were all obtained 
from Gibco (Paisley, UK). Thiazolyl blue tetrazolium bromide (MTT) was obtained 
from Sigma–Aldrich (St. Louis, USA).  
 
2.2. Preparation of PLGA nanoparticles 
 
The nanoparticles were prepared following the nanoprecipitation method [20]. Briefly, 
an accurately weighed amount of PLGA (20 or 40 mg) and CLZ (2 or 4 mg) were 
dissolved in acetone, at specified volumes (2 or 3 mL). The organic phase was slowly 
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added to PVA 1% (w/v) solution (5 or 10 mL), under probe sonication, during 2 min, 
with an amplitude (50 or 70%). A PVA solution (1 or 0.1% w/v) was then used as 
stabilizer to complete the final volume up to 20 mL. The final emulsion was maintained 
under magnetic stirring (RT 15 Power IKAMAG Multiposition Magnetic Stirrer, 
Staufen, Germany) at 350 rpm and room temperature. NPs-CLZ were washed three 
times with double deionized water, by centrifugation at 11,200 g for 30 min, using an 
Allegra X-15R centrifuge (Beckman Coulter, Brea, CA, USA). The amount of each 
variable was selected according to the experimental design (see section 2.3). Unloaded 
nanoparticles (NPs) were obtained for the selected formulation, following the same 
procedure. The resultant particles were freeze-dried when appropriate for 48 h, using a 
LyoQuest 85 plus v.407 Telstar freeze dryer (Telstar® Life Science Solutions, Terrassa, 
Spain). 
 
2.3. Experimental Design 
 
Different process and product variables which may influence the main critical 
parameters of NPs-CLZ were assessed by constructing a Plackett-Burman design 
(PBD).  The design was constructed with six factors and twelve experiments, using the 
STATISTICA 10 software (StatSoft®, Dell Software, Round Rock, TX, USA). The 
parameters studied were chosen according to literature and a preliminary investigation, 
which were (X1) volume of organic phase; (X2) stabilizer concentration; (X3) amount of 
polymer; (X4) amount of drug; (X5) amplitude of sonication; (X6) volume of aqueous 
phase.  The parameter level selection was based on prior knowledge and literature [21, 
22]. Non-studied variables as type of polymer (PLGA); ratio of PLGA co-polymerization 
(L:G - 50:50); organic solvent used (acetone); method of preparation (single emulsion 
– solvent evaporation); method of solvent  evaporation (magnetic stirring); final 
volume of nanosuspension (20 mL) were fixed. The selected responses were: particles 
size (Y1), polydispersity index (Y2), association efficiency (Y3) and drug loading (Y4).  
 
2.4. Formulation of CLZ-loaded PLGA nanoparticles (NPs-CLZ) 
 
Selected formulation was obtained after graphical and numerical analyses of the 
variables using STATISTICA 10 software based on the criteria of desirability namely 
(Y1) particle size closer to 200nm; (Y2) PDI < 0.2; (Y3) maximum association efficiency 
(AE) and (Y4) maximum drug loading (DL). 
The models were obtained following the equation: 
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@ = r% + r,A, + r/A/ + rBAB + ⋯+ rMAM 
 
where Y is the response, b0 is a constant and b0 - bn are the coefficients of the response 
values, X1–Xn are the factors under investigation. 
 
2.5. Physicochemical characterization of NPs-CLZ  
 
2.5.1. Particle size and polydispersity index  
 
Both mean particle size and polydispersity index (PDI) were analyzed using a 
ZetaPALS, Zeta Potential Analyzer (Brookhaven Instrument Corps, Holtsville, NY, 
USA), with a light incidence angle of 90º at 25ºC. The fresh colloidal dispersions were 
properly diluted with ultrapure water until reach a suitable concentration (Kcps 300-
500), and the obtained value is the representation of multiples runs (n=6). 
 
2.5.2. Determination of association efficiency and drug loading  
 
The quantification of CLZ within PLGA nanoparticles was carried out by determining 
the unentrapped drug applying the ultracentrifugation method. Briefly, samples were 
prepared by properly diluting NPs-CLZ with sodium dodecyl sulphate (SDS) 2% (w/v) 
so that the maximum concentration of CLZ did not exceed 100 µg mL-1 to ensure that 
unentrapped drug remains soluble. Samples were centrifuged at 11,200 xg for 30 min. 
The supernatant was read at 492 nm by UV-VIS spectroscopy (Jasco V-660, Easton, 
MD, USA). Standard curves were obtained for CLZ in SDS 2% and then the supernatant 
containing the aqueous phase was measured to determine the CLZ concentration. The 
results are expressed as mean ± standard deviation (n=3). Association efficiency (AE) 
and drug loading (DL) were calculated following the equations:  
 0c = t586829	27Gb56	Gd	;3bH	– 34fGa434;	;3bH8586829	27Gb56	Gd	;3bH ×100 
 
 en = 		 8586829	27Gb56	Gd	;3bH − 34fGa434;	;3bH8586829	27Gb56	Gd	;3bH + 8586829	27Gb56	Gd	1G9"743 ×100 
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2.5.3. Morphological analysis 
 
The morphology of designed NPs-CLZ and unloaded NPs were examined by 
transmission electron microscopy (TEM, JeolJEM-1400, JEOL Ltd., Tokyo, Japan). 
Images were obtained after dropping the colloidal dispersions properly diluted (40 
times) over a copper-mesh grid followed by negative staining with 0.75% (w/v) uranyl 
acetate (30 s at room temperature). The grid was exposed at the accelerating voltage of 
60 kV. 
 
2.5.4. Fourier transform infrared spectroscopy (FTIR) 
 
The spectra of CLZ, physical mixture (PM), PLGA NPs and NPs-CLZ were obtained to 
study possible CLZ-polymer chemical interactions. The IR spectra were obtained using 
the PerkinElmer® Spectrum 400 (Waltham, MA, USA) equipped with an attenuated 
total reflectance (ATR) device and zinc selenite crystals. The freeze-dried samples were 
transferred directly to the ATR compartment, and the result was obtained by 
combining the 16 scans. The spectra were recorded between 4000 and 600 cm-1 with a 
resolution of 4 cm-1. 
 
2.5.5. Differential scanning calorimetry (DSC) 
 
Differential scanning calorimetry thermograms of CLZ, PM, PLGA NPs and NPs-CLZ 
were obtained to evaluate the physical changes in CLZ crystallinity before and after the 
nanoparticles production process. The thermal analysis was performed using a DSC 
200 F3 Maia (Netzsch, Selb, Germany). 
Accurately weighted samples (1-2 mg) were poured into aluminum pans and 
hermetically sealed. The samples were scanned from 30 to 300 ºC, at 10 ºC.min-1. 
Nitrogen gas was used as purge gas, at 40 mL.min-1. The melting point (peak 
maximum), was calculated using the (NETZSCH Proteus® Software – Thermal Analysis 
– Version 6.1) software provided for the DSC equipment. 
 
2.5.6. In vitro drug release  
 
The in vitro drug release was performed using the methodology described elsewhere 
[22, 23]. Briefly, NPs-CLZ were dispersed into 1.5 mL of sodium dodecyl sulfate 
(SDS)solution (2% -w/v) aiming to provide solubility of CLZ in the aqueous phase, as 
already described for other poor soluble drugs [24]. The solubility of CLZ in different 
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surfactants namely Tween® 80 (1 and 2%), sodium salicylate (1 and 2%) and SDS (1 and 
2%) was previous study to select the suitable solubilizing agent (data not shown). 
Samples were incubated at 37ºC using a shaking water bath, at 250 rpm.  Samples were 
taken at pre-defined time intervals (0.5, 1, 2, 4, 6 and 8 h) and replaced with fresh 
medium at the same temperature. The recovered samples were centrifuged at 11200 g 
for 30 min using an Allegra X-15R centrifuge (Beckman Coulter, Brea, CA, USA) and 
free CLZ was determined by UV-VIS spectroscopy (Jasco V-660, Easton, MD, USA) at 
492nm, as described in 3.3.2. 
 
2.6 Cell culture assays 
 
Caco-2 and HT29-MTX cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% (v/v) of fetal bovine serum (FBS) and 1% (v/v) of 
penicillin-streptomycin. Cells were grown in a humidified incubator at 37 ºC and 5% 
CO2 atmosphere and 95% relative humidity. When reaching 80% confluence, cells were 
detached using trypsinization.  
 
2.6.1  In vitro cell viability studies 
 
The cell viability of unloaded NPs, NPs-CLZ and free CLZ was evaluated against Caco-2 
and HT29-MTX cells lines to compare its toxicity to the free drug. The method used 
was the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
colorimetric assay. Separately, each cell line was transferred into 96-well plates, at a 
density of 5 x 104 cells per well. After cell adhesion, the culture media was removed and 
the wells were incubated with 100 µL of culture media containing different 
concentrations of NPs, NPs-CLZ and free CLZ (6.25 – 50 µg mL-1 of CLZ). For free CLZ, 
the samples were prepared from a stock solution in DMSO, and appropriate dilutions 
were done to reach a maximum of 4% (v/v) of DMSO in the well, immediately before 
the assay. After a 24 h incubation period, the supernatant was removed and replaced by 
100 µL of MTT solution (0.5 mg mL-1). Upon 2 h at 37ºC, the MTT solution was 
removed and 100 µL of DMSO was added into each well to solubilizing of formazan 
crystal. The optical density of the solution was measured at a wavelength of 570 nm 
using SynergyTM HT Multi-mode microplate reader (BioTek Instruments Inc., 
Winooski, VT, USA). Untreated cells were taken as positive control with 100% viability 
and cells treated with 4% (v/v) DMSO in culture media used as control for free CLZ. 
Three independent MTT assays were performed with quadruplicate samples each and 
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results were expressed as mean values ±SD. The cell viability (%) in relation to control 
cells (untreated cells) was calculated by the equation: 
 ?499	a82$8986"	(%) = 0 f499O	85fb$264;	i86ℎ	dG37b9268G50 f499O	85fb$264;	i86ℎ	fb96b34	74;8b7×100 
 
2.6.2 CLZ permeation across Caco-2 monolayers 
 
For the permeability studies, Caco-2 cells were seeded on 12-well Transwell inserts 
(Corning Transwell Clear, pore size 3 µm, area 0.33 cm2) at a cell density of 105 cells per 
cm. The cells were grown in FBS-supplemented DMEM, and the culture medium was 
added to both apical and basolateral compartments, with changes every other day, 
during 21-23 days, until the monolayer achieve minimum of 400 Ω cm2 of 
transepithelial electrical resistance (TEER) values [24, 25]. The tightness of the Caco-2 
monolayer was assessed as the TEER values using a Millicell® ER-1 system 
voltohmmeter (Millipore Corporation, Bedford, MA), equipped with a pair of chopstick 
electrodes inserted into the apical medium. The TEER value at the beginning of the 
studies was higher than 400 Ω cm2, indicating an intact monolayer; TEER values were 
also obtained after completion of flux experiments upon 8 h. The resistance 
measurement of the medium without cells was considered as blank. The permeability 
was carried out by adding 0.5 mL of culture medium containing the equivalent of 40 µg 
mL-1 of CLZ as NPs-CLZ in the apical side of the cell monolayer. The formulations were 
incubated for 8 h, and at predetermined time intervals (1, 2, 3, 4, 6 and 8 h), 0.5 mL 
were sampled from the basolateral compartment and replaced with fresh culture 
medium. The amount of CLZ in the samples was analyzed by HPLC according the 
section 2.7. The experiments were carried out in triplicate. The cumulative amount of 
CLZ transported across the monolayers was calculated from the samples collected at 
the basolateral compartment. The apparent permeability (Papp) was calculated as 
described elsewhere [26]. 
 
2.7 CLZ determination by high-performance liquid chromatography  
 
CLZ quantification in cell culture media was performed by high-performance liquid 
chromatography (HPLC) with UV detection. The HPLC system (Jasco) comprised a 
high-pressure pump (PU-2089), an autosampler (AS-2057) and a diode array detector 
(MD-2015) programmed for peak detection at 280 nm, controlled by ChromNAV 
software. A reversed phase Kinetex® core-shell C18 column (250 x 4.1 mm, 5 µm 
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particle size, 100 Å; Phenomenex, Torrance, CA, USA) was used as stationary phase. 
Elution was performed in gradient mode using as mobile phase a mixture of aqueous 
acetate buffer (final concentration 50 mM, pH 4.8) and acetonitrile, at a flow rate of 1 
mL min-1. The selected gradient started with 30% (v/v) of acetonitrile, which was 
maintained up to 3 min. From 3 to 5.5 min, the contribution of acetonitrile was rapidly 
changed to 80% (v/v). This composition was maintained up to 7.5 min, after which the 
initial conditions were re-established and held during 5.5 min more to assure column 
equilibration. Hence, the total run time was 13 min. The injection volume was 20 µL. 
Standard CLZ solutions were prepared at 0.5, 1, 2.5, 5, 7.5, 10, 15 and 20 µg mL-1 in 
culture medium containing 40% (v/v) of acetonitrile and 50 mM acetate buffer, pH 4.8. 
To prepare the samples for HPLC analyses, 200 µL of each sample was added to 160 µL 
of acetonitrile and 40 µL of acetate buffer 500 mM, pH 4.8, to final concentrations of 
40% (v/v) and 50 mM, respectively. The mixtures were vortexed and centrifuged at 
18,000 × g for 10 min at room temperature. After centrifugation, supernatants were 
collected and analyzed by HPLC. 
 
2.8 Statistical analyses 
 
The statistical analysis of the experimental design was performed used STATISTICA10 
(StatSoft®) software. GraphPad Prism software (version 6, GraphPad Software, USA) 
was used for statistical comparisons of the results to control for the cytotoxicity studies. 
Statistical analysis of the results was performed using student (unpaired) t-test and 
one-way ANOVA test. All the other results were presented as mean and standard 
deviation (SD). The differences were assumed statistical significant when p < 0.05 
(95% confidence level), for cytotoxicity studies, and p < 0.01 (99% confidence level) for 
experimental design. 
 
3. Results and discussion 
 
3.1 Experimental Design 
 
Plackett–Burman (PB) designs are screening strategies which can be used to identify 
critical factors with a reasonable number of experimental runs and good degree of 
accuracy [27, 28]. In parallel, during the design of polymeric nanoparticles, several 
factors as: (i) method of preparation, (ii) drug solubility in the organic phase; (iii) 
choice of organic solvent; (iv) inclusion of a suitable stabilizer; (v) the ratio 
polymer/drug as well as their concentration in the nanosuspension may influence the 
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desired performance of the nanosuspension regarding association efficiency, drug 
loading, nanoparticles dispersity and stability [28, 29]. 
The emulsion-solvent evaporation is the most common method used to prepare 
polymeric nanoparticles, though the encapsulation of poorly soluble drugs is yet quite 
challenging due to the difficulty in achieve satisfactory drug loading [16, 30]. 
In this context, PBD seemed to be a suitable tool to assess nanoparticles design 
formulations and process critical factors. This study involved the production of twelve 
formulations based in six factors defined from on preliminary studies. The independent 
variables were (X1) volume of organic phase; (X2) stabilizer concentration; (X3) amount 
of polymer; (X4) amount of drug; (X5) amplitude of sonication; (X6) volume of aqueous 
phase. From preliminary studies some parameters were considered as the best choice 
and were fixed namely: the type of polymer (PLGA); the type of PLGA co-
polymerization (PLA: PGA - 50:50); organic solvent used (acetone); method of 
preparation (single emulsion- solvent evaporation); method of solvent evaporation 
(magnetic stirring); final volume of nanosuspension (20 mL). The selected responses, 
namely (Y1) particle size, (Y2) PDI; (Y3) AE and (Y4) DL, were determined for each 
formulation. The designed formulations and the obtained responses are shown in Table 
1.  
 
Table 1. Layout and observed responses of Plackett–Burman screening design 
formulations 
Formulation X1 
(mL) 
X2 
(%) 
X3 
(mg) 
X4 
(mg) 
X5 
(%) 
X6 
(mL) 
Size 
(nm) 
PDI 
 
AE 
(%) 
DL 
(%) 
F1 3 1.0 40 2 50 5 221.0 0.180 36.59 1.74 
F2 3 0.1 20 4 50 5 209.3 0.215 52.58 8.76 
F3 2 0.1 40 2 70 5 241.4 0.138 43.69 2.08 
F4 3 1.0 40 4 50 10 121.9 0.208 23.87 2.17 
F5 3 0.1 20 4 70 5 227.5 0.223 79.45 13.24 
F6 3 0.1 40 2 70 10 108.7 0.211 11.44 0.54 
F7 2 0.1 40 4 50 10 136.6 0.152 33.81 3.07 
F8 2 1.0 40 4 70 5 218.7 0.125 54.71 4.97 
F9 2 1.0 20 4 70 10 181.5 0.326 28.13 4.69 
F10 3 1.0 20 2 70 10 142.6 0.324 6.57 0.60 
F11 2 0.1 20 2 50 10 120.2 0.201 0.69 0.06 
F12 2 1.0 20 2 50 5 177.1 0.220 23.81 2.16 
Independent variables: X1 volume of organic solvent; X2 stabilizer concentration; X3 
amount of polymer; X4 amount of drug; X5 amplitude of sonication; X6 volume of 
aqueous phase. Dependent variables: Y1 particle size; Y2 PDI; Y3 AE and Y4 DL. 
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The quantitative standardized effects of the variables on the responses were assessed by 
plotting Pareto charts (Figure 1) which consists in bars with a length proportional to 
the absolute value of the estimated effects, divided by the standard error. The bars are 
ordered by magnitude of the effects, with the largest effects at the top [31]. The negative 
and positive sign of the coefficient indicate an indirect and direct relation to the 
response respectively [32]. 
 
Figure 1. Pareto charts showing the significance of the variables for (A) particle size, 
(B) polydispersity index, (F) association efficiency and (D) drug loading. The effects 
were considered statistically significant when p < 0.01, with 99% of confidence level. 
 
3.1.1 Effects on particle size 
 
The particles size (Y1) of the obtained formulations ranged from 108.7 nm (F4) to 241.4 
nm (F3). According to the regression analysis of the responses, the volume aqueous 
phase (X6) was the only factor that influenced statistically the particle size. The negative 
sign before the linear coefficient (-40.292) indicates a negative effect of the volume of 
aqueous phase on particles size, i.e., as the volume increases, the particle size decreases 
in size. This effect could be explained by the decrease in the levels of entrapped CLZ 
(see section 4.6.3), with the increasing in the volume of aqueous phase due drug 
precipitation, leading to formation of particles with lower diameter. In fact, considering 
only the particles prepared with the lowest volume of aqueous phase (F1, F2, F3, F5, F8 
A B 
C D 
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and F12), in general higher values of AE, DL and particle size was observed among the 
12 formulations, supporting the suggested explanation. 
 
3.1.2 Effects on PDI 
 
PDI values (Y2) of the obtained 12 formulations ranges from 0.125 (F8) to 0.326 (F9). 
The regression analysis showed that the amount of polymer (X3) statistically influenced 
the response. The negative sign before the regression coefficient (-0.041) reveals an 
inverse relationship between the response and changing in the levels of the factor. One 
possible explanation for this result is drug precipitation of at higher amounts and with 
lower amounts of the polymer, due to inefficient drug loading capacity. In fact, for 
formulations (F2, F5, F9, F10, F11 and F12) with low amount of polymer (20 mg), 
higher values of PDI were obtained. The low water solubility of CLZ lead to the 
formation of crystals of the non-entrapped drug that may influence the dispersity of the 
measurement. 
 
3.1.3 Effects on the association efficiency 
 
The AE (Y3) of the prepared formulations ranged from 0.69% (F11) to 79.45% (F5). The 
regression analysis evidenced that the volume of aqueous phase (X6) and drug amount 
(X4) significantly interfered in the Ae levels, at this order of significance. The negative 
sign before the (X6) coefficient reveals that the AE values decrease with the increasing 
in volume of aqueous phase. This phenomenon may be explained by the precipitation 
of CLZ with increased volumes of aqueous phase, due to its very high hydrophobicity as 
the ratio organic/aqueous phase decreases in a higher degree, even considering the 
changing in organic solvent volume. With the precipitation of CLZ, less drug is 
available to interact with the polymer and consequently to be entrapped. On the 
contrary, the positive sign before (X6) coefficient indicates a direct relation between the 
amount of drug and the AE values. The AE is related to the miscibility of the drug into 
the polymer. In the PLGA nanoparticles, with the same polymer concentration, 
changings in the initial amount of drug generally results in a maximum drug 
incorporation. Nevertheless, as the drug content increases, reaches its limiting value, 
determined by the drug miscibility in the polymer at a given processing conditions, 
reaching a plateau [33]. Because in PBD only two levels at a time of each variable are 
studied, the maximum capacity of the process could not be achieved, but a tendency in 
increasing AE with higher amounts of CLZ was detected.  
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3.1.4 Effects on the drug loading 
 
The DL (Y4) of the formulations ranged from 0.06% (F11) to 13.24% (F5). The 
regression analysis evidenced that the (X4) amount of drug and the (X6) volume of 
aqueous phase significantly interfered in the DL levels, at this order of significance. The 
amount of drug (p = 0.001) was more relevant than the volume of aqueous phase (p = 
0.003) in the values of DL obtained.  
The positive sign before the (X4) coefficient reveals that the DL values increases with 
the increasing in the initial amount of drug, probably to the same reason as discussed 
on section 4.4.3. For the calculation of the DL, the initial amount of polymer is 
considered, even though it seems that it was not relevant for the drug incorporation 
and the selected levels of the amount of PLGA did not increase significantly the 
entrapment of CLZ, while considerable differences in changing CLZ amount from 2 to 4 
mg promoted several important responses. The negative sign before (X6) coefficient 
indicates a negative relation between the volume of aqueous phase and the DL values 
probably due to drug precipitation when in contact with the aqueous medium, as 
already discussed. 
 
3.2 Formulation of CLZ-loaded PLGA nanoparticles (NPs-CLZ) 
 
The formulation of NPs-CLZ was based in the effects of the factors after preliminary 
screening through a PBD.  The mathematical correlation between the factors 
coefficients and their p values were analyzed via regression analysis, for each response, 
and are expressed in Table 2. The mean values of the obtained response (b0) 
corresponded to the intercept of the model. The magnitude and the sign of the 
polynomial coefficients indicate synergistic or antagonistic effect, when the signs are 
positive or negative, respectively.  
As shown in Table 2 the determination coefficients (R2) were very close to the unit, 
indicating reasonable agreement between the predicted and the observed values, and 
variations in the response over 90% could be explained by the obtained models. 
Moreover, obtained F value were compared with the theoretical value (Fisher test 
critical value) Fα (p − 1,N − p) (α, chosen risk, p the number of terms of the model, N the 
number of the experiments) to test the significance of the regression models. The 
theoretical value F0.05 (6,5) is 4.95. All the calculated F-ratios were found to be greater 
than the theoretical value (Table 2) evidencing the significance of the regression 
models, with a confidence level of 95% [32]. 
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Table 2. Data of the regression analysis for the considered responses Y1–Y4. 
 
Despite PBD are not commonly used to obtain optimum formulation, the validity of the 
obtained models allowed to investigate through the desirability software function to 
design nanoparticles with specific features namely size closer to 200 nm, PDI <0.2, 
maximum AE and DL. Selected NPs-CLZ were obtained with: (X1) 3 mL of organic 
phase; (X2) 0.1% (w/v) of stabilizer concentration; (X3) 40 mg of PLGA; (X4) 4 mg of 
CLZ; (X5) 70% of amplitude of sonication and (X6) 5 mL of aqueous phase. Unload 
nanoparticles (NPs) were also obtained, and both were characterized.  
 
3.3 Particle size and Polydispersity index  
 
It has been already reported that PLGA particles with diameter close to 200 nm can be 
taken by the enterocytes via clathrin-coated pit endocytosis [34]. Moreover, kinetic 
absorption of PLGA nanoparticles was reported to be size- dependent as smaller 
particles sizes was proved to be uptaken at a higher level compared to particles with 
diameter closer to 1µm [35]. 
Thus, our aim was to develop particles closer to the optimal diameter to improve CLZ 
uptake by intestinal cells, with the lower dispersity as possible. Accordingly, the particle 
size of the obtained NPs-CLZ was 210.8 ± 2.6 nm. The PDI values (0.211 ± 0.009) were 
below 0.3, which indicate that distribution is monomodal [24] being suitable for 
intestinal absorption. Similar results were obtained with PLGA nanoparticles 
previously [36]. Unloaded nanoparticles (NPs) were obtained as control, and presented 
values of particle size and PDI of 174.8 ± 13.4 nm and 0.215 ± 0.017, respectively. The 
presence of drug in the NPs-CLZ leads to ca. 40 nm increase in relation to unloaded 
NPs. 
  Particle size (Y1) PDI (Y2) AE (Y3) DL (Y4) 
Coefficient p-Value Coefficient p-Value Coefficient p-Value Coefficient p-Value 
β0 175.542 0.000 0.210 0.000 32.946 0.000 3.675 0.000 
X1 -3.708 0.642 0.017 0.091 2.138 0.372 0.835 0.058 
X2 1.592 0.840 0.020 0.051 -3.998 0.126 -0.952 0.038 
X3 -0.825 0.917 -0.041 0.003 1.073 0.644 -1.244 0.015 
X4 7.042 0.391 -0.002 0.804 12.480 0.002 2.477 0.001 
X5 11.192 0.196 0.014 0.133 4.386 0.101 0.679 0.103 
X6 -40.292 0.003 0.027 0.020 -15.526 0.001 -1.819 0.003 
 R² = 0.866 R² = 0.913 R² = 0.948 R² = 0.957 
 F calculated = 5.39 F calculated = 8.73 F calculated = 15.32 F calculated = 18.76 
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3.4 Determination of association efficiency and drug loading  
 
The association efficiency and drug loading of NPs-CLZ was 69.6 ± 5.0 % and 11.6 ± 
0.8%, respectively. The obtained DL was considered a good result, since this parameter 
is related to the decrease in the required administrated NPs-CLZ [34].  
 
3.5 Physicochemical characterization of NPs-CLZ 
 
3.5.1 Morphological analysis 
 
Electron micrographs of unloaded-NPs and NPs-CLZ before and after freeze-drying 
were obtained (Figure 2) to investigate structural and morphological features of the 
nanoparticles, and the influence of the lyophilization process on the nanoparticles 
morphology. From the images, it could be seen that the particles were well dispersed, 
and with spherical morphology. Unloaded-NPs and NPs-CLZ showed similar structures 
before (Figure 2 A and B) and after freeze-drying (Figure 2 C and D), confirming that 
the process did not alter the particles morphology. The freeze-drying could then be 
used to store the formulation. 
 
 
Figure 2. TEM micrographs of (A-C) unloaded NPs and (B-D) NPs-CLZ before (A, B) 
and after (C, D) freeze-drying process.  
A B 
C D 
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3.5.2 Fourier transform infrared spectroscopy studies 
 
The FTIR spectra of CLZ, PM, unloaded-NPs and NPs-CLZ are shown in Figure 3. The 
spectra of both NPs and NPs-CLZ showed a broader characteristic peak of PLGA at 
1750 cm-1, compared to the PM, which are indicative of C = O stretching. This 
phenomenon could be explained by intermolecular interaction of the nanoparticles 
constituents in both systems. Moreover, the spectrum of PM evidences characteristics 
peaks of CLZ namely bands of N−H bending frequency at 1550−1620 cm−1, and C=N 
stretching at 1625 cm-1  [9]. These peaks could not be seen in NPs-CLZ spectrum 
probably due to the amorphous state of entrapped CLZ as their intensity may be 
decreased and/or overlapped by others belonging to the major constituents of NPs-
CLZ. Overall, no strong chemical interaction was found between CLZ and other 
nanoparticles’ constituents as unknown peaks were not found in the spectra. Thus, all 
the components of the formulation are compatible. 
 
Figure 3. FTIR spectra of CLZ, physical mixture of bulk PLGA and CLZ (PM), 
unloaded-NPs and NP-CLZ. 
 
3.5.3 Differential scanning calorimetry studies 
 
The DSC thermograms of CLZ, PLGA, PVA, PM, unloaded-NPs and NPs-CLZ are 
shown in Figure 4.  The endothermic event of CLZ melting at 228ºC was not observed 
in NPs-CLZ, suggests that CLZ is entrapped in an amorphous form within the 
polymeric nanoparticle. Moreover, the thermograms of unloaded-NPs and NPs-CLZ 
were identical, evidencing that CLZ did not interacted with the formulation 
constituents. 
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The PM was performed with the presence of PVA to confirm the origin of any event 
present in load and unloaded NPs around the phase transition of CLZ (224ºC). The 
thermogram of PM evidences an endothermic peak at 51°C corresponding to the glass 
transition of PLGA, and a discrete event in 224ºC related to the melting of CLZ, 
suggesting that the formulation process interfered on physical state CLZ, shifting from 
crystalline to amorphous form, as in NPs-CLZ no endothermic event was found around 
224ºC. Furthermore, the event related to the phase transition of PVA at 180ºC is 
evident in PM, unloaded-NPs and NPs-CLZ. 
 
 
Figure 4. DSC thermograms of CLZ, PLGA, PVA, physical mixtures (PM) and 
unloaded (NPs) and loaded (NPs-CLZ) nanoparticles. 
 
3.5.4 In vitro drug release 
 
The in vitro drug release profile of CLZ from NPs-CLZ is show in Figure 5. To simulate 
the conditions at the small intestine, the experiment was conducted in a buffered 
solution pH 6.8 for 8 h [37]. The CLZ release profile from the NPs-CLZ is low and 
controlled reaching about 30 % of released drug at the end of the experiment.  
As already reported, drug release from a PLGA matrix depends dramatically on the 
degradation rate of the PLGA chains, and involves mainly two steps. The first one 
involves an autocatalytic hydrolysis in the polymer backbone and formation of the 
relatively high-molecular oligomers, leading to the pores formation in the polymeric 
matrix. Further on, with the continuing of the scission of the polymeric chain the 
formation of lower molecular weight products takes place, and the formed oligomers 
and monomers become water-soluble, and the particle size and weight eventually also 
decrease [38]. Based on studies performed elsewhere [38, 39], the first step of 
hydrolytic degradation lasts for at least 24 h. Thus, the release profile of CLZ during 8 h 
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of incubation is probably determined by drug desorption/from the polymer matrix. 
In parallel, the controlled release of CLZ from NPs may prevent drug recrystallization 
as supersaturated solutions are not formed that tend to change to a thermodynamically 
more stable system by precipitation of drug microcrystals [40]. 
Given described intracellular crystallization of CLZ, the release pattern observed may 
contribute to reduce this unwanted effect by avoiding drug recrystallization. Moreover, 
at the intestinal lumen, entrapped CLZ into PLGA nanoparticles may allow its 
absorption by the intestinal cells, avoiding its precipitation, leading to an improved 
bioavailability [37]. 
 
Figure 5 In vitro release profile of CLZ from NPs-CLZ in SDS solution (2%) at 37ºC. 
 
3.6 In vitro cell viability studies 
 
The developed NPs-CLZ is intended to oral delivery in leprosy therapy. Given the CLZ 
properties, namely its high hydrophobicity, difficulties may occur in the drug 
absorption due to drug precipitation at physiological pH, causing toxicity at the 
intestinal tissue. Thus, two cell lines were selected as models to mimic intestinal cell 
types, namely Caco-2 ant HT29-MTX [41, 42]. In order to evaluate NPs-CLZ cell 
viability in these cells, the studies were conducted with unloaded NPs, NPs-CLZ and 
CLZ as free drug. Different concentration of NPs-CLZ containing 6.26 – 50 µg mL-1 in 
CLZ the equivalent to 15.63 – 250 µg mL-1 in relation to the polymer were incubated 
during 24 h with Caco-2 and HT29-MTX (Figure 6).  
Caco-2 cells exposed to unloaded nanoparticles maintained cell viability above 80%, 
with no statistical differences from the untreated cells. The presence of CLZ in the 
PLGA nanoparticles leads to a decrease on the cell viability, as the polymer itself did 
not produce any effect (Figure 6A). Similar results were found for HT29-MTX cell line 
(Figure 6B). NPs-CLZ led to cell viability around 70 ± 9% and 75 ± 6% for the highest 
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tested concentration, in Caco-2 and HT-29, respectively. For both the studied intestinal 
cell lines, the exposure to CLZ solutions lead to a significant reduction of cell viability, 
resulting in IC50 values 16.3 and 20.3 µg mL-1 for Caco-2 and HT29-MTX, respectively 
(Figure 6). In fact, the high toxicity of CLZ has been already reported [43]. Upon 
prolonged oral administration CLZ seems to form intracellular insoluble drug 
precipitates, leading to high concentration bioaccumulation, being easily associated 
with unwanted side effects as reddish skin pigmentation, abdominal pain and 
cardiotoxicity [6].  
In this work, the incorporation of CLZ within the PLGA nanoparticles prevented the 
drug toxicity effect on the intestinal cells up to 24 h. Taken the results obtained, the 
encapsulation of CLZ in NPs-CLZ may prevent drug crystallization and the formation of 
such precipitates in vivo, as they are entrapped in its amorphous form. Thus, the 
formulations have potential to delivery CLZ and decrease the undesired effect, by 
preventing cells from the drug toxicity. 
 
 
Figure 6. Cell viability of the intestinal cells exposed to the unloaded-NPs (black bar), 
NPs-CLZ (light grey bar) and free CLZ (dark grey bar) assessed by the MTT assay. The 
viability of Caco-2 (A), HT29-MTX (B) cells after 24 h incubation with different CLZ 
concentrations (and equivalent NPs) at 37°C. Data expressed as the average ± standard 
deviation (n=5, of three different assays). **p < 0.01 and ***p < 0.001 in relation to 
control cells. 
 
3.7 CLZ permeation across Caco-2 monolayers 
 
The in vitro bioassay with Caco-2 cells monolayer has been widely used as model to 
predict drug permeability and have been well correlated with in vivo absorptions in 
humans [41]. Therefore, Caco-2 monolayer assay was conducted to analyze the 
permeability of CLZ as loaded in NPs-CLZ. The tested concentrations were selected 
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according to the cytotoxicity assays, which was 40 µg mL-1 of CLZ equivalent to 200 µg 
mL-1 in polymer concentration in the NPs-CLZ formulations. Free CLZ was not 
included in the intestinal permeability assay due to its toxicity towards Caco-2 cells 
(Figure 6A). 
The cells monolayer integrity was evaluated by TEER measurements throughout the 
experiments, and no cellular lesion which changes TEER values was detected (data not 
shown). Initial TEER values were higher than 400 Ωcm2 in the beginning of the 
experiment, as recommended for absorption studies [44]. The addition of the studied 
samples did not affect these values until the end of the experiment (8 h). 
 
 
Figure 7. In vitro CLZ permeation across Caco-2 monolayers. Amount of permeated 
CLZ as NPs-CLZ for 8 h. The experiments were conducted from the apical-to-
basolateral direction in culture medium at 37 °C. Error bars represent mean ± s.d. (n ≥ 
3). 
 
The permeation trend of CLZ as NPs-CLZ across Caco-2 intestinal monolayer is shown 
in Figure 7. About 12 µg of permeated CLZ was detected at the basolateral chamber, 
after incubation with NPs-CLZ, representing about 25% of the initial amount. This 
outcome is similar to the observed in the in vitro release studies, as the polymeric 
matrix slowly diffused CLZ reaching ca. 30 % of drug released within 8 h. Besides the 
low water solubility of CLZ may also contribute to the low drug amounts quantified at 
the basolateral chamber of the Caco-2 monolayer. The Papp value for CLZ when 
incorporated within NPs-CLZ was 3.8± 0.2 x 10-6 (cm s-1). The developed NPs-CLZ 
allowed to assess CLZ intestinal permeability, due to their protector behavior which can 
be considered an important achievement taking due to the high toxicity of CLZ.  
New technologies for the improvement of leprosy MDT  
		
 222 
Peak plasma concentrations CLZ were found 8 h after administration. Reports describe 
concentrations of 0.41 µg mL-1 for CLZ upon 200 mg, thus, NPs-CLZ were able to 
reach suitable concentration after intestinal permeation, to achieve the intended 
therapeutic effect [3]. 
 
4. Conclusions 
 
In this study, NPs-CLZ were successfully developed and characterized after the 
identification of critical variables through PBD. The volume of aqueous phase, amount 
of polymer and the amount of drug were found to be the most significant variables that 
affected the selected responses namely particle diameter, PDI, AE and DL. 
The selected formulation was achieved based on the desirability tool and satisfactory 
responses regarding particle size (around 200 nm), PDI below 0.3, and feasible AE and 
DL considering the oral route. FTIR revealed the absence of interactions between CLZ 
and the other constituents of the formulation; while, DSC evidenced the amorphous 
characteristic of entrapped CLZ. The polymeric nanoparticles had a spherical 
morphology. The in vitro drug release revealed the sustained pattern of CLZ released 
from NPs-CLZ upon 8 h under simulated intestinal conditions. The controlled release 
of CLZ is a promising strategy to overcome its recrystallization at the intestinal lumen 
and intracellularly avoiding the formation of supersaturated solutions. 
In vitro cytotoxicity studies evidenced that the obtained NPs-CLZ prevent the toxic 
effect of free CLZ, that presented IC50 values of 16.3 and 20.3 µg mL-1 for Caco-2 and 
HT29-MTX cells, respectively. In fact, the entrapment of drugs into nanoparticles at 
their amorphous form may prevent drug precipitation, which is, in the case of CLZ, 
associated with the formation of intracellular crystal aggregation and correlated with 
the undesired and toxicological effects. CLZ permeated the Caco-2 cells monolayer as 
when entrapped in the PLGA nanoparticles, reaching about 25% of the initial added 
amount. Given the controlled drug release from the NPs-CLZ, a longer time may be 
required for the CLZ permeate the Caco-2 monolayer at a higher extent. 
Based on the obtained results, it can be concluded that the obtained system could be 
properly designed considering the important variables for poorly soluble drugs. NPs-
CLZ represents a promising platform for the oral delivery of CLZ. 
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ABSTRACT 
The aim of this work was to assess the feasibility of drug nanosystems combination for 
multibacillary leprosy oral therapy. The anti-leprotic drugs dapsone (DAP) and 
clofazimine (CLZ) were incorporated within polymeric nanosystems and studied per se 
and in combination. DAP was loaded in Eudragit L100 nanoparticles (NPs-DAP) while 
CLZ was loaded in (poly(lactic-co-glycolic acid) (NPs-CLZ). The nanosystems exhibited 
around 200 nm in size and a drug loading of 12% for both drugs. In vitro cytotoxicity on 
intestinal Caco-2 cells revealed that after 8 h incubation, DAP alone and within NPs were 
not toxic up to 100 µg mL-1, while CLZ per se was toxic, reducing cell viability to 30% at 50 
µg mL-1. Caco-2 exposed to NPs-DAP/ NPs-CLZ combination at 100 and 50 µg mL-1, 
respectively exhibited 80% viability. Caco-2 monolayer permeability assays revealed that 
DAP and CLZ in the nanosystems per se or in NPs-DAP/ NPs-CLZ combination crossed 
the intestinal barrier. No significant differences were observed between the single 
nanosystems or in combination for the apparent permeability values and the amount of 
permeated drug. Thus, the NPs-DAP/ NPs-CLZ combination seems to be a promising 
platform to deliver both drugs in association, representing an important step toward the 
improvement of multibacillary leprosy therapy. 
 
 
Keywords: Caco-2 cells; Cytotoxicity; Eudragit L-100; Leprosy; PLGA  
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1. Introduction 
 
Leprosy is a chronic and infectious disease caused by the Mycobacterium leprae that 
continues to be a significant issue of public health globally [1-3], being one of the most 
common causes of non-traumatic peripheral neuropathy [4]. For treatment purposes, the 
World Health Organization (WHO) suggests a simple scheme to categorize leprosy 
patients based on visible symptoms [5], as having paucibacillary (PB) leprosy (1-5 skin 
patches) or multibacillary (MB) leprosy (with > 5 skin patches) [5]. The actual 
recommended treatment for leprosy disease is based in a multidrug therapy (MDT), 
consisting of rifampicin, clofazimine (CLZ), and dapsone (DAP) to treat MB leprosy 
patients during 12 months, while rifampicin and DAP are used in PB leprosy patients 
during 6 months [5]. The rifampicin is monthly administered under supervision of healthy 
regional professionals, while DAP (alone or associated with CLZ) is daily administered 
without supervision [5]. 
The standardization of the MDT regarding time of treatment and therapeutic agents 
appears to be a trend in leprosy eradication program as these strategies may promote 
patient compliance and efficiency in patient management [6]. Thus, the daily 
administered drugs (DAP and CLZ) become the most important components of leprosy 
MDT [7]. On the other hand, the non-supervised administration may highlight the risk of 
antimicrobial resistance [7]. In this context, research in the leprosy therapy is still needed, 
and efforts must be done specially to improve delivery of drugs and patient compliance.  
Despite their proven effectiveness, the therapeutic potential of DAP and CLZ is limited by 
their poor water solubility [8], leading to undesired bioavailability, which may 
compromise the success of MDT. In this context, it is of great relevance the development 
of new delivery strategies to both drugs in order to overcome these issues, and even 
improve leprosy therapy through drug association. Few works have reported new 
approaches to overcome the poor solubility of DAP [9] and CLZ [10]. In the literature, so 
far there is no report on the drug association through the combination of nanodelivery 
systems. 
The aim of this work was to evaluate the biological properties of the combination of 
nanosystems containing MB anti-leprosy drugs, namely DAP and CLZ for oral delivery. 
The previously optimized nanosystems were combined according to MB therapy and 
assessed for cytotoxicity and permeability using an in vitro intestinal barrier model.  
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2.  Materials and methods 
 
2.1.  Materials 
 
DAP was purchased from CHEMOS GmbH (Regenstauf, Germany) and clofazimine (CLZ) 
from Hangzhou Heta Pharm & Chem Co. Pluronic® F-68 and polyvinyl alcohol (PVA) were 
adquired from Sigma–Aldrich (St. Louis, USA); poly(methacrylic acid-co-methyl 
methacrylate) 1:1 (Eudragit® L100) was obtained from Evonik Roehm GmbH, (Darmstadt, 
Germany). Ethanol was purchased from VWR chemicals (Carnaxide, Portugal) and 
acetone from JGMS (Odivelas, Portugal). Poly (lactic-co-glycolic acid) (PLGA) (50:50 
Purasorb® PDLG 5002A) was a kind gift from Purac Biomaterials (Gorinchem, The 
Netherlands).  Caco-2 cell line was obtained from the American Type Culture Collection 
(ATCC, Wesel, Germany) (passage number 35 - 55) and HT29-MTX cell line was kindly 
provided by Dr. T. Lesuffleur (INSERM U178, Villejuif, France). Dulbecco’s Modified 
Eagle Medium (DMEM), fetal bovine serum (FBS, South America origin), penicillin- 
streptomycin mixture (Pen-Strep) and trypsin-EDTA 0.25% (w/v) were all obtained from 
Gibco (Paisley, UK). 
 
2.2.  Methods 
 
2.2.1. Nanoparticles preparation and characterization 
 
Dapsone-loaded nanoparticles (NPs-DAP) were produced with Eudragit L100 (EL100) 
polymer via the nanoprecipitation method, previously described [11, 12], with slight 
modifications. Briefly, known amounts of EL100 and DAP were co-dissolved in 3 mL of 
ethanol-acetone (1:1) mixture. The organic solution was subsequently slowly dripped (0.5 
mL min-1) in the 10 mL of PVA 1% (w/v) solution previous acidified to pH 3. The final 
solution was maintained under magnetic stirring at 350 rpm (RT 15 Power IKAMAG 
Multiposition Magnetic Stirrer, Staufen, Germany) and room temperature until complete 
solvent diffusion. Unloaded nanoparticles (EL100 NPs) were obtained for the selected 
formulation, following the same procedure.  Freshly prepared nanosuspensions were used 
to perform cells assays. 
CLZ nanoparticles were prepared using PLGA (NPs-CLZ) also following nanoprecipitation 
method [11, 12]. Briefly, 20 mg of PLGA and 2 mg of CLZ were dissolved in 3 mL acetone, 
which was slowly added to 5 mL of PVA 1% (w/v) solution under probe sonication, during 
2 min, with an amplitude of 70%. A PVA solution (0.1% w/v) was then used as stabilizer. 
The final emulsion was maintained under magnetic stirring (RT 15 Power IKAMAG 
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Multiposition Magnetic Stirrer, Staufen, Germany) at 350 rpm and room temperature. 
Unloaded nanoparticles (PLGA NPs) were obtained for the selected formulation, following 
the same procedure. 
The nanoparticles were characterized regarding mean particle size using a ZetaPALS, Zeta 
Potential Analyzer (Brookhaven Instrument Corps, Holtsville, NY, USA), with a light 
incidence angle of 90º at 25ºC and the obtained value represent multiple runs (n=6). The 
quantification of DAP and CLZ within the nanoparticles was carried out by determining 
the unentrapped drug separated by centrifugation (11,200 xg for 30 min). For the 
quantification of CLZ, NPs-CLZ samples were properly diluted with sodium dodecyl 
sulphate (SDS) 2% (w/v) so that the maximum concentration of CLZ did not exceed 100 
µg mL-1. The supernatant was read at 492 nm by UV-VIS spectroscopy (Jasco V-660, 
Easton, MD, USA). For the quantification of DAP, NPs-DAP were diluted 5 times with 
acidified ultrapure water (pH 3) and then centrifuged (11,200 xg for 30 min). Absorbance 
of supernatant was measured at 391 nm. Association efficiency (AE) and drug loading 
(DL) were calculated following the equations:  
 0c = 8586829	27Gb56	Gd	;3bH	– 34fGa434;	;3bH8586829	27Gb56	Gd	;3bH ×100 en = 		 8586829	27Gb56	Gd	;3bH − 34fGa434;	;3bH8586829	27Gb56	Gd	;3bH + 8586829	27Gb56	Gd	1G9"743 ×100 
 
2.2.2. Cell culture studies 
 
Caco-2 and HT29-MTX cells were cultured in DMEM supplemented with 10% (v/v) of 
FBS and 1% (v/v) of penicillin-streptomycin. Cells were grown in a humidified incubator 
at 37 ºC and 5% CO2 atmosphere and 95% relative humidity. When reaching 80% 
confluence, cells were detached using trypsinization.  
 
2.2.2.1.  In vitro cell viability assessment 
 
The cell viability of unloaded nanoparticles (EL100-NPs and PLGA-NPs), NPs-DAP, NPs-
CLZ, and free drugs (DAP and CLZ) was evaluated in Caco-2 cell lines. The method used 
was the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
colorimetric assay. The cells were incubated with 100 µL of culture media containing 
different concentrations of EL100-NPs, PLGA-NPs, NPs-CLZ, NPs-DAP and free drugs, 
namely for DAP 12.5 – 100.0 µg mL-1 and for CLZ 6.3 – 50.0 µg mL-1, equivalent dosage. 
For drug association (DAP/ CLZ) the ratio DAP:CLZ (2:1) was selected based on the daily 
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administered dosage in MB leprosy treatment. After 8 h incubation, the supernatant was 
removed and replaced by 100 µL of MTT solution (0.5 mg mL-1). The formazan crystals 
were dissolved with dimethyl sulphoxide and then the optical density of the solution was 
measured at a wavelength of 570 and 630 nm using SynergyTM HT Multi-mode microplate 
reader (BioTek Instruments Inc., Winooski, VT, USA). Untreated cells were taken as 
positive control with 100% viability. Three independent MTT assays were performed with 
quadruplicate samples each and results were expressed as mean values ± standard 
deviation. The cell viability (%) in relation to control cells (untreated cells) was calculated 
by the equation: 
 ?499	a82$8986"	(%) = 0 570 − 630	f499O	85fb$264;	i86ℎ	dG37b9268G50 570 − 630	f499O	85fb$264;	i86ℎ	fb96b34	74;8b7×100 
 
2.2.2.2 Permeation studies using Caco-2 monolayers 
 
For the permeability studies, Caco-2 cells were seeded on 12-well Transwell inserts 
(Corning Transwell Clear, pore size 3 µm, area 0.33 cm2) at a cell density of 105 cells per 
cm. The cells were grown in DMEM supplemented with FBS, during 21-23 days, until the 
monolayer achieved suitable initial transepithelial electrical resistance (TEER) values. The 
TEER at the beginning of these studies was higher than 400 Ω cm2, indicating an intact 
monolayer; TEER values were also obtained after completion of flux experiments at 8 h. 
The resistance measurement of the medium without cells was considered as blank. The 
permeability was carried out by adding 0.5 mL of culture medium containing the 
equivalent of 80 µg mL-1 of DAP (as NPs-DAP), 40 µg mL-1 of CLZ (as NPs-CLZ), or the 
combination NPs-DAP/ NPs-CLZ (80 µg mL-1/ 40 µg mL-1) in the apical side of the cell 
monolayer. The samples were incubated for 8 h, and at predetermined time intervals (1, 2, 
3, 4, 6 and 8 h), 0.5 mL were sampled from the basolateral compartment and replaced 
with fresh culture medium. The amount of DAP and CLZ in the samples was quantified by 
HPLC. The experiments were carried out in triplicate. The cumulative amounts of DAP, 
CLZ and DAP/ CLZ that permeated the monolayers were calculated from the 
concentrations measured in the basolateral compartment. The apparent permeability 
(Papp) was calculated following the equation: 
 01123456	143742$8986"	 :211 = 	;<;6 × 10×?% 
 
where, Papp is the apparent permeability coefficient (cm s-1), dQ/dt is the linear 
appearance rate of the compound on the receiver end based on its cumulative transport 
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for 8 h (µg s-1), A is the surface area of the cell monolayer (cm) and C0 is the initial 
concentration of compound in the donor chamber (µg mL-1). 
 
2.2.3. Dapsone and clofazimine determination by high-performance 
liquid chromatography 
 
The quantification of DAP, CLZ and the DAP/ CLZ association in the permeability studies 
samples was performed by high-performance liquid chromatography (HPLC) with UV 
detection. The HPLC system (Jasco) comprised a high-pressure pump (PU-2089), an 
autosampler (AS-2057) and a diode array detector (MD-2015) programmed for peak 
detection at 280 nm, controlled by ChromNAV software. A reversed phase Kinetex® core-
shell C18 column (250 x 4.1 mm, 5 µm particle size, 100 Å; Phenomenex, Torrance, CA, 
USA) was used as stationary phase. Elution was performed in gradient mode using as 
mobile phase a mixture of aqueous acetate buffer (final concentration 50 mM, pH 4.8) and 
acetonitrile, at a flow rate of 1 mL min-1. The selected gradient started with 30% (v/v) of 
acetonitrile, which was maintained up to 3 min. From 3 to 5.5 min, the contribution of 
acetonitrile was rapidly changed to 80% (v/v). This composition was maintained up to 7.5 
min, after which the initial conditions were re-established and held during 5.5 min more 
to assure column equilibration. Hence, the total run time was 13 min. The injection 
volume was 20 µL. Standard solutions for both drugs were prepared at 0.5, 1, 2.5, 5, 7.5, 
10, 15 and 20 µg mL-1 in culture medium containing 40% (v/v) of acetonitrile and 50 mM 
acetate buffer, pH 4.8. To prepare the samples for HPLC analyses, 200 µL of each sample 
was added to 160 µL of acetonitrile and 40 µL of acetate buffer 500 mM, pH 4.8, to final 
concentrations of 40% (v/v) and 50 mM, respectively. The mixtures were vortexed and 
centrifuged at 18,000 × g for 10 min at room temperature. After centrifugation, 
supernatants were collected and analyzed by HPLC. 
 
3.3 Statistical analyses 
 
The statistical analysis was performed using GraphPad Prism software (version 6, 
GraphPad Software, La Jolla, CA, USA) for statistical comparisons of the results to control 
for the cell viability studies. Statistical analysis of the results was performed using student 
(unpaired) t-test and one-way ANOVA test. All the other results were presented as mean 
and standard deviation (SD). The differences were assumed statistical significant when p 
< 0.05 (95% confidence level). 
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3. Results and discussion 
 
3.1. Nanoparticles characterization 
 
Nanoparticles with diameter close to 200 nm have an improved uptake by the intestinal 
tissue when compared to larger particles [13]. The previously optimized nanosystems were 
characterized regarding particle size, AE and DL. The mean of particle size for NPs-DAP 
was 198 ± 6 nm and no statistical differences between load and unloaded nanoparticles 
were found (p<0.05). The AE and DL were 48 ± 4% and 12 ± 1% respectively. As for NPs-
CLZ AE and DL were 70 ± 5% and 12 ± 1%, respectively, and the mean particle size was 
211 ± 3 nm and unloaded nanoparticles presented values of 175 ± 13 nm. 
 
3.2. In vitro cell viability studies 
 
The nanosystems were developed for oral administration in MB leprosy therapy. Given the 
limited physicochemical properties of DAP and CLZ specifically regarding their high 
hydrophobicity, difficulties may occur in the drug absorption due to drug precipitation at 
physiological pH, causing toxicity at the intestinal tissue. To mimic the intestinal 
absorption barrier Caco-2 cell line was selected as a model [14]. The daily administered 
doses are in a ratio of 2:1 DAP/ CLZ, thus the drug association assays were conducted in 
this proportion. The permeability assays studies were performed during 8 h, aiming to 
unravel the effect of drugs closer to real physiological conditions as the intestinal transit 
time. The tested concentrations ranged from 6.3 to 100.0 µg mL-1 for DAP, and from 3.1 to 
50.0 µg mL-1 for CLZ as free drug and as loaded within the optimized nanosystems, 
wherein containing an equivalent polymer concentration between 12.5 to 200.0 µg mL-1 of 
EL100 or PLGA. 
The effect of DAP/ CLZ association on the viability of intestinal cells was studied. Figure 1 
depicts the cell viability of single DAP, CLZ and of the association DAP/ CLZ. DAP alone 
was not toxic up to 100 µg mL-1, while single CLZ led to statistically significant differences 
compared to the untreated samples for the highest tested concentrations (12.5 to 50.0 µg 
mL-1), in relation to the untreated control. Drug association at 2:1 ratio (DAP/ CLZ) 
reduced Caco-2 viability for the concentrations 25 to and 100 µg mL-1 of DAP, 
corresponding to 12.5 – 50 µg mL-1 of CLZ in relation to the control (untreated cells), 
resulting in cell viabilities between 75 and 33%. The decrease in Caco-2 viability observed 
with the drug association treatment was probably due to the presence of CLZ, as the same 
amount of single CLZ provided similar results. Moreover, statistical differences between 
DAP and DAP/ CLZ for the highest tested concentrations were found (Figure 1). In fact, it 
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has been described that upon prolonged oral administration CLZ forms intracellular 
insoluble drug precipitates, leading to bioaccumulation, which is associated with 
unwanted side effects as reddish skin pigmentation, abdominal pain and cardiotoxicity 
[10]. 
 
 
Figure 1. Cell viability of Caco-2 cells, assessed by the MTT assay, when exposed to DAP 
(black bar), CLZ (light grey bar) and DAP/ CLZ (2:1, dark grey bar) drug association upon 
8 h of incubation. Data expressed as the average ± standard deviation (n=5, of three 
different assays). ***p < 0.001 
 
The influence on cell viability of the drug association per se and in the developed 
nanosystems (NPs-DAP and NPs-CLZ) was also evaluated on the Caco-2 cell line. Figure 2 
shows that 8 h incubation with NPs-DAP/ NPs-CLZ, at the highest studied concentrations, 
results in 75 ± 7 % cell viability, while equivalent dose of DAP/ CLZ association reduces 
significantly cell viability to 35%. The unloaded nanosystems do not exert any significant 
influence on the Caco-2 cells viability. Moreover, the loading of the drugs into polymeric 
nanosystems could overcome the reduction in cell viability found for free CLZ. Taken the 
obtained results, the nanosystems may prevent DAP/ CLZ association toxicity, most 
probably by preventing CLZ crystallization and the formation of CLZ precipitates. The 
combination of the nanosystems have the potential to deliver DAP/ CLZ association, and 
decreases the undesired toxic effect. 
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Figure 2. Cell viability of Caco-2 cells, upon 8 h exposure to unloaded NPs (black bar), 
NPs-DAP/ NPs-CLZ (light grey bar) and DAP/ CLZ (2:1, dark grey bar). Data expressed as 
the average ± standard deviation (n=5, of three different assays). **p < 0.01; ***p < 0.001 
 
3.3. Nanosystems permeation across Caco-2 monolayers 
 
The in vitro bioassay with Caco-2 cells monolayer has been widely used as model to 
predict drug permeability and have been well correlated with in vivo absorptions in 
humans [14]. Therefore, Caco-2 monolayer assay was conducted to analyze the 
permeability of DAP and CLZ per se and in DAP/ CLZ association, using the developed 
polymeric nanoparticles. The cells monolayer integrity was evaluated by TEER 
measurements throughout the experiment (Table 1). It can be inferred that during the 8 h 
incubation with the developed nanosystems for DAP and CLZ per se and the NPs-DAP/ 
NPs-CLZ combination did not influence statistically the Caco-2 monolayer’s integrity. The 
TEER values were higher than 400 Ωcm2 in the beginning of the experiment, as 
recommended for absorption studies [15].  
 
Table 1. TEER values prior, during and after Caco-2 permeation assays  
 TEER values (Ohms cm2) 
 Control NPs-DAP NPs-CLZ NPs-DAP/ NPs-CLZ 
0 h 455 ± 30 460 ± 25 460 ± 35 450 ± 25 
4 h 480 ± 45 475 ± 30 480 ± 30 465 ± 35 
8 h 470 ± 35 480 ± 40 475 ± 40 470 ± 30 
Data expressed as mean ± standard deviation (n=3) and 3 independent measurements per 
well. 
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The permeation assessment of NPs-DAP and NPs-CLZ per se and in combination can be 
observed in Figure 3. 
 
 
Figure 3. Effect of DAP and CLZ nanosystems on drug (A) apparent permeability (Papp, 
in relation to the drug in bold) and (B) permeation profile, through Caco-2 monolayer at 
37ºC. Different formulations were studied: NPs-DAP (open square), NPs-CLZ (open 
circle) and the association NPs-DAP/ NPs-CLZ (at 2:1, black square/ black circle). Data 
represents average ± standard deviation (n=3). 
 
The combination of NPs-DAP and NPs-CLZ did not interfere with the Papp values nor the 
permeation profile of DAP and CLZ in comparison to each individual nanosystem. Due to 
the toxic effect observed with the free CLZ, the DAP/ CLZ drug association per se (Fig 2) 
was not evaluated in the permeation assay. About 40-50% of the initially added amount of 
drugs to the apical chamber reached the basolateral chamber after 8 h of exposure, 
accounting for ca. 40 µg DAP and ca. 15 µg CLZ. Considering the polymeric nature of the 
nanosystems and the 200-nm size it may be hypothesized that the NPs will interact with 
the Caco-2 cells through endocytic and transcytosis processes, which allow the drug 
permeation across the mimetic intestinal barrier [16].  
Peak plasma concentrations for DAP and CLZ were found 8 h after administration. 
Reports describe concentrations of 0.41 µg mL-1 for CLZ upon 200 mg administration and 
1.35 µg mL-1 for DAP after administration of 100 mg. Thus, the developed nanosystems 
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were able to reach suitable concentration per se or in combination after intestinal 
permeation, to achieve the intended therapeutic effect. Moreover, the ratio DAP/ CLZ 
adopted in MB leprosy treatment could be achieved as at the end of the assay, the ratio 2:1 
was almost maintained.  
 
4. Conclusions 
 
This study demonstrates that DAP/ CLZ drug association delivered as polymeric 
nanosystems permeates the intestinal barrier. The in vitro cytotoxicity studies upon 8 h 
evidenced that DAP per se was not toxic towards Caco-2 cells, while CLZ decreased cell 
viability to 33%, at 50 µg mL-1. DAP/ CLZ association was similarly toxic most probably 
due to the CLZ presence. The nanosystems combination did no exert any statistically 
significant toxic effects. The incorporation of DAP and CLZ into polymeric nanosystem 
provided good intestinal cell viability, compared to free drug association. Both drugs were 
able to permeate the intestinal barrier when incorporated in the nanosystems. The NPs-
DAP/ NPs-CLZ combination exhibited similar behavior as each of the nanosystem in the 
Caco-2 permeability. The amount of permeated drugs is above the plasmatic 
concentration previously reported, which indicates the ability to reach the intended daily 
therapeutic dosage. Based on the obtained results, it can be concluded that polymeric 
nanosystems with DAP and CLZ in combination seem to be a promising platform to 
overcome the toxic effects and low patient compliance related to the actual MB leprosy 
treatment.  
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F. Integrated Discussion 
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Integrated discussion 
 
The hypothesis of this thesis was based on the current difficulties in the management of 
leprosy treatment as recommend by the WHO, which results in a lack of patient 
compliance, most of the times due to duration of treatment, and appearance of undesired 
side effects. Thus, it was envisaged that the association of the main first-line drugs, DAP 
and CLZ, could promote leprosy eradication worldwide, particularly in Brazil, endemic 
country that founded this research. DAP and CLZ are classified according to the BDS as 
class II drugs, presenting water solubility of 160 and 0.5 µg mL-1 respectively, at 25ºC [1]. 
Therefore, the study was always based on the selection of appropriate systems for poorly 
water-soluble drugs. 
The development of drug delivery systems was designed separately for each drug, mainly 
to avoid chemical interactions between the drugs and other formulations constituents, or 
degradation acceleration, as already reported before with other studies with drug 
association [2, 3]. In fact, DAP chemical reactions with other drugs has already been 
reported, under non-severe conditions [4]. The choice of solid dispersions (SD) as DAP 
drug delivery system was based on their scale-up feasibility, associated low cost and 
general physical stability [5]. Indeed, SD could be successfully developed and provided an 
increasing in DAP solubility three-fold higher compared to free DAP, at physiological pH 
and 37ºC. During the preformuation studies, equilibrium solubility of DAP in different pH 
conditions (1.2; 4.5 6.8 and 7.4) was performed as recommended by the Food and Drug 
Administration (FDA)[6]. It was observed that solubility of DAP was much higher at acidic 
conditions, due to the protonation amino groupings [1]. Despite the positive results 
obtained from SD with DAP (Chapter IV.A) it was hypothesized that its higher solubility 
under acidic conditions would be the reason of DAP relevant digestive problems such as 
nausea, vomiting, and stomatitis. Besides, the DAP hydrolysis under acidic environment 
have been reported by non-enzymatic manner [7]. Thus, to overcome this drawback, DAP 
was incorporated within pH-sensitive nanoparticles aiming to achieve site-specific deliver 
of the drug as an alternative to the solid dispersions and the supersaturated solutions. By 
this way, DAP would be protected from the acidic gastric environment, and would be 
delivered only at the intestine for absorption. The selection of nanoparticles as drug 
delivery systems was based on their supplementary advantages such as: protection of the 
drug against potential degradation conditions, possibility to attach on nanoparticles 
surface ligands to further tissue-specific drug delivery, and to provide a controlled release, 
compared to solid dispersions as drug delivery systems. In fact, the developed 
nanosystems based on Eudragit L100 (Chapter IV.B) resisted to lower pH (1.2) in 
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comparison to more alkaline conditions (pH 6.8), with no toxic effects on gastric and 
intestinal cell lines. 
Contrary to DAP, the initial preformulation study with CLZ was not conducted by 
determining its equilibrium solubility. The solubility assays were hampered due to the lack 
of a fast and feasible method to quantify the drug using a minimum amount of aqueous 
phase, and with suitable sensitivity to detect low concentrations. Thus, it was thought that 
the development of a fast, solvent-free, precise, sensitive and robust method to quantify 
CLZ would be useful to the work progress (Chapter IV.C). Moreover, after literature 
review, it could be concluded that the application of solid dispersions to deliver CLZ would 
not be a suitable strategy. It was already discussed that solid dispersions may improve 
drugs solubility buy delivering them through a very fine colloidal dispersion, promoting a 
supersaturated solution in the media [5, 8]. Although it has been demonstrated that 
amorphous systems can provide faster dissolution rates and higher solution 
concentrations than their crystalline counter, the drugs tend to crystallize via a solid-to-
solid transition [9]. As already mentioned along the thesis, CLZ seems to form insoluble 
precipitates inside cells, which can be associated to its toxicity as the intracellular crystals 
act as intracellular drug depots, accounting for the drug’s prolonged elimination, 
bioaccumulation and extended half-life [10, 11]. Thus, the improvement of CLZ absorption 
per se would not be enough to overcome its physicochemical limitations. As alternative, 
SLNs seemed to be a promising system to deliver CLZ (Chapter IV.C). Besides improve 
solubility of poorly soluble compounds through the reduction of particle size, SLNs in 
general could offer additional advantages, such as protection of the drug from 
gastrointestinal degradation, active and passive targeting to specific intestinal cells and 
even reduce systemic side effects. Particularly, SLNs were the first chosen nanocarriers 
due to its theoretical capability to entrap lipophilic compounds considering the lipid 
nature of the matrix. Moreover, it was considered their feasibility to scale-up, low cost, 
and production without the use of organic solvents. Despite the lipophilic nature of SLNs, 
it was found that most of the tested solid lipids during preliminary studies were not able to 
solubilize CLZ, as crystals were still present after lipid melting, at the ratio 10:1 (w/w) 
lipid:drug. Precirol ATO was found to be suitable for the development of SLNs loaded with 
CLZ (SLNs-CLZ), with proper particle size, potential zeta and polydispersity index. 
Regarding AE (71%) and DL (2.4%), even if the obtained values can be considered positive 
results for nano-delivery systems, it would be difficult to reach the oral administered 
dosage adopted in leprosy treatment (50 mg) with this drug payload. Moreover, the 
hypothesis that SLNs could improve poorly soluble drugs permeability did not apply for 
SLNs-CLZ. After 8 h of permeation across Caco-2 monolayers, no CLZ was found at the 
receptor compartment, or the permeated amount of CLZ was below the detection limit of 
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the quantification method (Chapter III, 6.2). One explanation for this result is that the 
permeability assay across Caco-2 monolayer using Transwell® systems may not be the 
most appropriated assay to evaluate SLNs since the lipid density is lower than the medium 
used for the assay, resulting in false negative or inconclusive results. Likewise, it has been 
reported that negatively charged SLNs may aggregate in the buffer medium due to the 
presence of high concentration of salts in the buffer, which may bypass the negative 
charges on the surface of SLNs, leading to the aggregation, avoiding uptake by Caco-2 cells 
[12]. On the other hand, high amounts of SLNs-CLZ could be internalized by the Caco-2 
cells, and follow some degradation pathway, or simply remain inside cells unable to 
permeate the monolayer, resulting in not detectable quantification. However, these 
hypotheses were not confirmed, and need further investigation. To overcome the 
described issues concerning SLNs, the development of polymeric nanoparticles with CLZ 
appeared to be an alternative. Compared to lipid-based nanocarriers, polymeric 
nanoparticles have advantages such as higher stability in acidic environment, and 
possibility to achieve a more controlled drug release by modulating physicochemical 
characteristics [13]. In addition, less amount of dispersive matrix is required, compared to 
SLNs, which would increase the DL of the nanosystem. The choice of poly(lactic-co-
glycolic acid) (PLGA) as matrix was due to its ability to encapsulate poor soluble 
compounds as already reported in the literature [14-17]. In fact, the obtained polymeric 
nanoparticles loaded with CLZ (NPs-CLZ) (Chapter IV.D) showed higher DL (11.6%) 
compared to SLNs (2.4%). AE efficiencies were found ca 70% for both nanosystems. 
Regarding toxicity, both nanoparticles did not affect intestinal cells viability, in relation to 
pure CLZ that induce toxicity (Chapter IV C and D). The most important outcomes when 
comparing SLNs and NPs loaded with CLZ were regarding permeability assays across 
Caco-2 cell monolayer. Differently from SLNs-CLZ, the CLZ within polymeric 
nanoparticles were able to cross the intestinal cell monolayer. Even though, longer time 
may be required for the CLZ permeate the Caco-2 monolayer at a higher extent (Chapter 
IV.D). The data obtained from the permeability assays could emphasizes that further 
studies should be conduct to compare the uptake mechanism of lipid-based and polymer-
based nanoparticles with CLZ by Caco-2 cells.  
The final ultimate of this thesis was to perform DAP/CLZ association through the 
optimized and most promising nanosystems. Intestinal permeability assays with DAP 
solid dispersions and EL100 nanoparticles were performed, even though no statistical 
differences were found concerning the amount of permeated DAP. Due the advantages of 
the NPs-EL100-DAP nanoparticles, this system was chosen to be combined with the NPs-
CLZ (Chapter IV.E). Permeability assays across Caco-2 monolayer revealed that DAP and 
CLZ in the nanosystems per se or in combination crossed the intestinal barrier, and no 
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significant differences were observed between the nanosystems per se or in combination. 
Nevertheless, complementary assays regarding physicochemical characterization of 
nanosystems combination, and pharmacokinetics profiles must be performed. 
Overall, different drug delivery systems with DAP and CLZ could be well designed and 
have their individual importance, as each of them present negative and positive aspects. In 
the framework of pharmaceutical technology, it should always be considered several 
aspects regarding the via of administration, drug physicochemical features, 
pharmacokinetics profile, elimination and degradation mechanism, duration of treatment, 
administered dosage, and an infinity of other parameters [5]. On the other hand, the 
advances in the search for new drug platforms to delivery active compounds is increasing 
day by day, and different alternatives are being available to overcome the drugs clinical 
limitations. Fortunately, there are very efficient tools to assess their performance, either in 
vitro or in vivo, leading to exhaustive work searching for the “perfect” formulation. Even 
though, the research will never end, as all pharmaceutical product will have their 
associated risk, leading the work to the beginning! (Personal note). 
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1. Concluding remarks 
 
The actual MDT for leprosy disease with CLZ and DAP as daily first-line drugs to treat 
patients with MB leprosy seems to be a trend in leprosy treatment management. Even 
though, despite the already stablished efficiency of the anti-leprotic agents, the 
biopharmaceutical properties of these drugs may be limiting their performance during 
the treatment. Besides, the reported resistance of DAP, associated with the toxicity 
effects of CLZ probably due to its tissue accumulation and in vivo precipitation may be 
jeopardizing the patient compliance, and the ultimate success of leprosy treatment. 
Therefore, the investigation of new strategies to deliver DAP and CLZ in order to 
overcome their physicochemical limitations was found to be useful for the 
improvement of leprosy therapy. 
The implementation of the Quality by Design (QbD) concept recommended by the 
International Conference on Harmonization was successfully applied along this thesis 
by the application of combined analytical approaches such as design of experiments 
(DoE), response surface methodology (RSM) and optimization aiming to systematically 
construct suitable drug delivery systems with DAP and CLZ. 
Solid dispersions (SD) systems were considered a promising technique to improve the 
aqueous solubility of DAP. The preparation of amorphous SD with DAP and PVP-K30 
was developed based on preliminary investigation of DAP solubility enhancement after 
phase diagram solubility assay. Moreover, the addition of Pluronic® F68 as a third 
component in the SD did not interfere in the improvement of DAP solubility. Higher 
solubility and dissolution rate was found for freeze-dried SD, compared to kneaded and 
physical mixtures, which could be attribute to the improved wettability and particle size 
reduction, by the conversion from crystalline to the amorphous form and by the 
molecular interactions between drug and polymer in resultant dispersions. 
pH-sensitive nanoparticles produced with DAP and Eudragit L100 polymer (NPs-
EL100-DAP) were successfully developed after the identification of the most critical 
variables, through Placket-Burman screening design, with subsequent optimization by 
the application of BBD regarding the selected responses (particle diameter, PDI and 
AE). The in vitro drug release at different pH conditions confirmed the pH sensitivity 
of NPs-EL100-DAP, being able to provide enhanced drug delivery at the intestinal 
environment. No toxicity was observed in different gastro-intestinal cell lines up to 400 
µg.mL-1 of DAP. Moreover, 2-fold enhanced intestinal permeability was observed when 
DAP was incorporated within NPs-EL100 in comparison to free DAP. 
Regarding CLZ drug delivery systems, risk management tools helped to identify 
potential factors that could affect SLNs-CLZ performance, and allowed the 
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implementation of control actions to obtain suitable nanosystems. A BBD was used to 
optimize SLNs-CLZ with the desired parameters (particle size, zeta potential, AE and 
DL). Physicochemical characterization confirmed the amorphous state of CLZ within 
SLNs. The developed SLNs-CLZ showed to be stable under the established storage 
conditions (4ºC) for 12 weeks, and no toxicity was found up to 50µg mL-1 in CLZ for 
SLNs-CLZ towards gastrointestinal cells, on the contrary of the free CLZ solutions. 
SLNs-CLZmay be an useful platform to decrease CLZ associated side effects. 
A second nanosystem was developed with CLZ and PLGA, after the identification of 
critical variables by PBD. Physicochemical characterization confirmed the amorphous 
state of CLZ into the polymeric nanoparticles, and their spherical morphology The in 
vitro drug release revealed the sustained pattern of CLZ released from NPs-CLZ upon 8 
h. In vitro cytotoxicity studies evidenced that the obtained NPs-CLZ prevented the 
toxic effect of free CLZ. CLZ permeated the Caco-2 cells monolayer when entrapped in 
the PLGA nanoparticles, exhibiting Papp values of 3.8± 0.2 x 10-6 (cm s-1). Despite the 
long-term controlled CLZ release from the NPs-CLZ, the developed nanoparticles were 
able to reach intended concentration to promote therapeutic effect after 8h or 
permeability assay, according described reports.DAP/ CLZ association was as toxic as 
CLZ alone, evidencing that the toxicity of the drug association was probably due to the 
CLZ presence. The nanosystems combination did no exert any significant toxic effects. 
On the contrary, the incorporation of DAP and CLZ into polymeric nanosystem 
provided a good intestinal cell viability.  
To summarize, the results of this thesis provided different platforms to deliver DAP and 
CLZ separately, aiming to overcome the limitations associated with both drugs, 
representing promising systems to the future leprosy therapy as single systems or in 
association. Nevertheless, complementary assays regarding physicochemical 
characterization of nanosystems association, and determination of pharmacokinetics 
profiles must be conducted to better elucidate the performance of DAP – CLZ 
association into nanodelivery systems.  
 
2. Future Perspectives 
	
Following the obtained outcomes from presented work, it would be ofgreat value to 
assess physicochemical stability and characterization of the nanosystems (NPs-DAP 
and NPs-CLZ) in combination, and compare with the nanosystems alone. Performing 
in vitro drug release studies with the associated nanosystems, using more complex 
biorelevant media aiming to correlate more precisely with in vivo results seem to be an 
important aspect to be studied. In addition, the uptake mechanisms by intestinal cells 
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of the nanosystems to better understand the behavior of tissue permeability would be 
of great relevance. The performance of in vivo assays for the assessment of the efficacy 
of nanosystems combination and determination of pharmacokinetic profile after oral 
administration to adjust dosages for leprosy treatment purposes would be interesting 
points to be approached. 
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